(12) STANDARD PATENT (11) Application No. **AU 2015230942 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Gene therapy for retinitis pigmentosa

(51) International Patent Classification(s)
A61K 48/00 (2006.01) ***C12N 15/86*** (2006.01)
A61K 31/7105 (2006.01)

(21) Application No: **2015230942** (22) Date of Filing: **2015.03.20**

(87) WIPO No: **WO15/143418**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/969,027	**2014.03.21**	**US**

(43) Publication Date: **2015.09.24**
(44) Accepted Journal Date: **2020.11.19**

(71) Applicant(s)
Genzyme Corporation

(72) Inventor(s)
O'Riordan, Catherine;Adamowicz, Matthew

(74) Agent / Attorney
Griffith Hack, Level 10 161 Collins St, MELBOURNE, VIC, 3000, AU

(56) Related Art
WO 2008125846 A2
MAO H ET AL, HUMAN GENE THERAPY, (2012-04-01), vol. 23, no. 4, pages 356 - 366
GREENWALD D L ET AL, GENE THERAPY, (2013-04-01), vol. 20, no. 4, pages 425 - 434
Behrman, S. et al. .J. Cell Biol., 2011, Vol.192, No.6, 919-927
WO 2010138263 A2
US 8617876 B2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 September 2015 (24.09.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/143418 A3

(51) International Patent Classification:
A61K 48/00 (2006.01) *C12N 15/86* (2006.01)
A61K 31/7105 (2006.01)

(21) International Application Number:
PCT/US2015/021896

(22) International Filing Date:
20 March 2015 (20.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/969,027 21 March 2014 (21.03.2014) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 500 Kendall Street, Cambridge, MA 02142 (US).

(72) Inventors: **O'RIORDAN, Catherine**; C/o Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807 (US). **ADAMOWICZ, Matthew**; C/o Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807 (US).

(74) Agents: **ZHOU, Jie** et al.; Morrison & Foerster Llp, 425 Market Street, San Francisco, CA 94105-2482 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

[Continued on next page]

(54) **Title**: GENE THERAPY FOR RETINITIS PIGMENTOSA

FIG. 1A



FIG. 1B



FIGS. 1A & 1B

(57) **Abstract**: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.

WO 2015/143418 A3

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
19 November 2015

GENE THERAPY FOR RETINITIS PIGMENTOSA

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the priority benefit of U.S. Provisional Application Serial No. 61/969,027, filed March 21, 2014, which is incorporated herein by reference in its entirety.

SEQUENCE LISTING

[0002] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 159792010040SeqList.txt, date recorded: March 17, 2015, size: 63 KB).

FIELD OF THE INVENTION

[0003] The present invention relates to AAV vectors and methods of using AAV vectors for treating retinitis pigmentosa.

BRIEF SUMMARY OF THE INVENTION

[0004] Retinitis pigmentosa (RP) is the most common cause of inherited retinal degeneration, which is clinically characterized by night blindness and the loss of peripheral vision. Mutations in the rod visual pigment rhodopsin are recognized as the most common cause of autosomal dominant RP (ADRP), and although a number of treatments for rhodopsin RP have been proposed and tested in animal models and clinical studies, the disease remains incurable (Kalloniatis, M., *et al.* (2004) *Clin. Exp. Optom.* 87(2):65-80). Much data supports the view that rhodopsin RP is a protein-misfolding disease in which the misfolding or misassembly of a mutant protein alters its cellular fate and induces cell death (Gregersen, N. *et al.* (2006) *Annu. Rev. Genomics Hum. Genet.* 7:103-24). Known RP mutations in the rhodopsin gene include missense and short, in-frame deletion mutations, with a single base substitution in codon 23 (P23H) of the rhodopsin gene accounting for ~7% of all cases of dominant Retinitis Pigmentosa in the US (Dryja, T.P., *et al.* (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92(22):10177-81). In cultured cells, the P23H mutant protein, unlike wild type (WT) protein, is retained in the ER, leading to induction of the unfolded protein response (UPR), inhibition of the proteasome, and aggregation of the mutant protein

into oligomeric, high molecular weight species that form intracellular inclusions (Saliba, R.S., *et al.* (2002) *J. Cell Sci.* 115:2907-18). Similarly, P23H rhodopsin mislocalizes and/or aggregates in the rod cells of animal RP models (Olsson, J.E., *et al.* (1992) *Neuron* 9(5):815-30), suggesting that cell culture models may be predictive of *in vivo* models of this disease. What is needed is a means of ameliorating the symptoms of RP.

[0005] The invention described herein provides methods for treating retinitis pigmentosa in a mammal, comprising administering to the eye of the mammal a recombinant adeno-associated virus (rAAV) viral particle comprising a vector encoding a miR-708. In some embodiments, the rAAV vector comprising nucleic acid encoding a miR-708 and rhodopsin. In some embodiments, the invention provides methods for treating retinitis pigmentosa comprising administering to the eye of the mammal a first rAAV viral particle comprising a first rAAV vector comprising nucleic acid encoding a miR-708 and a second rAAV viral particle comprising a second rAAV vector comprising nucleic acid encoding a rhodopsin. In other embodiments, the invention provides methods for treating retinitis pigmentosa comprising administering to the eye of the mammal a rAAV viral particle comprising a rAAV vector comprising nucleic acid encoding a miR-708 and rhodopsin. In some embodiments, treating retinitis pigmentosa comprises reducing or preventing symptoms associated with the retinitis pigmentosa. In some embodiments or the invention, methods of treating retinitis pigmentosa include methods of reducing a symptom associated with RP, methods of preventing retinal degeneration, methods for arresting progression of RP, methods for increasing photoreceptor function, and the like. Symptoms and/or pathology of RP include but are not limited to loss of sight, loss of night vision, loss of peripheral visual fields, loss of ERG function; loss of visual acuity and contrast sensitivity; loss of visually guided behavior, reduction in rod photoreceptor function, rod photoreceptor cell death, decreased scotopic vision, reduction in retinal cell changes (loss of photoreceptor structure or function; thinning or thickening of the outer nuclear layer (ONL); thinning or thickening of the outer plexiform layer (OPL); disorganization followed by loss of rod and cone outer segments; shortening of the rod and cone inner segments; retraction of bipolar cell dendrites; thinning or thickening of the inner retinal layers including inner nuclear layer, inner plexiform layer, ganglion cell layer and nerve fiber layer; opsin mislocalization; overexpression of neurofilaments; and the like. In some embodiments, the invention

provides methods to prevent deterioration of rod cell function and rod cell death and cone cell function and cone cell death.

[0006] In some aspects, the invention provides methods for treating endoplasmic reticulum (ER) stress in a cell comprising administering to the mammal a rAAV viral particle comprising a rAAV vector comprising nucleic acid encoding a miR-708. In some embodiments, the mammal has or is at risk of having RP. In some embodiments, the mammal is a human that has or is at risk of having RP. In some embodiments, the rAAV particle is administered to an eye of the mammal. In some embodiments, the cell is an ocular cell. In further embodiments, the cell is a photoreceptor cell. In yet further embodiments, the cell is a rod photoreceptor cell. In some embodiments, the method comprises reducing one or more cellular markers of ER stress. In further embodiments, the one or more cellular marker of ER stress is spliced XBP-1, CHOP or Grp78. In some embodiments, the rAAV vector comprises nucleic acid encoding a miR-708 and rhodopsin. In other embodiments, the invention provides methods for treating endoplasmic reticulum (ER) stress in a cell comprising administering to the mammal a first rAAV vector comprising nucleic acid encoding a miR-708 and a second rAAV viral particle comprising a second rAAV vector comprising nucleic acid encoding a rhodopsin.

[0007] In some embodiments of the invention, the nucleic acid encoding miR-708 is operably linked to a promoter. In some embodiments, the promoter is capable of expressing the miR-708 in photoreceptor cells (*e.g.*, a rod photoreceptor cell). In further embodiments, the promoter comprises a rhodopsin kinase (RK) promoter or an opsin promoter. In other embodiments of the invention, the nucleic acid encoding rhodopsin is operably linked to a promoter. In some embodiments, the promoter is capable of expressing the rhodopsin in photoreceptor cells (*e.g.*, a rod photoreceptor cell). In further embodiments, the promoter comprises a RK promoter or an opsin promoter.

[0008] In some embodiments, the invention provides methods to treat RP and/or ER stress comprising administering to a mammal, a rAAV particle comprising a rAAV vector comprising nucleic acid encoding miR-708 and rhodopsin. In some embodiments, the nucleic acid encoding miR-708 and the nucleic acid encoding rhodopsin are operably linked to one RK promoter. In other embodiments, the nucleic acid encoding miR-708 is operably linked to a first RK promoter or a first opsin promoter and the nucleic acid encoding

rhodopsin is operably linked to a second RK promoter or a second opsin promoter. In some embodiments, the first and/or second opsin promoter includes an MVM intron (*e.g.*, an intron of SEQ ID NO:23). In some embodiments, the nucleic acid encoding miR-708 is 5' to the nucleic acid encoding rhodopsin. In other embodiments, the nucleic acid encoding miR-708 is 3' to the nucleic acid encoding rhodopsin. In some embodiments, the nucleic acid encoding miR-708 is operably linked to the chicken β-actin (CBA) promoter. In some embodiments, the nucleic acid encoding rhodopsin is operably linked to the chicken β-actin (CBA) promoter. In some embodiments, a sequence derived from a minute virus of mouse (MVM) intron is located 3' to the promoter. In some embodiments, the MMV intron comprises the nucleotide sequence of SEQ ID NO:23. In some embodiments, the promoter further comprises i) a CMV enhancer; ii) a sequence derived from a photoreceptor specific transcription factor; iii)a sequence derived from a rod photoreceptor specific transcription factor; iv) a sequence derived from a neural retinal basic zipper factor; v) a sequence derived from a cone rod homeobox-containing transcription factor sequence; vi) a CMV enhancer and at least one or more of a sequence derived from a photoreceptor specific transcription factor, a sequence derived from a rod photoreceptor specific transcription factor, a sequence derived from a neural retinal basic zipper factor; a sequence derived from a cone rod homeobox-containing transcription factor sequence; vii)a neural retinal basic leucine zipper factor, a CMV enhancer and an Opsin promoter (-500 to +17); viii) a neural retinal basic leucine zipper factor, a CMV enhancer, an Opsin promoter (-500 to +17), and an MVM intron; ix) a CMV enhancer comprising SEQ ID NO:29; x) a neural retinal basic leucine zipper factor sequence comprising SEQ ID NO:30; xi) a sequence derived from a cone rod homeobox-containing transcription factor sequence comprising SEQ ID NO:28; xii) a CMV enhancer comprising SEQ ID NO:29 and at least one or more of a sequence derived from a photoreceptor specific transcription factor, a sequence derived from a rod photoreceptor specific transcription factor, a sequence derived from a neural retinal basic zipper factor comprising SEQ ID NO:30; a sequence derived from a cone rod homeobox-containing transcription factor sequence comprising SEQ ID NO:28; xiii) a neural retinal basic leucine zipper factor comprising SEQ ID NO:30, a CMV enhancer comprising SEQ ID NO:29 and an Opsin promoter (-500 to +17) comprising SEQ ID NO:22; or xiv) a neural retinal basic leucine zipper factor comprising SEQ ID NO:28, a CMV enhancer comprising SEQ ID NO:29, an Opsin promoter (-500 to +17) comprising SEQ ID NO:22, and an MVM intron comprising SEQ ID NO:23. In some embodiments, the nucleic acid encoding miR-

708 is embedded in an intron. In some embodiments, the nucleic acid encoding miR-708 comprises an endogenous miR-708 scaffold or a miR-155 scaffold.

[0009] In some embodiments, the invention provides methods to treat RP and/or ER stress comprising administering to a mammal, a rAAV particle comprising a rAAV vector comprising nucleic acid encoding miR-708. In some embodiments, the nucleic acid encoding miR-708 comprises the nucleic acid of SEQ ID NO:1. In some embodiments, the nucleic acid encoding miR-708 comprises a nucleic acid having about at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:1.

[0010] In some embodiments, the invention provides methods to treat RP and/or ER stress comprising administering to a mammal, a rAAV particle comprising a rAAV vector comprising nucleic acid encoding rhodopsin. In some embodiments, the rhodopsin is mammalian rhodopsin or functional equivalent thereof. In some embodiments, the rhodopsin is human rhodopsin or functional equivalent thereof. In some embodiments, the rhodopsin lacks the 3' untranslated region (UTR) miR-708 target sequence. In some embodiments, the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid in the miR-708 target sequence. In some embodiments, the substitution, insertion or deletion reduces or prevents recognition by miR-708. In some embodiments, the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid in the miR-708 target sequence wherein the miR-708 target sequence is SEQ ID NO:19. In some embodiments, expression of the rhodopsin is refractory to suppression by miR-708. In some embodiments, the rhodopsin comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin comprises an amino acid sequence having about at least t 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:2. In some embodiments, the nucleic acid encoding the rhodopsin comprises nucleic acid of SEQ ID NO:3. In some embodiments, the nucleic acid encoding the rhodopsin comprises a nucleic acid having about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:3.

[0011] In some embodiments, the invention provides methods to treat RP and/or ER stress comprising administering to a mammal, a rAAV particle comprising a polynucleotide of SEQ ID NO:5., SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9. In some embodiments, the AAV viral particle comprises a recombinant viral genome

comprises a polynucleotide having about at least t 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:5, SEQ ID NO:6 SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27.

[0012] In some embodiments, the invention provides methods to treat RP and/or ER stress comprising administering to a mammal, a rAAV particle wherein the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, or mouse AAV capsid rAAV2/HBoV1 serotype capsid. In some embodiments, the rAAV viral particle comprises an AAV serotype 5 capsid. In some embodiments, the rAAV viral particle comprises an AAV serotype 5 tyrosine mutant capsid.

[0013] In some embodiments, the invention provides methods of treating RP and/or ER stress comprising administering to a mammal a first rAAV virus particle comprising nucleic acid encoding miR-708 and a second rAAV virus particle encoding rhodopsin. In some embodiments, the first rAAV particle and/or the second rAAV virus particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, or mouse AAV capsid rAAV2/HBoV1 serotype capsid. In some embodiments, the first rAAV viral particle and/or the second rAAV viral particle comprise an AAV serotype 5 capsid. In some embodiments, the first rAAV viral particle and/or the second rAAV viral particle comprise an AAV serotype 5 tyrosine mutant capsid.

[0014] In some embodiments, the invention provides methods to treat RP and/or ER stress comprising administering to a mammal, a rAAV particle wherein the AAV vector comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITR. In some embodiments, the invention provides methods of treating RP and/or ER stress comprising administering to a mammal a first rAAV virus particle comprising a first rAAV vector comprising nucleic acid encoding miR-708 and a second rAAV virus particle comprising a second rAAV vector encoding

rhodopsin. In some embodiments, the first rAAV vector and/or the second rAAV virus vector comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITR.

[0015] In some embodiments of the invention, the rAAV vectors of the method comprise AAV serotype 2 ITRs. In some embodiments, the ITR and the capsid of the rAAV viral particle are derived from the same AAV serotype. In other embodiments, the ITR and the capsid of the rAAV viral particles are derived from different AAV serotypes. In some embodiments, the rAAV viral particle comprises an AAV-5 capsid, and wherein the vector comprises AAV2 ITRs. In some embodiments, the rAAV viral particle comprises an AAV-5 tyrosine mutant capsid, and wherein the vector comprises AAV2 ITRs.

[0016] In some embodiments, the invention provides methods to treat RP and/or ER stress in a mammal wherein the rAAV particles are injected into the subretinal space of the retina of the mammal. In some embodiments, the rAAV is administered to more than one location of the subretinal space of the retina of the mammal. In other embodiments, the rAAV particles are injected intravitreally to the mammal. In some embodiments, at least 10-30% of the photoreceptor cells (*e.g.*, rod photoreceptor cells) are transduced by the AAV.

[0017] In some embodiments, the invention provides methods to treat RP and/or ER stress in a mammal, wherein the mammal has a mutation in the endogenous rhodopsin gene. In some embodiments, the mutation in the endogenous rhodopsin gene is an autosomal dominant mutation. In some embodiments, the retinitis pigmentosa is autosomal dominant retinitis pigmentosa. In some embodiments, the mammal is a human. In some embodiments, the human has a P23H mutation in the endogenous rhodopsin gene.

[0018] In some embodiments, the invention provides methods of treating RP and/or ER stress comprising administering to a mammal a first rAAV virus particle comprising nucleic acid encoding miR-708 and a second rAAV virus particle encoding rhodopsin wherein the first rAAV viral particle encoding the miR-708 and the second rAAV viral particle encoding the rhodopsin are administered to the mammal at the same time. In some embodiments, the first rAAV viral particle encoding the miR-708 and the rAAV viral particle encoding the rhodopsin are administered to the mammal sequentially. In some

embodiments, the rAAV viral particle encoding the miR-708 is administered to the mammal first and the rAAV viral particle encoding the rhodopsin is administered to the mammal second. In some embodiments, the rAAV viral particle encoding the rhodopsin is administered to the mammal first and the rAAV viral particle encoding the miR-708 is administered to the mammal second.

[0019] In some embodiments of the invention, the rAAV viral particles are in a pharmaceutical composition. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the invention provides a composition comprising a rAAV particle comprising a rAAV vector comprising nucleic acid encoding miR-708 used in the methods described herein. In some embodiments, the invention provides a rAAV particle comprising a rAAV vector comprising nucleic acid encoding a miR708 for use in treating retitinis pigmentosa or reducing ER stress according to any of the methods described herein. In some embodiments, the invention provides a first rAAV particle comprising a rAAV vector comprising nucleic acid encoding a miR708 and a second rAAV particle comprising a rAAV vector comprising nucleic acid encoding rhodopsin for use in treating retitinis pigmentosa or reducing ER stress according to any of the methods described herein. In some embodiments, the rAAV particle comprises a rAAV vector comprising nucleic acid encoding a miR708 and rhodopsin for use in treating retitinis pigmentosa or reducing ER stress according to any one of the methods described herein.

[0020] In some aspects, the invention described herein provides compositions for treating retinitis pigmentosa in a mammal, comprising a recombinant adeno-associated virus (rAAV) viral particle comprising a vector encoding a miR-708. In some embodiments, the rAAV vector comprising nucleic acid encoding a miR-708 further comprises nucleic acid encoding rhodopsin. In some embodiments, the invention provides compositions for treating retinitis pigmentosa comprising a first rAAV viral particle comprising a first rAAV vector comprising nucleic acid encoding a miR-708 and a second rAAV viral particle comprising a second rAAV vector comprising nucleic acid encoding a rhodopsin. In other embodiments, the invention provides compositions for treating retinitis pigmentosa comprising a rAAV viral particle comprising a rAAV vector comprising nucleic acid encoding a miR-708 and rhodopsin.

[0021] In some aspects, the invention provides compositions for treating endoplasmic reticulum (ER) stress in a cell comprising a rAAV viral particle comprising a rAAV vector comprising nucleic acid encoding a miR-708. In some aspects, the invention provides compositions for treating endoplasmic reticulum (ER) stress in a cell comprising a rAAV viral particle comprising a rAAV vector comprising nucleic acid encoding a miR-708 and rhodopsin. In some embodiments, the mammal with ER stress has or is at risk of having RP. In some embodiments, the mammal with ER stress is a human who has or is at risk of having RP. In some embodiments, the rAAV particle is administered to an eye of the mammal. In some embodiments, the cell is an ocular cell. In further embodiments, the cell is a photoreceptor cell. In yet further embodiments, the cell is a rod photoreceptor cell. In some embodiments, the composition reduces one or more cellular markers of ER stress. In further embodiments, the one or more cellular marker of ER stress is spliced XBP-1, CHOP or Grp78. In some embodiments, the rAAV vector comprises nucleic acid encoding a miR-708 further comprises nucleic acid encoding rhodopsin. In other embodiments, the invention provides compositions for treating endoplasmic reticulum (ER) stress in a cell comprising a first rAAV vector comprising nucleic acid encoding a miR-708 and a second rAAV viral particle comprising a second rAAV vector comprising nucleic acid encoding a rhodopsin.

[0022] In some embodiments of the invention, the nucleic acid encoding miR-708 is operably linked to a promoter. In some embodiments, the promoter is capable of expressing the miR-708 in photoreceptor cells (*e.g.*, rod photoreceptor cells). In further embodiments, the promoter comprises a rhodopsin kinase (RK) promoter or an opsin promoter. In other embodiments of the invention, the nucleic acid encoding rhodopsin is operably linked to a promoter. In some embodiments, the promoter is capable of expressing the rhodopsin in photoreceptor cells (*e.g.*, rod photoreceptor cells). In further embodiments, the promoter comprises a RK promoter or an opsin promoter.

[0023] In some embodiments, the invention provides compositions to treat RP and/or ER stress comprising a rAAV particle comprising a rAAV vector comprising nucleic acid encoding miR-708 and rhodopsin. In some embodiments, the nucleic acid encoding miR-708 and the nucleic acid encoding rhodopsin are operably linked to one RK promoter. In other embodiments, the nucleic acid encoding miR-708 is operably linked to a first RK promoter or a first opsin promoter and the nucleic acid encoding rhodopsin is operably

linked to a second RK promoter or a second opsin promoter. In some embodiments, the first and/or second opsin promoter includes an MVM intron (*e.g.*, an intron of SEQ ID NO:23). In some embodiments, the nucleic acid encoding miR-708 is 5' to the nucleic acid encoding rhodopsin. In other embodiments, the nucleic acid encoding miR-708 is 3' to the nucleic acid encoding rhodopsin. In some embodiments, the nucleic acid encoding miR-708 is operably linked to the chicken β-actin (CBA) promoter. In some embodiments, the nucleic acid encoding rhodopsin is operably linked to the chicken β-actin (CBA) promoter. In some embodiments, the first and/or second opsin promoter includes an MVM intron (*e.g.*, an intron of SEQ ID NO:23). In some embodiments, the nucleic acid encoding miR-708 is 5' to the nucleic acid encoding rhodopsin. In other embodiments, the nucleic acid encoding miR-708 is 3' to the nucleic acid encoding rhodopsin. In some embodiments, the nucleic acid encoding miR-708 is operably linked to the chicken β-actin (CBA) promoter. In some embodiments, the nucleic acid encoding rhodopsin is operably linked to the chicken β-actin (CBA) promoter. In some embodiments, a sequence derived from a minute virus of mouse (MVM) intron is located 3' to the promoter. In some embodiments, the MMV intron comprises the nucleotide sequence of SEQ ID NO:23. In some embodiments, the promoter further comprises i) a CMV enhancer; ii) a sequence derived from a photoreceptor specific transcription factor; iii)a sequence derived from a rod photoreceptor specific transcription factor; iv) a sequence derived from a neural retinal basic zipper factor; v) a sequence derived from a cone rod homeobox-containing transcription factor sequence; vi) a CMV enhancer and at least one or more of a sequence derived from a photoreceptor specific transcription factor, a sequence derived from a rod photoreceptor specific transcription factor, a sequence derived from a neural retinal basic zipper factor; a sequence derived from a cone rod homeobox-containing transcription factor sequence; vii) a neural retinal basic leucine zipper factor, a CMV enhancer and an Opsin promoter (-500 to +17); viii) a neural retinal basic leucine zipper factor, a CMV enhancer, an Opsin promoter (-500 to +17), and an MVM intron; ix) a CMV enhancer comprising SEQ ID NO:29; x) a neural retinal basic leucine zipper factor sequence comprising SEQ ID NO:30; xi) a sequence derived from a cone rod homeobox-containing transcription factor sequence comprising SEQ ID NO:28; xii) a CMV enhancer comprising SEQ ID NO:29 and at least one or more of a sequence derived from a photoreceptor specific transcription factor, a sequence derived from a rod photoreceptor specific transcription factor, a sequence derived from a neural retinal basic zipper factor comprising SEQ ID NO:30; a sequence derived from a cone rod

homeobox-containing transcription factor sequence comprising SEQ ID NO:28; xiii) a neural retinal basic leucine zipper factor comprising SEQ ID NO:30, a CMV enhancer comprising SEQ ID NO:29 and an Opsin promoter (-500 to +17) comprising SEQ ID NO:22; or xiv) a neural retinal basic leucine zipper factor comprising SEQ ID NO:28, a CMV enhancer comprising SEQ ID NO:29, an Opsin promoter (-500 to +17) comprising SEQ ID NO:22, and an MVM intron comprising SEQ ID NO:23. In some embodiments, the nucleic acid encoding miR-708 is embedded in an intron. In some embodiments, the nucleic acid encoding miR-708 comprises an endogenous miR-708 scaffold or a miR-155 scaffold.

[0024] In some embodiments, the invention provides compositions to treat RP and/or ER stress comprising a rAAV particle comprising a rAAV vector comprising nucleic acid encoding miR-708. In some embodiments, the nucleic acid encoding miR-708 comprises the nucleic acid of SEQ ID NO:1. In some embodiments, the nucleic acid encoding miR-708 comprises a nucleic acid having about at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:1.

[0025] In some embodiments, the invention provides compositions to treat RP and/or ER stress comprising a rAAV particle comprising a rAAV vector comprising nucleic acid encoding rhodopsin. In some embodiments, the rhodopsin is mammalian rhodopsin or functional equivalent thereof. In some embodiments, the rhodopsin is human rhodopsin or functional equivalent thereof. In some embodiments, the rhodopsin lacks the 3' untranslated region (UTR) miR-708 target sequence. In some embodiments, the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid in the miR-708 target sequence. In some embodiments, the substitution, insertion or deletion reduces or prevents recognition by miR-708. In some embodiments, the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid in the miR-708 target sequence wherein the miR-708 target sequence is SEQ ID NO:19. In some embodiments, expression of the rhodopsin is refractory to suppression by miR-708. In some embodiments, the rhodopsin comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin comprises an amino acid sequence having about at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:2. In some embodiments, the nucleic acid encoding the rhodopsin comprises nucleic acid of SEQ ID NO:3. In some embodiments, the nucleic acid encoding the rhodopsin comprises a

nucleic acid having about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:3.

[0026] In some embodiments, the invention provides compositions to treat RP and/or ER stress comprising a rAAV particle comprising a polynucleotide of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9. In some embodiments, the AAV viral particle comprises a recombinant viral genome comprises a polynucleotide having about at least t 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27.

[0027] In some embodiments, the invention provides compositions to treat RP and/or ER stress comprising a rAAV particle wherein the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, or mouse AAV capsid rAAV2/HBoV1 serotype capsid. In some embodiments, the rAAV viral particle comprises an AAV serotype 5 capsid. In some embodiments, the rAAV viral particle comprises an AAV serotype 5 tyrosine mutant capsid.

[0028] In some embodiments, the invention provides compositions for treating RP and/or ER stress comprising a first rAAV virus particle comprising nucleic acid encoding miR-708 and a second rAAV virus particle encoding rhodopsin. In some embodiments, the first rAAV particle and/or the second rAAV virus particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, or mouse AAV capsid rAAV2/HBoV1 serotype capsid. In some embodiments, the first rAAV viral particle and/or the second rAAV viral particle comprise an AAV serotype 5 capsid. In some embodiments, the first rAAV viral particle and/or the second rAAV viral particle comprise an AAV serotype 5 tyrosine mutant capsid.

[0029] In some embodiments, the invention provides compositions to treat RP and/or ER stress comprising a rAAV particle wherein the AAV vector comprises an AAV1, AAV2,

AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITR. In some embodiments, the invention provides compositions for treating RP and/or ER stress comprising a first rAAV virus particle comprising a first rAAV vector comprising nucleic acid encoding miR-708 and a second rAAV virus particle comprising a second rAAV vector encoding rhodopsin. In some embodiments, the first rAAV vector and/or the second rAAV virus vector comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITR.

[0030] In some embodiments of the invention, the rAAV vectors of the composition comprise AAV serotype 2 ITRs. In some embodiments, the ITR and the capsid of the rAAV viral particle are derived from the same AAV serotype. In other embodiments, the ITR and the capsid of the rAAV viral particles are derived from different AAV serotypes. In some embodiments, the rAAV viral particle comprises an AAV-5 capsid, and wherein the vector comprises AAV2 ITRs. In some embodiments, the rAAV viral particle comprises an AAV-5 tyrosine mutant capsid, and wherein the vector comprises AAV2 ITRs.

[0031] In some embodiments, the invention provides compositions to treat RP and/or ER stress in a mammal, wherein the mammal has a mutation in the endogenous rhodopsin gene. In some embodiments, the mutation in the endogenous rhodopsin gene is an autosomal dominant mutation. In some embodiments, the retinitis pigmentosa is autosomal dominant retinitis pigmentosa. In some embodiments, the mammal is a human. In some embodiments, the human has a P23H mutation in the endogenous rhodopsin gene.

[0032] In some embodiments, the invention provides kits to treat RP or to reduce ER stress in a mammal comprising an effective amount of rAAV particles according to the methods described herein. In some embodiments, the kits comprise an effective amount of a composition as described herein. In some embodiments, the kit comprises an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708. In some embodiments, the kit comprises an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708 and rhodopsin. In

some embodiments, the kit comprises an effective amount of first rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708 and an effective amount of second rAAV particles comprising a second rAAV vector comprising nucleic acid encoding rhodopsin. In further embodiments, the kit comprising instructions for use of the rAAV particles in the treatment of retinitis pigmentosa and/or reduction of ER stress. In further embodiments, the kit comprising instructions for use in any one of the methods described herein.

[0033] In some aspects, the invention provides an article of manufacture comprising an effective amount of rAAV particles according to the methods described herein. In some embodiments, the article of manufacture comprises an effective amount of any of the compositions described herein. In some embodiments, the article of manufacture comprises an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708. In some embodiments, the article of manufacture comprises an effective amount of rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708 and rhodopsin. In some embodiments, the article of manufacture comprises an effective amount of first rAAV particles comprising a rAAV vector comprising nucleic acid encoding miR-708 and an effective amount of second rAAV particles comprising a second rAAV vector comprising nucleic acid encoding rhodopsin.

[0034] Is some aspects, the invention provides a nucleic acid comprising an intron derived from an MVM. In some embodiments, the MVM intron comprises SEQ ID NO:23. In some embodiments, the nucleic acid further comprises a promoter. In some embodiments, the nucleic acid further comprises an enhancer. In some embodiments, the promoter is located 5' to the MVM intron. In some embodiments, the invention provides an expression construct comprising the nucleic acid. In some embodiments, the invention provides a vector comprising the nucleic acid or the expression construct. In some embodiments, the invention provides a cell comprising the nucleic acid, the expression construct, or the vector.

BRIEF DESCRIPTION OF THE DRAWINGS

[0035] **FIGS. 1A & 1B** show the localization of wild-type (**FIG. 1A**) and P23H mutant (**FIG. 1B**) rhodopsin in human retinal pigmented epithelial cells. Cells are stained for rhodopsin (green), α-tubulin (red), and DNA (blue). The staining pattern of wild-type rhodopsin is characteristic of membrane localization (solid arrow), whereas the staining pattern of P23H mutant rhodopsin is characteristic of perinuclear/reticular localization (dashed arrow).

[0036] **FIGS. 2A & 2B** show that P23H mutant rhodopsin forms non-native oligomers and retains ER-specific oligosaccharides. (**FIG. 2A**) Western blot of detergent soluble extracts from cells expressing wild-type ("wt") or P23H mutant rhodopsin. (**FIG. 2B**) Western blot of detergent soluble extracts from cells expressing wild-type ("wt") or P23H mutant rhodopsin. Extracts were treated with Endoglycosidase H ("Endo-H") or left untreated.

[0037] **FIGS. 3A & 3B** show that cells expressing P23H rhodopsin have higher expression of UPR markers and a higher propensity toward apoptosis. (**FIG. 3A**) Relative expression of C/EBP homologous protein (CHOP; a.k.a. *Ddit3*), binding immunoglobulin protein (BiP; a.k.a. *Hspa5*), and rhodopsin genes in cells expressing wild-type ("wt") or P23H mutant rhodopsin. The relative expression of each gene was compared to beta-glucoronidase expression using the $\Delta\Delta C_t$ method. (**FIG. 3B**) Percentage of apoptotic cells in cells expressing control (pcDNA), wild-type rhodopsin, or P23H mutant rhodopsin, as measured by TUNEL staining.

[0038] **FIG. 4** shows a diagram of the construction of an expression vector for expressing miR-708 under the control of a ubiquitous promoter (chicken β-actin, CBA) or a photoreceptor-specific promoter (rhodopsin kinase, RK). DNA encoding the miR-708 stem and loop sequences was synthesized and cloned between 5' and 3' miR-155 scaffold sequence. This scaffold sequence contains the target sites required for Drosha to process pri-miR-708 into pre-miR-708 in the nucleus, allowing subsequent processing of pre-miR-708 by Dicer in the cytoplasm.

[0039] **FIG. 5** shows the expression of rhodopsin protein in cells expressing miR-708 or a control miRNA, relative to untransfected cells. All cells are HEK-293 cells expressing

mP23H rhodopsin which has a 3'UTR miR708 target sequence. Rhodopsin protein expression is normalized to hGAPDH expression. Rhodopsin protein levels are decreased in the presence of miR708 compared to control miR.

[0040] **FIG. 6** shows that HEK-293 cells expressing mP23H rhodopsin have reduced RNA levels of the UPR marker genes CHOP and BiP upon expression of miR-708, compared to cells expressing a control miRNA ("Scramble").

[0041] **FIGS. 7A & 7B** show that down-regulation of rhodopsin by endogenous miR-708 is dependent upon the presence of a miR-708 target sequence in the rhodopsin 3' UTR. HEK-293 cells were transfected with a mouse P23H rhodopsin gene including the miR-708 target sequence (**FIG. 7A**), or with a human P23H rhodopsin gene lacking the miR-708 target sequence (**FIG. 7B**). Cells were also transfected with a control pre-miRNA or an anti-miR-708 pre-miRNA to inhibit endogenous miR-708. Rhodopsin protein was measured relative to hGAPDH protein, and rhodopsin mRNA was measured relative to hGAPDH mRNA. Levels of endogenous miR-708 are also shown (right axis and rightmost two columns in **FIGS. 7A & 7B**).

[0042] **FIG. 8** depicts a diagram of an AAV vector for expressing miR-708 in rod photoreceptors. Relevant vector features are labeled.

[0043] **FIGS. 9A & 9B** show that expression of miR-708 using an AAV vector down-regulates P23H mutant rhodopsin. (**FIG. 9A**) Expression of miR-708 in WERI or RPE cells upon transfection of a vector encoding miR-708 driven by the RK promoter or a control miRNA ("Scramble"). Expression is depicted relative to expression of miR-16. (**FIG. 9B**) Expression of P23H rhodopsin mRNA in WERI cells transfected with a pRK-miR-708 plasmid, relative to cells transfected with a control plasmid.

[0044] **FIGS. 10A-10C** show that subretinal delivery of an AAV5 miR-708 vector results in knockdown of mouse rhodopsin. (**FIG. 10A**) Expression of mRhodopsin in mouse retinas injected with AAV5 miR-708 or AAV5 miR-Control. (**FIG. 10B**) Expression of RdCVF in mouse retinas injected with AAV5 miR-708 or AAV5 miR-Control. (**FIG. 10C**) Expression of miR-708 in mouse retinas injected with AAV5 miR-708 or AAV5 miR-Control.

[0045] **FIGS. 11A & 11B** show that treatment of eyes with AAV5 miR-708 reduces rod-mediated, but not cone-mediated, responses. (**FIG. 11A**) Three representative electroretinograms representing scoptopic responses in eyes receiving AAV5 miR-708 or AAV5 miR-Control ("Scram"). (**FIG. 11B**) Three representative electroretinograms representing photopic responses in the same eyes as in (**FIG. 11A**) receiving AAV5 miR-708 or AAV5 miR-Control ("Scram").

[0046] **FIG. 12** provides a diagram of the miR-708 intron-embedded hRhodopsin suppression/replacement vector.

[0047] **FIG. 13** shows that an intron-embedded miR-708 vector reduces expression of mRhodopsin, hCHOP, and hBiP in WERI cells transfected with P23H mRhodopsin, as compared to a miR-Control vector.

[0048] **FIG. 14** shows that miR-708 expression from the intron-embedded vector has reduced expression compared to the non-embedded vector in WERI cells, the caveat being that the intron-embedded vector pRK-hRHO-intron miR-708 also co-expresses hRhodopsin. All vectors driving miR-708 expression using the RK promoter had orders of magnitude lower expression than a vector using the CBA promoter.

[0049] **FIG. 15** shows that hRhodopsin expression from the intron-embedded suppression/replacement vector is refractory to knockdown by co-expressed miR-708. The levels of hRhodopsin RNA are the same in cells transfected with vectors expressing miR-708 or miR-Control.

[0050] **FIG. 16** shows that the miR-708 suppression/replacement vector reduces XBP-1 splicing, a marker of ER stress, in WERI cells expressing mutant rhodopsin. This reduction is observed only if the 3'UTR miR-708 target sequence is present in the rhodopsin transcript.

[0051] **FIG. 17** shows a diagram of a vector with the miR-708 human β-globin intron scaffold in the 3' UTR of the rhodopsin cDNA.

[0052] **FIG. 18** shows that a vector with the miR-708 human β-globin intron scaffold in the 3' UTR of the rhodopsin cDNA produces higher hRhodopsin and miR-708 expression than a vector with the scaffold in the 5' UTR.

[0053] **FIG. 19** shows a diagram of an alternate vector design using separate promoters to drive expression of miR-708 (RK promoter) and hRhodopsin (mouse opsin promoter).

[0054] **FIG. 20** shows hRhodopsin (left) and miR-708 (right) expression in WERI cells transfected with the specified vector. Expression is expressed as copy number calculated against a DNA standard.

[0055] **FIGS. 21A-C** show the levels of miR-708 (**FIG. 21A**), mouse rhodopsin (**FIG. 21B**), and human rhodopsin (**FIG. 21C**) in mouse retinas three weeks after subretinal injection with an AAV5 capsid vector driving expression of human rhodopsin and miR-708 (miR 708/708), or human rhodopsin and control miRNA (miR-Cont), in a miR-708 scaffold using the opsin promoter. For each experiment, expression is shown as fold expression, as compared to the contralateral, uninjected eye.

[0056] **FIG. 22** shows a schematic of the opsin promoter construct, including the neural retinal basic zipper factor sequence (NRL), the CMV enhancer, the opsin promoter, and the MVM intron sequence, which includes a hybrid intron sequence from CBA exon 1 and an intron from the minute virus of mice (MVM).

[0057] **FIG. 23A** shows a schematic of the miR-708 sequence embedded in a beta-globin intron.

[0058] **FIGS. 23B & 23C** show schematics of the miR-708 sequence in the context of either the miR-708 endogenous scaffold (**FIG. 23B**) or the miR-155 scaffold (**FIG. 23C**), embedded in a beta globin intron. The miR-155 "loop sequence" between the 5' and 3' miR flanking sequences is labeled in **FIG. 23C**.

[0059] **FIG. 24** shows the evaluation of candidate vectors harboring the miR-708 sequence, either in the miR-155 or the miR-708 scaffold (embedded in the beta-globin intron), and the human rhodopsin coding sequence (hRhodopsin; also lacking a 3'UTR miR-708 target sequence) driven by either the rhodopsin kinase (GRK1) promoter or the opsin (Ops) promoter. All four combinations were tested for effects on miR-708 and hRhodopsin expression, as shown.

2015230942 02 Nov 2020

DETAILED DESCRIPTION

[0060] It is to be understood that if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art in Australia or any other country.

[0060a] In the claims which follow and in the proceeding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features, integers, steps or components but not to preclude the presence or addition of further features integers, steps, components or groups thereof in various embodiments of the invention.

[0060b] The present invention provides methods for treating retinitis pigmentosa (RP) in a mammal, comprising administering to the eye of the mammal a recombinant adeno-associated virus (rAAV) viral particle comprising a vector encoding a miR-708. The miR-708 targets a region in the 3' untranslated region of the rhodopsin gene and as such, may suppress activity of a mutant rhodopsin associated with RP. In some aspects, the invention provides methods for treating retinitis pigmentosa in a mammal, comprising administering to the eye of the mammal a recombinant adeno-associated virus (rAAV) viral particle comprising a vector encoding a miR-708 and a wild-type rhodopsin nucleic acid. As such, the vector may suppress the activity of a mutant rhodopsin associated with RP while concurrently replacing the mutant rhodopsin with a wild-type rhodopsin. In some embodiments, the nucleic acid encoding the wild-type rhodopsin does not include the 3' UTR target of miR-708 such that the miR-708 will only target expression of mutant rhodopsin. The invention also provides compositions comprising rAAV particles encoding miR-708 and rAAV particles encoding rhodopsin. In some embodiments, the invention provides compositions comprising rAAV particles encoding both miR-708 and rhodopsin.

I. General Techniques

[0061] The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized methodologies described in *Molecular Cloning: A Laboratory Manual* (Sambrook *et al.*, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2012); *Current Protocols in Molecular Biology* (F.M. Ausubel, *et al.* eds., 2003); the series *Methods in Enzymology* (Academic Press, Inc.); *PCR 2: A Practical Approach* (M.J. MacPherson, B.D. Hames and G.R. Taylor eds., 1995); *Antibodies, A Laboratory Manual (*Harlow and Lane, eds., 1988); *Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications* (R.I. Freshney, 6th ed., J. Wiley and Sons, 2010); *Oligonucleotide Synthesis* (M.J. Gait, ed., 1984); *Methods in Molecular Biology*, Humana Press; *Cell Biology: A Laboratory Notebook* (J.E. Cellis, ed., Academic Press, 1998); *Introduction to Cell and Tissue Culture* (J.P. Mather and P.E. Roberts, Plenum Press, 1998); *Cell and Tissue Culture: Laboratory Procedures* (A. Doyle, J.B. Griffiths, and D.G. Newell, eds., J. Wiley and Sons, 1993-8); *Handbook of Experimental*

Immunology (D.M. Weir and C.C. Blackwell, eds., 1996); *Gene Transfer Vectors for Mammalian Cells* (J.M. Miller and M.P. Calos, eds., 1987); *PCR: The Polymerase Chain Reaction*, (Mullis *et al.*, eds., 1994); *Current Protocols in Immunology* (J.E. Coligan *et al.*, eds., 1991); *Short Protocols in Molecular Biology* (Ausubel *et al.*, eds., J. Wiley and Sons, 2002); *Immunobiology* (C.A. Janeway *et al.*, 2004); *Antibodies* (P. Finch, 1997); *Antibodies: A Practical Approach* (D. Catty., ed., IRL Press, 1988-1989); *Monoclonal Antibodies: A Practical Approach* (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); *Using Antibodies: A Laboratory Manual* (E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press, 1999); *The Antibodies* (M. Zanetti and J. D. Capra, eds., Harwood Academic Publishers, 1995); and *Cancer: Principles and Practice of Oncology* (V.T. DeVita *et al.*, eds., J.B. Lippincott Company, 2011).

II. Definitions

[0062] A "vector," as used herein, refers to a recombinant plasmid or virus that comprises a nucleic acid to be delivered into a host cell, either in vitro or in vivo.

[0063] The term "polynucleotide" or "nucleic acid" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes, but is not limited to, single-, double- or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups. Alternatively, the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphoramidates and thus can be an oligodeoxynucleoside phosphoramidate ($P\text{-}NH_2$) or a mixed phosphoramidate-phosphodiester oligomer. In addition, a double-stranded polynucleotide can be obtained from the single stranded polynucleotide product of chemical synthesis either by synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using a DNA polymerase with an appropriate primer.

[0064] The terms "polypeptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length. Such polymers of

amino acid residues may contain natural or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and fragments thereof are encompassed by the definition. The terms also include post-expression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like. Furthermore, for purposes of the present invention, a "polypeptide" refers to a protein which includes modifications, such as deletions, additions, and substitutions (generally conservative in nature), to the native sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.

[0065] A "recombinant viral vector" refers to a recombinant polynucleotide vector comprising one or more heterologous sequences (*i.e.*, nucleic acid sequence not of viral origin). In the case of recombinant AAV vectors, the recombinant nucleic acid is flanked by at least one, preferably two, inverted terminal repeat sequences (ITRs).

[0066] A "recombinant AAV vector (rAAV vector)" refers to a polynucleotide vector comprising one or more heterologous sequences (*i.e.*, nucleic acid sequence not of AAV origin) that are flanked by at least one, preferably two, AAV inverted terminal repeat sequences (ITRs). Such rAAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been infected with a suitable helper virus (or that is expressing suitable helper functions) and that is expressing AAV rep and cap gene products (*i.e.* AAV Rep and Cap proteins). When a rAAV vector is incorporated into a larger polynucleotide (*e.g.*, in a chromosome or in another vector such as a plasmid used for cloning or transfection), then the rAAV vector may be referred to as a "pro-vector" which can be "rescued" by replication and encapsidation in the presence of AAV packaging functions and suitable helper functions. An rAAV vector can be in any of a number of forms, including, but not limited to, plasmids, linear artificial chromosomes, complexed with lipids, encapsulated within liposomes, and, most preferable, encapsidated in a viral particle, particularly an AAV particle. A rAAV vector can be packaged into an AAV virus capsid to generate a "recombinant adeno-associated viral particle (rAAV particle)".

[0067] "Heterologous" means derived from a genotypically distinct entity from that of the rest of the entity to which it is compared or into which it is introduced or incorporated. For example, a polynucleotide introduced by genetic engineering techniques into a different cell type is a heterologous polynucleotide (and, when expressed, can encode a heterologous polypeptide). Similarly, a cellular sequence (*e.g.*, a gene or portion thereof) that is incorporated into a viral vector is a heterologous nucleotide sequence with respect to the vector.

[0068] The term "transgene" refers to a polynucleotide that is introduced into a cell and is capable of being transcribed into RNA and optionally, translated and/or expressed under appropriate conditions. In aspects, it confers a desired property to a cell into which it was introduced, or otherwise leads to a desired therapeutic or diagnostic outcome. In another aspect, it may be transcribed into a molecule that mediates RNA interference, such as siRNA.

[0069] The terms "genome particles (gp)," "genome equivalents," or "genome copies" as used in reference to a viral titer, refer to the number of virions containing the recombinant AAV DNA genome, regardless of infectivity or functionality. The number of genome particles in a particular vector preparation can be measured by procedures such as described in the Examples herein, or for example, in Clark *et al.* (1999) *Hum. Gene Ther.*, 10:1031-1039; Veldwijk *et al.* (2002) *Mol. Ther.*, 6:272-278.

[0070] The terms "infection unit (iu)," "infectious particle," or "replication unit," as used in reference to a viral titer, refer to the number of infectious and replication-competent recombinant AAV vector particles as measured by the infectious center assay, also known as replication center assay, as described, for example, in McLaughlin *et al.* (1988) *J. Virol.*, 62:1963-1973.

[0071] The term "transducing unit (tu)" as used in reference to a viral titer, refers to the number of infectious recombinant AAV vector particles that result in the production of a functional transgene product as measured in functional assays such as described in Examples herein, or for example, in Xiao *et al.* (1997) *Exp. Neurobiol.*, 144:113-124; or in Fisher *et al.* (1996) *J. Virol.*, 70:520-532 (LFU assay).

[0072] An "inverted terminal repeat" or "ITR" sequence is a term well understood in the art and refers to relatively short sequences found at the termini of viral genomes which are in opposite orientation.

[0073] An "AAV inverted terminal repeat (ITR)" sequence, a term well-understood in the art, is an approximately 145-nucleotide sequence that is present at both termini of the native single-stranded AAV genome. The outermost 125 nucleotides of the ITR can be present in either of two alternative orientations, leading to heterogeneity between different AAV genomes and between the two ends of a single AAV genome. The outermost 125 nucleotides also contains several shorter regions of self-complementarity (designated A, A', B, B', C, C' and D regions), allowing intrastrand base-pairing to occur within this portion of the ITR.

[0074] A "terminal resolution sequence" or "trs" is a sequence in the D region of the AAV ITR that is cleaved by AAV rep proteins during viral DNA replication. A mutant terminal resolution sequence is refractory to cleavage by AAV rep proteins.

[0075] A "helper virus" for AAV refers to a virus that allows AAV (which is a defective parvovirus) to be replicated and packaged by a host cell. A number of such helper viruses have been identified, including adenoviruses, herpesviruses and poxviruses such as vaccinia. The adenoviruses encompass a number of different subgroups, although Adenovirus type 5 of subgroup C (Ad5) is most commonly used. Numerous adenoviruses of human, non-human mammalian and avian origin are known and are available from depositories such as the ATCC. Viruses of the herpes family, which are also available from depositories such as ATCC, include, for example, herpes simplex viruses (HSV), Epstein-Barr viruses (EBV), cytomegaloviruses (CMV) and pseudorabies viruses (PRV).

[0076] "Percent (%) sequence identity" with respect to a reference polypeptide or nucleic acid sequence is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues or nucleotides in the reference polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly

available computer software programs, for example, those described in Current Protocols in Molecular Biology (Ausubel et al., eds., 1987), Supp. 30, section 7.7.18, Table 7.7.1, and including BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. A preferred alignment program is ALIGN Plus (Scientific and Educational Software, Pennsylvania). Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. For purposes herein, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows: 100 times the fraction W/Z, where W is the number of nucleotides scored as identical matches by the sequence alignment program in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.

[0077] An "isolated" molecule (*e.g.*, nucleic acid or protein) or cell means it has been identified and separated and/or recovered from a component of its natural environment.

[0078] An "effective amount" is an amount sufficient to effect beneficial or desired results, including clinical results (e.g., amelioration of symptoms, achievement of clinical endpoints, and the like). An effective amount can be administered in one or more administrations. In terms of a disease state, an effective amount is an amount sufficient to ameliorate, stabilize, or delay development of a disease.

[0079] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (*e.g.*, cows, sheep, cats, dogs, and horses), primates (*e.g.*, humans and non-human primates such as monkeys), rabbits, and rodents (*e.g.,* mice and rats). In certain embodiments, the individual or subject is a human.

[0080] As used herein, "treatment" is an approach for obtaining beneficial or desired clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (e.g., not worsening) state of disease, preventing spread (e.g., metastasis) of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment.

[0081] "Retinitis pigmentosa (RP)" refers to a heterogeneous group of diseases characterized by progressive loss of sight. Symptoms generally stem from degeneration or abnormalities of the retina, which may include the loss of photoreceptor cell function.

[0082] "Rhodopsin" refers to a member of the G-protein-coupled receptor family that functions in light perception in the rod photoreceptor cells of the retina. A visual pigment, rhodopsin contains a polypeptide opsin reversibly bound to its cofactor retinal. Light causes isomerization of retinal from an 11-cis to an all-trans form. This in turn causes a conformational change in the polypeptide that leads to G-protein activation. By converting the presence of light into a biochemical response, rhodopsin enables visual perception. Its function is required for scotopic vision (*i.e.,* noncolor vision in dim light), and it is also thought to be required for photoreceptor cell viability.

[0083] As used herein, "rhodopsin" may refer to the full visual pigment including retinal or simply the amino acid component or sequence of the molecule. Rhodopsin may also be known as OPN2, Opsin-2, or RP4. Examples of rhodopsin proteins may include without limitation human, mouse, dog, and cat rhodopsin, *e.g.,* NCBI Reference Sequences NP_000530, NP_663358, NP_001008277, and NP_001009242. Examples of rhodopsin genes may include without limitation human, mouse, dog, and cat rhodopsin genes, *e.g.,* GenBank Entrez Gene ID 6010 (*RHO,* a.k.a. *RP4, OPN2,* and *CSNBAD1*), GenBank Entrez Gene ID 212541 (*Rho*, a.k.a. *Ops, RP4, Opn2,* and *Noerg1*), GenBank Entrez Gene ID 493763, and GenBank Entrez Gene ID 493762. The term rhodopsin as used herein also

includes functional equivalents of rhodopsin (*e.g.*, rhodopsin variants) including mutations, truncations, deletions, and/or insertions, provided that the functional equivalent maintains at least a portion of the activity of wild-type rhodopsin to ameliorate symptoms of retinitis pigmentosa.

[0084] As used herein "refractory" refers to resistance to modulation. For example, a rhodopsin gene that is refractory to suppression by miR-708 is substantially or totally resistant to suppression by miR-708.

[0085] "Opsin promoter" refers to a polynucleotide sequence derived from an opsin gene (*e.g.,* mouse opsin) that drives expression specifically in rod photoreceptor cells (*e.g.*, rod photoreceptor cells). As used herein, "opsin promoter" may refer to an entire promoter sequence or a fragment of the promoter sequence sufficient to drive rod-specific expression, such as the sequences described in Quiambao, A.B., *et al.* (1997) *Vis. Neurosci.* 14(4):617-25 and Le, Y.Z., *et al.* (2006) *Mol. Vis.* 12:389-98. In some embodiments, the opsin promoter contains a 676bp fragment encoding a 400bp CMV enhancer upstream of a portion of the opsin promoter sequence (-500bp - +15bp). In addition 65bp NRL sequence is included; this encodes a neural retinal basic zipper factor (a Rod photoreceptor specific transcription factor).

[0086] "Rhodopsin kinase (RK) promoter" refers to a polynucleotide sequence derived from a rhodopsin kinase gene (*e.g.,* human RK, represented by GenBank Entrez Gene ID 6011) that drives expression specifically in rod and cone photoreceptor cells, as well as retinal cell lines such as WERI Rb-1. As used herein, "rhodopsin kinase promoter" may refer to an entire promoter sequence or a fragment of the promoter sequence sufficient to drive photoreceptor-specific expression, such as the sequences described in Khani, S.C., *et al.* (2007) *Invest. Ophthalmol. Vis. Sci.* 48(9):3954-61 and Young, J.E., *et al.* (2003) *Invest. Ophthalmol. Vis. Sci.* 44(9):4076-85. In some embodiments, the RK promoter spans from -112 to +180 relative to the transcription start site.

[0087] "miR-708" refers to a micro-RNA (miRNA) polynucleotide sequence comprising the stem and loop sequences as shown in **FIG. 4**. Examples of miR-708 polynucleotides may include without limitation human, mouse, dog, and cat miR-708, *e.g.,* as represented by GenBank Entrez Gene IDs 100126333, 735284, and 100885899. miRNAs are small, non-coding RNA molecules that regulate the expression of genes (*e.g.,* by downregulation

of the gene transcript) containing a target site recognized by the miRNA (Bartel, D.P. (2004) *Cell* 116(2):281-97). miR-708 is known to be induced by CHOP and may be involved in the regulating rhodopsin expression (Behrman, S., *et al.* (2011) *J. Cell Biol.* 192(6):919-27). As used herein, "miR-708" may refer to the processed miR-708 polynucleotide or any intermediate in the processing pathway, *e.g.,* pri-miRNA or pre-miRNA. As used herein, "miR-708" may refer to a DNA sequence that is transcribed to yield miR-708 RNA, or the RNA sequence itself.

[0088] Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter *per se*. For example, description referring to "about X" includes description of "X."

[0089] As used herein, the singular form of the articles "a," "an," and "the" includes plural references unless indicated otherwise.

[0090] It is understood that aspects and embodiments of the invention described herein include "comprising," "consisting," and/or "consisting essentially of" aspects and embodiments.

III. Retinitis pigmentosa and experimental models thereof

[0091] As described above, retinitis pigmentosa (RP) refers to a group of degenerative eye diseases that can cause progressive loss of sight, including loss of night vision, loss of peripheral visual fields, and total blindness. In America, the incidence of RP is thought to be approximately 1 in 4,000 people. RP is often inherited, and autosomal dominant, autosomal recessive, and X-linked RP disorders have been described. Mutations in more than 50 different genes have been associated with RP, including components involved in the phototransduction cascade, the retinal cycle, and splicing factors, as well as over 100 distinct mutations in rhodopsin itself. In many cases, mutations associated with RP lead to loss of rod photoreceptor function and/or cell death. This loss results in decreased scotopic vision and may manifest as night blindness or decreased peripheral vision. Rod cell death has also been associated with subsequent cone cell death, causing loss of high acuity vision and, combined with rod cell death, blindness.

[0092] A variety of cell- and animal-based models have been established for examining the cellular basis of RP and for testing experimental treatments. One cell-based model for RP is cultured human retinal pigmented epithelial (RPE) cells (Adamowicz, M., *et al.* (2012) *Adv. Exp. Med. Biol.* 723:573-9). This model may be used to express mutant proteins implicated in RP and test the effect of these mutations on protein function, or the effect of mutant proteins on cellular function and/or viability. For example, human wild-type and mutant rhodopsin may be expressed, using any appropriate promoter (*e.g.,* CMV). Without wishing to be bound to theory, it is thought that misfolding of opsin polypeptides results in ER retention and stress, induction of the unfolded protein response (UPR), and increased cell death. This model may be used to examine the effect of any RP-associated mutation, for example a rhodopsin mutation such as P23H.

[0093] Animal-based RP models may include mice harboring mutations known or suspected to cause RP in mice, or mutations orthologous to those found in humans. In some embodiments, mouse models may include mice engineered to express a rhodopsin, for example a mutated human or mouse form, in photoreceptor cells. Examples of mouse models include the rhodopsin P347S mouse (Li, T., *et al.* (1996) *Proc. Natl. Acad. Sci.* 93(24):14176-81), the *Rho*$^{-/-}$ mouse (Humphries, M.M., *et al.* (1997) *Nat. Genet.* 15(2):216-9), and a mouse expressing P23H mutant rhodopsin ("P23H mouse") (Olsson, J.E., *et al.* (1992) *Neuron* 9(5):815-30). In the P23H mouse, mutant human rhodopsin may be inserted into the mouse germline. Any promoter known in the art to express in photoreceptor cells may be used (*e.g.,* the mouse opsin or human RK promoter). In some embodiments, rhodopsin may be expressed using an AAV vector.

[0094] Other animal models for RP may also be used. In addition to mouse models, rat, dog, pig, frog (Tam, B.M. and Moritz, O.L. (2006) *Invest. Ophthalmol. Vis. Sci.* 47(8):3234-41), and non-human primate models may also be used.

IV. Methods to treat retinitis pigmentosa

[0095] In some aspects, the invention provides methods and compositions for treating retinitis pigmentosa in a mammal comprising administering to the mammal (*e.g.*, to the retina) an effective amount of rAAV viral particles comprising a vector encoding a miR-708. The methods can be used for treating a human with RP, to improve the pathologies and vision impairment associated with RP. In some embodiments, the invention includes

administering an effective amount of rAAV viral particles comprising a vector comprising nucleic acid encoding rhodopsin (*e.g.*, a normal or wild-type rhodopsin). In some embodiments, the miR-708 serves to suppress activity of a mutated rhodopsin associated with RP. In some embodiments, the normal or wild-type rhodopsin serves to supplement the eye with a functional rhodopsin. In some embodiments, the viral particle comprises an AAV serotype 5 capsid (AAV5 capsid) and either AAV 2 or AAV 5 inverted terminal repeats. In some embodiments, the viral particle comprises an AAV serotype 5 tyrosine mutant capsid and either AAV 2 or AAV 5 inverted terminal repeats.

[0096] In some aspects, the invention provides methods and compositions for ameliorating a symptom of RP, comprising administration to the eye of a mammal an effective amount of rAAV viral particles comprising a vector encoding a miR-708. In other aspects, the invention provides methods and compositions for ameliorating a symptom of RP, comprising administration to the eye of a mammal an effective amount of rAAV viral particles comprising a vector encoding a miR-708 and a rhodopsin. In some embodiments the symptoms of RP include, but is not limited to, blindness, night blindness, decreased peripheral vision, and loss of high acuity vision. In some embodiments, treating retinitis pigmentosa comprises reducing or preventing symptoms associated with the retinitis pigmentosa including but not limited to methods of preventing retinal degeneration, methods for arresting progression of RP, methods for increasing photoreceptor function, and the like. Symptoms and/or pathology of RP include but are not limited to loss of sight, loss of night vision, loss of peripheral visual fields, loss of ERG function; loss of visual acuity and contrast sensitivity; loss of visually guided behavior, reduction in rod photoreceptor function, rod photoreceptor cell death, decreased scotopic vision, reduction in retinal cell changes (loss of photoreceptor structure or function; thinning or thickening of the outer nuclear layer (ONL); thinning or thickening of the outer plexiform layer (OPL); disorganization followed by loss of rod and cone outer segments; shortening of the rod and cone inner segments; retraction of bipolar cell dendrites; thinning or thickening of the inner retinal layers including inner nuclear layer, inner plexiform layer, ganglion cell layer and nerve fiber layer; opsin mislocalization; overexpression of neurofilaments; and the like. In some embodiments, the invention provides methods to prevent deterioration of rod cell function and rod cell death and cone cell function and cone cell death.

[0097] In some aspects, the invention provides methods to prevent or delay progression of RP. Autosomal dominant RP is a genetic disease that can be genotyped. Onset and progression of RP may be determined by Optical Coherence Tomography (OCT) which allows examination of outer plexiform layer (OPL) abnormalities.

[0098] Means for determining amelioration of the symptoms of RP are known in the art. For example, measurement of visual fields (e.g., Goldmann visual fields), determination of electroretinogram (ERG), fundus photographs, optical coherence tomography, and fluorescein angiography. Improvements in visually-evoked behavior can also be used to determine amelioration of the symptoms of RP; for example, statements such as "I can find things that drop," "I can see faces during a candle-lit dinner," "I can see stripes on my shirt," "I can see stars at night," "I can read regular books and sit in the front of the classroom," "now I can play soccer and don't need someone next to me to help me find the ball," "I can ride my bicycle around my neighborhood by myself," "I achieved my dream: I saw my daughter hit a homerun," and "when can I have my other eye injected?"

[0099] In some aspects of the invention, the methods and compositions are used for the treatment of humans with RP. RP can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. X-linked RP can be either recessive, affecting primarily only males, or dominant, affecting both males and females. RP may be caused by mutations in the rho gene that encodes the rhodopsin protein. In some embodiments of the invention, the methods are used to treat humans with a mutation in the rho gene and/or in the rhodopsin protein. In some embodiments of the invention, the mutation in the rhodopsin protein is a P23H mutation (substitution of histidine for proline at amino acid residue 23 of the rhodopsin protein). In other embodiments, the mutation in the rhodopsin protein is a T58R, P347L, or P347S, or a deletion of residue I255. Mutations associated with retinitis pigmentosa are provided by McWilliam, P, *et al.*, (1989) *Genomics* 5:619–622; Dryja, TP *et al.*, (1990) *Nature* 343:364–266; Farrar, GJ *et al.*, (1990) *Genomics* 8:35–40; Farrar, GJ *et al.*, (2002) *EMBO J.* 21:857–864; all incorporated herein by reference.

[0100] miR-708 is a CHOP regulated micro RNA that regulated rhodopsin expression (Behrman, S., *et al.* (2011) *J. Cell Biol.* 192(6):919-27). miR-708 is an intronic micro RNA residing within the CHOP inducible gene Odz4 (*Tenurin-4*). CHOP regulates miR-708

expression during ER stress. There is a putative miR-708 sequence in the 3' UTR of the rhodopsin gene that is highly conserved (see Figure 4 of Behrman *et al.*, *ibid*)

[0101] In some embodiments, the invention provides methods for treating a human with RP. In some embodiments, the invention provides methods for treating a human with autosomal dominant RP. In some embodiments, the invention provides methods for treating a human with RP associated with a mutation in the rhodopsin gene. In some embodiments, the invention provides a method for treating a human with RP by administering an effective amount of an AAV vector encoding miR-708 to suppress the activity of a mutated rhodopsin. In some embodiments, the invention provides methods for treating a mammal (*e.g.*, a dog or a cat) with RP. In some embodiments, the miR-708 nucleic acid may include without limitation nucleic acid represented by GenBank Entrez Gene IDs 100126333, 735284, or 100885899.

[0102] In some embodiments of the invention, the suppression of a mutant rhodopsin is supplemented by the delivery of an effective amount of AAV vector encoding a wild-type rhodopsin or a rhodopsin with activity essentially the same as a wild-type rhodopsin. In some embodiments, the rhodopsin is a human rhodopsin. In some embodiments, the invention provides a method for treating a human with RP by administering an effective amount of an AAV vector encoding miR-708 to suppress the activity of a mutated rhodopsin and an effective amount of an AAV vector encoding a human rhodopsin with wild-type activity. In some embodiments, the AAV vector encoding miR-708 and the AAV vector encoding the human rhodopsin are the same AAV vector. In some embodiments, the AAV vector encoding miR-708 and the AAV vector encoding the human rhodopsin are the different AAV vectors. In some embodiments, nucleic acid encoding rhodopsin may include without limitation nucleic acid provided by identified by NCBI Reference Sequences NP_000530, NP_663358, NP_001008277, and NP_001009242.

[0103] In some aspects, the invention provides methods for treating endoplasmic reticulum (ER) stress in a cell comprising administering to the mammal a rAAV viral particle comprising a rAAV vector comprising nucleic acid encoding a miR-708. In some embodiments, the cell is an ocular cell. In further embodiments, the cell is a photoreceptor cell. In yet further embodiments, the cell is a rod photoreceptor cell. In some embodiments, the method comprises reducing one or more cellular markers of ER stress. In further

embodiments, the one or more cellular marker of ER stress is spliced XBP-1, CHOP or Grp78. In some embodiments, the rAAV vector comprises nucleic acid encoding a miR-708 further comprises nucleic acid encoding rhodopsin. In other embodiments, the invention provides methods for treating endoplasmic reticulum (ER) stress in a cell comprising administering to the mammal a first rAAV vector comprising nucleic acid encoding a miR-708 and a second rAAV viral particle comprising a second rAAV vector comprising nucleic acid encoding a rhodopsin.

[0104] In some aspects, the invention provides methods to deliver miR-708 or miR-708 and rhodopsin to a mammal with RP, the method comprising administering to the retina of the mammal, an effective amount of rAAV viral particles comprising vector encoding the miR-708 and/or rhodopsin. The administration delivers the transgene product to the photoreceptor cells, where the miR-708 and/or rhodopsin mediates a beneficial effect on the photoreceptor cell and surrounding photoreceptor cells. In some embodiments, delivery of AAV viral particles to the retina is by injection of viral particles to the sub-retinal space of the retina. In some embodiments, the delivery of AAV particles to the retina is by intravitreal delivery provided the AAV particle is capable of penetrating to the back of the eye and transduces photoreceptor cells. In some embodiments, the AAV particles are administered in one or more locations in the sub-retinal space of the retina.

[0105] In some embodiments, the administration to the retina of an effective amount of rAAV viral particles comprising a vector encoding miR-708 and/or rhodopsin transduces photoreceptor cells at or near the site of administration. In some embodiments, more than about any of 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 100% of photoreceptor cells are transduced. In some embodiments, about 5% to about 100%, about 10% to about 50%, about 10% to about 30%, about 25% to about 75%, about 25% to about 50%, or about 30% to about 50% of the photoreceptor cells are transduced. Methods to identify photoreceptor cells transduced by AAV expressing miR-708 and/or rhodopsin are known in the art; for example, immunohistochemistry or the use of a marker such as enhanced green fluorescent protein can be used to detect expression of miR-708 and/or rhodopsin.

[0106] In some embodiments of the invention, the methods comprise administration to the retina (*e.g.*, the subretinal space) of a mammal an effective amount of AAV viral particles

comprising a vector encoding a miR708 and/or rhodopsin for treating a mammal, *e.g.*, a human, with RP. In some embodiments, the composition is injected to one or more subretinal spaces to allow expression of miR-708 and/or rhodopsin in photoreceptor cells. In some embodiments, the composition is injected into any one of one, two, three, four, five, six, seven, eight, nine, ten or more than ten locations in the subretinal space of the retina.

[0107] In some embodiments the rAAV viral particles are administered to more than one location simultaneously or sequentially. In some embodiment, multiple injections of rAAV viral particles are no more than one hour, two hours, three hours, four hours, five hours, six hours, nine hours, twelve hours or 24 hours apart.

[0108] In some embodiments, first rAAV viral particles encoding miR-708 and second rAAV viral particles encoding rhodopsin are administered to one or more locations simultaneously or sequentially. In some embodiment, multiple injections of rAAV viral particles are no more than one hour, two hours, three hours, four hours, five hours, six hours, nine hours, twelve hours or 24 hours apart. In some embodiments the first rAAV viral particles encoding miR-708 are administered before the second rAAV viral particles encoding rhodopsin are administered. In some embodiments the first rAAV viral particles encoding miR-708 are administered after the second rAAV viral particles encoding rhodopsin are administered.

[0109] In some embodiments, the invention provides a method for treating a human with RP by administering an effective amount of a pharmaceutical composition comprising an AAV vector encoding miR-708 to suppress the activity of a mutated rhodopsin. In some embodiments, the invention provides a method for treating a human with RP by administering an effective amount of a pharmaceutical composition comprising an AAV vector encoding miR-708 to suppress the activity of a mutated rhodopsin and an effective amount of a pharmaceutical composition comprising an AAV vector encoding rhodopsin to supplement photoreceptors with wild-type rhodopsin activity. In some embodiments, the pharmaceutical composition comprising an AAV vector encoding miR-708 and the pharmaceutical composition comprising an AAV vector encoding the human rhodopsin are the same pharmaceutical composition. In some embodiments, the pharmaceutical composition comprising an AAV vector encoding miR-708 and the pharmaceutical composition comprising an AAV vector encoding the human rhodopsin are the different

pharmaceutical composition. In some embodiments, the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients.

[0110] In some embodiments of the invention, the volume of the composition injected to the subretinal space of the retina or intravitreally is more than about any one of 1 µl, 2 µl, 3 µl, 4 µl, 5 µl, 6 µl, 7 µl, 8 µl, 9 µl, 10 µl, 15 µl, 20 µl, 25 µl, 50 µl, 75 µl, 100 µl, 200 µl, 300 µl, 400 µl, 500 µl, 600 µl, 700 µl, 800 µl, 900 µl, or 1 mL, or any amount therebetween.

[0111] Compositions of the invention (*e.g.*, AAV viral particles comprising a vector encoding miR-708 and/or rhodopsin) can be used either alone or in combination with one or more additional therapeutic agents for treating RP. The interval between sequential administration can be in terms of at least (or, alternatively, less than) minutes, hours, or days.

V. Expression Constructs

[0112] In some embodiments, the transgene (*e.g.*, miRNA 708 and/or rhodopsin) is operably linked to a promoter. Exemplary promoters include, but are not limited to, the cytomegalovirus (CMV) immediate early promoter, the RSV LTR, the MoMLV LTR, the phosphoglycerate kinase- 1 (PGK) promoter, a simian virus 40 (SV40) promoter and a CK6 promoter, a transthyretin promoter (TTR), a TK promoter, a tetracycline responsive promoter (TRE), an HBV promoter, an hAAT promoter, a LSP promoter, chimeric liver-specific promoters (LSPs), the E2F promoter, the telomerase (hTERT) promoter; the cytomegalovirus enhancer/chicken beta-actin/Rabbit β-globin promoter (CAG promoter; Niwa *et al.*, *Gene*, 1991, 108(2):193-9) and the elongation factor 1-alpha promoter (EFl-alpha) promoter (Kim *et al.*, *Gene*, 1990, 91(2):217-23 and Guo *et al.*, *Gene Ther.*, 1996, 3(9):802-10). In some embodiments, the promoter comprises a human β-glucuronidase promoter or a cytomegalovirus enhancer linked to a chicken β-actin (CBA) promoter. The promoter can be a constitutive, inducible or repressible promoter. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to a CBA promoter. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding rhodopsin (*e.g.*, human rhodopsin) operably linked to a CBA promoter. In some embodiments, the invention provides an AAV vector comprising

nucleic acid encoding miR-708 and nucleic acid encoding rhodopsin (*e.g.*, human rhodopsin) operably linked to a CBA promoter.

[0113] In some embodiments, the promoter is capable of expressing the transgene in photoreceptor cells. In embodiments, the promoter is a rhodopsin kinase (RK) promoter; *e.g.*, a human RK promoter. In some embodiments, the promoter is an opsin promoter; *e.g.*, a human opsin promoter or a mouse opsin promoter.

[0114] In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to an RK promoter. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding rhodopsin (*e.g.*, human rhodopsin) operably linked to an RK promoter. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 and rhodopsin (*e.g.*, human rhodopsin) operably linked to an RK promoter. In some embodiments, the nucleic acid encoding miR-708 is 5' to nucleic acid encoding rhodopsin. In other embodiments, the nucleic acid encoding miR-708 is 3' to nucleic acid encoding rhodopsin. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to a first RK promoter and nucleic acid encoding rhodopsin operably linked to a second RK promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to a first RK promoter is 5' to nucleic acid encoding rhodopsin operably linked to a second RK promoter. In other embodiments, the nucleic acid encoding miR-708 operably linked to a first RK promoter is 3' to nucleic acid encoding rhodopsin operably linked to a second RK promoter. In some embodiments, the miR-708 comprises the sequence of SEQ ID NO:1. In some embodiments, the miR-708 comprises a nucleotide sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:1. In some embodiments, the rhodopsin comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin comprises an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin is a functional equivalent of wild-type rhodopsin. In some embodiments, expression of rhodopsin from the AAV vector is refractory to suppression by miR-708. In some embodiments, nucleic acid encoding rhodopsin lacks the miR-708 target site in the 3' UTR of the rhodopsin gene. In some embodiments, nucleic acid encoding rhodopsin comprises a mutation (*e.g.*, a

deletion, a substitution, an insertion, *etc.*) in the miR-708 target site in the 3' UTR of the rhodopsin gene such that it is refractory to suppression by miR-708.

[0115] In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to an opsin promoter. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding rhodopsin (*e.g.*, human rhodopsin) operably linked to an opsin promoter. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 and nucleic acid encoding rhodopsin (*e.g.*, human rhodopsin) operably linked to an opsin promoter. In some embodiments, the nucleic acid encoding miR-708 is 5' to nucleic acid encoding rhodopsin. In other embodiments, the nucleic acid encoding miR-708 is 3' to nucleic acid encoding rhodopsin. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to a first opsin promoter and nucleic acid encoding rhodopsin operably linked to a second opsin promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to a first opsin promoter is 5' to nucleic acid encoding rhodopsin operably linked to a second opsin promoter. In other embodiments, the nucleic acid encoding miR-708 operably linked to a first opsin promoter is 3' to nucleic acid encoding rhodopsin operably linked to a second opsin promoter. In some embodiments, the miR-708 comprises the sequence of SEQ ID NO:1. In some embodiments, the miR-708 comprises the sequence of SEQ ID NO:1. In some embodiments, the miR-708 comprises a nucleotide sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:1. In some embodiments, the rhodopsin comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin comprises an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin is a functional equivalent of wild-type rhodopsin. In some embodiments, expression of rhodopsin from the AAV vector is refractory to suppression by miR-708. In some embodiments, nucleic acid encoding rhodopsin lacks the miR-708 target site in the 3' UTR of the rhodopsin gene. In some embodiments, nucleic acid encoding rhodopsin comprises a mutation (*e.g.*, a deletion, a substitution, an insertion, *etc.*) in the miR-708 target site in the 3' UTR of the rhodopsin gene such that it is refractory to suppression by miR-708.

[0116] In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to an RK promoter and nucleic acid encoding rhodopsin operably linked to an opsin promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to the RK promoter is 5' to nucleic acid encoding rhodopsin operably linked to an opsin promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to the RK promoter is 3' to nucleic acid encoding rhodopsin operably linked to an opsin promoter. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to an opsin promoter and nucleic acid encoding rhodopsin operably linked to an RK promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to the opsin promoter is 5' to nucleic acid encoding rhodopsin operably linked to an RK promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to the opsin promoter is 3' to nucleic acid encoding rhodopsin operably linked to an RK promoter. In some embodiments, the miR-708 comprises the sequence of SEQ ID NO:1. In some embodiments, the miR-708 comprises the sequence of SEQ ID NO:1. In some embodiments, the miR-708 comprises a nucleotide sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:1. In some embodiments, the rhodopsin comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin comprises an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin is a functional equivalent of wild-type rhodopsin. In some embodiments, expression of rhodopsin from the AAV vector is refractory to suppression by miR-708. In some embodiments, nucleic acid encoding rhodopsin lacks the miR-708 target site in the 3' UTR of the rhodopsin gene. In some embodiments, nucleic acid encoding rhodopsin comprises a mutation (*e.g.*, a deletion, a substitution, an insertion, *etc.*) in the miR-708 target site in the 3' UTR of the rhodopsin gene such that it is refractory to suppression by miR-708.

[0117] In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to a CBA promoter and nucleic acid encoding rhodopsin operably linked to an RK promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to the CBA promoter is 5' to nucleic acid encoding

rhodopsin operably linked to an RK promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to the CBA promoter is 3' to nucleic acid encoding rhodopsin operably linked to an RK promoter. In some embodiments, the invention provides an AAV vector comprising nucleic acid encoding miR-708 operably linked to an RK promoter and nucleic acid encoding rhodopsin operably linked to a CBA promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to the RK promoter is 5' to nucleic acid encoding rhodopsin operably linked to a CBA promoter. In some embodiments, the nucleic acid encoding miR-708 operably linked to the RK promoter is 3' to nucleic acid encoding rhodopsin operably linked to a CBA promoter. In some embodiments, the miR-708 comprises the sequence of SEQ ID NO:1. In some embodiments, the miR-708 comprises the sequence of SEQ ID NO:1. In some embodiments, the miR-708 comprises a nucleotide sequence that is at least about 80%, 85%, 90%, or 95% identical to the sequence of SEQ ID NO:1. In some embodiments, the rhodopsin comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin comprises an amino acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to the amino acid sequence of SEQ ID NO:2. In some embodiments, the rhodopsin is a functional equivalent of wild-type rhodopsin. In some embodiments, expression of rhodopsin from the AAV vector is refractory to suppression by miR-708. In some embodiments, nucleic acid encoding rhodopsin lacks the miR-708 target site in the 3' UTR of the rhodopsin gene. In some embodiments, nucleic acid encoding rhodopsin comprises a mutation (*e.g.*, a deletion, a substitution, an insertion, *etc.*) in the miR-708 target site in the 3' UTR of the rhodopsin gene such that it is refractory to suppression by miR-708.

[0118] In some embodiments, nucleic acid encoding miR-708 comprises an endogenous miR-708 scaffold. In some embodiments, the miR-708 scaffold is provided by SEQ ID NO:14. In some embodiments, nucleic acid encoding miR-708 comprises a heterologous miRNA scaffold. In some embodiments, use of a heterologous miRNA scaffold is used to modulate miRNA expression; for example, to increase miRNA expression or to decrease miRNA expression. In some embodiments, nucleic acid encoding miR-708 comprises an endogenous miR-155 scaffold. In some embodiments, the miR-155 scaffold is provided by SEQ ID NO:14.

Recombinant viral vector

[0119] The present invention contemplates the use of a recombinant viral genome for introduction of one or more nucleic acid sequences encoding for a miR-708 miRNA and/or a rhodopsin protein described herein for packaging into an AAV viral particle. The recombinant viral genome may include any element to establish the expression of a miR-708 miRNA and/or a rhodopsin protein, for example, a promoter, a miR-708 miRNA and/or a rhodopsin transgene, an ITR, a ribosome binding element, terminator, enhancer, selection marker, intron, polyA signal, and/or origin of replication.

VI. Viral particles and methods of producing viral particles

rAAV viral particles

[0120] The invention provides methods of using rAAV particles to treat retinitis pigmentosa and provides compositions comprising rAAV particles. In some embodiments, the viral particle is a recombinant AAV particle comprising a nucleic acid comprising a sequence encoding miR-708 miRNA and/or a rhodopsin protein described herein flanked by one or two ITRs. The nucleic acid is encapsidated in the AAV particle. The AAV particle also comprises capsid proteins. In some embodiments, the nucleic acid comprises the coding sequence(s) of interest (*e.g.*, nucleic acid encoding miR-708 miRNA and/or a rhodopsin protein) operatively linked components in the direction of transcription, control sequences including transcription initiation and termination sequences, thereby forming an expression cassette. In some embodiments, nucleic acid encoding the miR-708 is embedded in an intron. The expression cassette is flanked on the 5' and 3' end by at least one functional AAV ITR sequences. By "functional AAV ITR sequences" it is meant that the ITR sequences function as intended for the rescue, replication and packaging of the AAV virion. See Davidson *et al.*, *PNAS*, 2000, 97(7)3428-32; Passini *et al.*, *J. Virol.*, 2003, 77(12):7034-40; and Pechan *et al.*, *Gene Ther.*, 2009, 16:10-16, all of which are incorporated herein in their entirety by reference. For practicing some aspects of the invention, the recombinant vectors comprise at least all of the sequences of AAV essential for encapsidation and the physical structures for infection by the rAAV. AAV ITRs for use in the vectors of the invention need not have a wild-type nucleotide sequence (*e.g.*, as described in Kotin, *Hum. Gene Ther.*, 1994, 5:793-801), and may be altered by the insertion, deletion or substitution of nucleotides or the AAV ITRs may be derived from any

of several AAV serotypes. More than 40 serotypes of AAV are currently known, and new serotypes and variants of existing serotypes continue to be identified. See Gao *et al.*, *PNAS*, 2002, 99(18): 11854-6; Gao *et al.*, *PNAS*, 2003, 100(10):6081-6; and Bossis *et al.*, *J. Virol.*, 2003, 77(12):6799-810. Use of any AAV serotype is considered within the scope of the present invention. In some embodiments, a rAAV vector is a vector derived from an AAV serotype, including without limitation, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV capsid serotype ITRs or the like. In some embodiments, the nucleic acid in the AAV comprises an ITR of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV capsid serotype ITRs or the like. In some embodiments, the nucleic acid in the AAV further encodes miR-708, rhodopsin, or miR-708 and rhodopsin as described herein. For example, the nucleic acid in the AAV can comprise at least one ITR of any AAV serotype contemplated herein and can further encode a miR-708 comprising the nucleic acid of SEQ ID NO:1 and/or nucleic acid encoding a human rhodopsin comprising the amino acid sequence of SEQ ID NO:2. In some embodiments, the nucleic acid in the AAV comprises 5' to 3' nucleic acid encoding the following: an AAV ITR, a stuffer fragment (*e.g.*, SEQ ID NO:11), a chimeric intron (*e.g.*, SEQ ID NO:10), a miR-708, a bovine growth hormone polyadenylation sequence, a stuffer fragment, and an AAV ITR. In some embodiments, the nucleic acid in the AAV comprises 5' to 3' nucleic acid encoding the following: an AAV ITR, an RK promoter, a β globin intron, a miR-708 imbedded in the β globin intron, a human rhodopsin, a bovine growth hormone polyadenylation sequence, and an AAV ITR. In some embodiments, the nucleic acid in the AAV comprises 5' to 3' nucleic acid encoding the following: an AAV ITR, a stuffer fragment (*e.g.*, SEQ ID NO:11), an RK promoter, a chimeric intron (*e.g.*, SEQ ID NO:10), a human rhodopsin, a β-globin intron, a miR-708 embedded in a β-globin intron, a bovine growth hormone polyadenylation sequence, a stuffer fragment, and an AAV ITR. In some embodiments, the nucleic acid in the AAV comprises 5' to 3' nucleic acid encoding the following: an AAV ITR, a stuffer fragment (*e.g.*, SEQ ID NO:11), an RK promoter, a chimeric intron (*e.g.*, SEQ ID NO:10), a miR-708, a mouse opsin promoter, a human rhodopsin, a bovine growth hormone polyadenylation sequence, and an AAV ITR. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid of SEQ ID NO:5. In some embodiments, the

nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:5. In some embodiments, the nucleic acid in the AAV the nucleic acid of SEQ ID NO:6. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:6. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid of SEQ ID NO:7. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:7. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid of SEQ ID NO:8. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:8. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid of SEQ ID NO:9. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:9. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid of SEQ ID NO:24. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:24. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid of SEQ ID NO:25. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:25. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid of SEQ ID NO:26. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:26. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid of SEQ ID NO:27. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:27. In further embodiments, the rAAV particle comprises capsid proteins of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, mouse AAV capsid rAAV2/HBoV1 serotype

capsid, or mutants of these capsid proteins. In some embodiments, a mutant capsid protein maintains the ability to form an AAV capsid. In some embodiments, the rAAV particle comprises AAV5 tyrosine mutant capsid (Zhong L. *et al.*, (2008) *Proc Natl Acad Sci U S A* 105(22):7827-7832. In further embodiments, the rAAV particle comprises capsid proteins of an AAV serotype from Clades A-F (Gao, *et al., J. Virol.* 2004, 78(12):6381). In some embodiments, the nucleic acid in the AAV comprises the nucleic acid sequence selected from the group consisting of SEQ ID NOs:5-8, and is flanked by at least one AAV2 ITR. In some embodiments, the nucleic acid in the AAV comprises the nucleic acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid selected from the group consisting of SEQ ID NOs:5-9, and is flanked by at least one AAV2 ITR.

[0121] Different AAV serotypes are used to optimize transduction of particular target cells or to target specific cell types within a particular target tissue (*e.g.*, a diseased tissue). A rAAV particle can comprise viral proteins and viral nucleic acids of the same serotype or a mixed serotype. For example, in some embodiments a rAAV particle can comprise AAV5 capsid proteins and at least one AAV2 ITR or it can comprise AAV2 capsid proteins and at least one AAV5 ITR. In other embodiments a rAAV particle can comprise AAV5 tyrosine mutant capsid proteins and at least one AAV2 ITR. In yet another example, a rAAV particle can comprise capsid proteins from both AAV5 and AAV2, and further comprise at least one AAV2 ITR. Any combination of AAV serotypes for production of a rAAV particle is provided herein as if each combination had been expressly stated herein. In some embodiments, the invention provides rAAV particles comprising AAV5 capsid proteins and a nucleic acid encoding miR-708 RNA and/or a rhodopsin transgene, flanked by at least one AAV2 ITR.

Self-complementary AAV viral genomes

[0122] In some aspects, the invention provides viral particles comprising a recombinant self-complementing genome. AAV viral particles with self-complementing genomes and methods of use of self-complementing AAV genomes are described in US Patent Nos. 6,596,535; 7,125,717; 7,765,583; 7,785,888; 7,790,154; 7,846,729; 8,093,054; and 8,361,457; and Wang Z., *et al.*, (2003) *Gene Ther* 10:2105-2111, each of which are incorporated herein by reference in its entirety. A rAAV comprising a self-complementing

genome will quickly form a double stranded DNA molecule by virtue of its partially complementing sequences (*e.g.*, complementing coding and non-coding strands of a transgene). In some embodiments, the invention provides an AAV viral particle comprising an AAV genome, wherein the rAAV genome comprises a first heterologous polynucleotide sequence (*e.g.*, miR-708 and/or a rhodopsin coding strand) and a second heterologous polynucleotide sequence (*e.g.*, antisense strand of miR-708 and/or a rhodopsin noncoding or antisense strand) wherein the first heterologous polynucleotide sequence can form intrastrand base pairs with the second polynucleotide sequence along most or all of its length. In some embodiments, the first heterologous polynucleotide sequence and a second heterologous polynucleotide sequence are linked by a sequence that facilitates intrastrand basepairing; *e.g.*, a hairpin DNA structure. Hairpin structures are known in the art, for example in siRNA molecules. In some embodiments, the first heterologous polynucleotide sequence and a second heterologous polynucleotide sequence are linked by a mutated ITR (*e.g.*, the right ITR). In some embodiments, the ITR comprises the polynucleotide sequence 5'-
CACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGC
CCACGCCCGGGCTTTGCCCGGGCG – 3' (SEQ ID NO:20). The mutated ITR comprises a deletion of the D region comprising the terminal resolution sequence. As a result, on replicating an AAV viral genome, the rep proteins will not cleave the viral genome at the mutated ITR and as such, a recombinant viral genome comprising the following in 5' to 3' order will be packaged in a viral capsid: an AAV ITR, the first heterologous polynucleotide sequence including regulatory sequences, the mutated AAV ITR, the second heterologous polynucleotide in reverse orientation to the first heterologous polynucleotide and a third AAV ITR. In some embodiments, the invention provides AAV viral particles comprising a recombinant viral genome comprising a functional AAV2 ITR, a first polynucleotide sequence encoding miR-708 RNA and/or a rhodopsin transgene, a mutated AAV2 ITR comprising a deletion of the D region and lacking a functional terminal resolution sequence, a second polynucleotide sequence comprising the complementary sequence to the sequence encoding miR-708 RNA and/or a rhodopsin, of the first polynucleotide sequence and a functional AAV2 ITR.

Production of AAV particles

[0123] The rAAV particles can be produced using methods know in the art. See, e.g., U.S. Pat. Nos. 6,566,118; 6,989,264; and 6,995,006. In practicing the invention, host cells for producing rAAV particles include mammalian cells, insect cells, plant cells, microorganisms and yeast. Host cells can also be packaging cells in which the AAV rep and cap genes are stably maintained in the host cell or producer cells in which the AAV vector genome is stably maintained. Exemplary packaging and producer cells are derived from 293, A549 or HeLa cells. AAV vectors are purified and formulated using standard techniques known in the art.

[0124] In some aspects, a method is provided for producing any rAAV particle as disclosed herein comprising (a) culturing a host cell under a condition that rAAV particles are produced, wherein the host cell comprises (i) one or more AAV package genes, wherein each said AAV packaging gene encodes an AAV replication and/or encapsidation protein; (ii) an rAAV pro-vector comprising a nucleic acid encoding miR-708 RNA and/or any rhodopsin transgene as described herein flanked by at least one AAV ITR, and (iii) an AAV helper function; and (b) recovering the rAAV particles produced by the host cell. In some embodiments, a nucleic acid encodes miR-708 RNA of SEQ ID NO:1 and/or a transgene encoding a rhodopsin; *e.g.*, a rhodopsin with the amino acid of SEQ ID NO:2. In some embodiments, said at least one AAV ITR is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITR or the like. In some embodiments, said encapsidation protein is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6 (*e.g.,* a wild-type AAV6 capsid, or a variant AAV6 capsid such as ShH10, as described in U.S. PG Pub. 2012/0164106), AAV7, AAV8, AAVrh8, AAVrh8R, AAV9 (*e.g.,* a wild-type AAV9 capsid, or a modified AAV9 capsid as described in U.S. PG Pub. 2013/0323226), AAV10, AAVrh10, AAV11, AAV12, a tyrosine capsid mutant, a heparin binding capsid mutant, an AAV2R471A capsid, an AAVAAV2/2-7m8 capsid, an AAV DJ capsid (*e.g.,* an AAV-DJ/8 capsid, an AAV-DJ/9 capsid, or any other of the capsids described in U.S. PG Pub. 2012/0066783), AAV2 N587A capsid, AAV2 E548A capsid, AAV2 N708A capsid, AAV V708K capsid, goat AAV capsid, AAV1/AAV2 chimeric capsid, bovine AAV capsid, mouse AAV capsid, rAAV2/HBoV1 capsid, an AAV capsid described in U.S. Pat. No. 8,283,151 or International Publication No. WO/2003/042397, or mutants thereof. In

some embodiments, the encapsidation protein is an AAV5 tyrosine mutant capsid protein. In further embodiments, the rAAV particle comprises capsid proteins of an AAV serotype from Clades A-F. In some embodiments, the rAAV particles comprise an AAV5 capsid and a recombinant genome comprising AAV2 ITRs, a mutant AAV2 ITR and nucleic acid encoding miR-708 and/or rhodopsin. In some embodiments, the rAAV particles comprise an AAV5 tyrosine mutant capsid and a recombinant genome comprising AAV2 ITRs, a mutant AAV2 ITR and nucleic acid encoding miR-708 and/or rhodopsin. In a further embodiment, the rAAV particles are purified. The term "purified" as used herein includes a preparation of rAAV particles devoid of at least some of the other components that may also be present where the rAAV particles naturally occur or are initially prepared from. Thus, for example, isolated rAAV particles may be prepared using a purification technique to enrich it from a source mixture, such as a culture lysate or production culture supernatant. Enrichment can be measured in a variety of ways, such as, for example, by the proportion of DNase-resistant particles (DRPs) or genome copies (gc) present in a solution, or by infectivity, or it can be measured in relation to a second, potentially interfering substance present in the source mixture, such as contaminants, including production culture contaminants or in-process contaminants, including helper virus, media components, and the like.

[0125] Also provided herein are pharmaceutical compositions comprising a rAAV particle comprising a transgene encoding miR-708 and/or a rhodopsin transgene of the invention and a pharmaceutically acceptable carrier. In some embodiments, the composition comprises rAAV particles comprising a transgene encoding miR-708 and rAAV particles comprising a rhodopsin transgene. In some embodiments, the composition comprises rAAV particles comprising a transgene encoding miR-708 and a rhodopsin transgene. The pharmaceutical compositions may be suitable for any mode of administration described herein. A pharmaceutical composition of a rAAV comprising a nucleic acid encoding miR-708 RNA and/or a rhodopsin transgene, described herein can be introduced to the eye; for example, by subretinal administration or intravitreal administration.

[0126] In some embodiments, the pharmaceutical compositions comprising a rAAV described herein and a pharmaceutically acceptable carrier is suitable for administration to human. Such carriers are well known in the art (see, *e.g.*, Remington's Pharmaceutical

Sciences, 15th Edition, pp. 1035-1038 and 1570-1580). In some embodiments, the pharmaceutical compositions comprising a rAAV described herein and a pharmaceutically acceptable carrier is suitable for ocular injection. Such pharmaceutically acceptable carriers can be sterile liquids, such as water and oil, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and the like. Saline solutions and aqueous dextrose, polyethylene glycol (PEG) and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. The pharmaceutical composition may further comprise additional ingredients, for example preservatives, buffers, tonicity agents, antioxidants and stabilizers, nonionic wetting or clarifying agents, viscosity-increasing agents, and the like. The pharmaceutical compositions described herein can be packaged in single unit dosages or in multidosage forms. The compositions are generally formulated as sterile and substantially isotonic solution.

VII. Articles of Manufacture and Kits

[0127] Also provided are kits or articles of manufacture for use in the methods described herein. In aspects, the kits comprise the compositions described herein (*e.g.*, rAAV particles comprising nucleic acid encoding miR-708 RNA and/or a rhodopsin transgene) in suitable packaging. Suitable packaging for compositions (such as ocular compositions) described herein are known in the art, and include, for example, vials (such as sealed vials), vessels, ampules, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. These articles of manufacture may further be sterilized and/or sealed.

[0128] The present invention also provides kits comprising compositions described herein and may further comprise instruction(s) on methods of using the composition, such as uses described herein. The kits described herein may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein. For example, in some embodiments, the kit comprises an rAAV comprising a transgene encoding miR-708 RNA and/or a rhodopsin transgene for intraocular delivery of at least 1×10^9 genome copies to a primate as described herein, a pharmaceutically acceptable carrier suitable for intraocular injection, and one or more of: a buffer, a diluent, a filter, a needle, a syringe, and a package insert with instructions for performing ocular injections. In some embodiments, the kit comprising instructions for treating retinitis

pigmentosa with the rAAV particles described herein. In some embodiments, the kit comprising instructions for reducing ER stress in a cell with the rAAV particles described herein. In some embodiments, the kit comprising instructions for using the rAAV particles described herein according to any one of the methods described herein.

EXAMPLES

[0129] The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention. It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

Example 1: Development of a cellular model of retinitis pigmentosa

[0130] A therapeutic strategy for RHO-associated autosomal dominant RP would be to knock down both mutant and wild-type rhodopsin and alleviate ER stress. This could be achieved by co-delivering a micro-RNA (miR) that would inhibit the rhodopsin alleles and optionally co-delivering a wild-type rhodopsin sequence refractory to knockdown by the exogenously delivered miR. A CHOP-regulated miR, miR-708, regulates rhodopsin expression (Behrman, S., *et al.* (2011) *J. Cell Biol.* 192(6):919-27). miR-708 is an intronic miR residing within the CHOP-inducible gene Odz4 (Tenurin-4). CHOP regulates miR-708 expression during ER stress, and there is a putative miR-708 sequence in the 3' UTR of rhodopsin.

[0131] Described herein are methods for using an AAV vector to deliver exogenous miR-708 targeting both wild type and mutant rhodopsin through the 3' UTR miR-708 target sequence present in both alleles. In embodiments, a wild-type rhodopsin replacement sequence is also co-delivered. This replacement rhodopsin sequence may be engineered to have decreased binding to miR-708 (e.g., nucleotide substitution, deletion or addition to the 3' UTR) and thus will be refractory to knockdown by the exogenous miR-708. In embodiments, the replacement rhodopsin sequence lacks a 3' UTR miR-708 target sequence. In short, these AAV vectors would knock down expression of the rhodopsin that causes ER stress (and therefore photoreceptor cell death) and optionally supplementing

expression of a wild-type, or codon-optimized, rhodopsin gene that is refractory to miR-708-induced knockdown, thereby restoring normal expression and function of rhodopsin.

Methods

Cell Culture

[0132] HEK-293 cells were engineered to express human or mouse Rhodopsin P23H using the T-Rex Tetracycline Inducible system from Invitrogen. Confluent cells in 6 well plates were transfected with 4 μg miR-708 (pcDNA) vector or a control miRNA vector using Lipofectamine 2000 (Invitrogen) per the manufacturer's instructions. 48 hours post-transfection the medium was replaced with medium containing 2 μM Tetracycline. The cells were incubated an additional 24 hours and the medium was removed from each well.

Western blotting

[0133] Cells were lysed in 400 μL RIPA buffer (Thermo Scientific) containing 1mM PMSF, and passed through a 25g syringe several times. The lysate was centrifuged at 14,000rpm for 10 min. Cells were kept at 4°C throughout the process. 30 μL of supernatant was loaded onto a 4-12% Bis/Tris Gel and SDS-PAGE was performed in MOPS buffer (Invitrogen). Proteins were then transferred to a Nitrocellulose membrane using the I-Blot system from Invitrogen. The membrane was blocked for an hour at room temperature in PBS containing 0.05% Tween-20 (PBS-T) and 0.1 % I-Block (Invitrogen). The membrane was incubated overnight at 4°C in PBS-T containing 1 μg/mL anti Rhodopsin mAb 1D4 (Abcam). After washing in PBS-T several times the membrane was incubated in secondary antibody solution containing a 1:1000 dilution of anti-mouse IgG HRP conjugated Ab (R&D Systems) for an hour at room temperature. The membrane was washed in PBS-T several times and developed using ECL Reagent (Thermo Scientific). mRhodopsin protein levels were quantified using the Image-J software. The membrane was stripped of proteins in PBS containing 0.1M Glycine pH 2 and then rinsed several times in PBS-T. The membrane was then probed for hGAPDH in PBS-T containing a 1:20,000 dilution of anti GAPDH pAb (Sigma) for 2 hours at Room Temperature. After washing several times in PBS-T, secondary antibody (Anti-Rabbit IgG-HRP, R&D Systems) was diluted 1:1000 in PBS-T and incubated for 1 hour at room temperature. The membrane was washed several times and developed using ECL reagent (Thermo

Scientific). mRhodopsin protein levels were then normalized to hGAPDH protein levels using Image J software.

Endogenous miR-708 knockdown in HEK-293 cells

[0134] HEK-293 cells expressing mouse or human rhodopsin (described above) were transfected with 100 pmol pre-miR-708, anti-miR-708, or control miRNA (Ambion) using the Lipofectamine 2000 protocol for transfection with siRNA molecules (Invitrogen). At 48 hours post-transfection, the medium was replaced with medium containing 2 uM Tetracycline to induce Rhodopsin expression. 24 hours later each well was split into 2 samples. One was probed for mRhodopsin and hGAPDH using the western blot protocol above, and RNA was extracted from the other for TaqMan® (Life Technologies) analysis of Rhodopsin and miR-708 RNA expression. Total RNA (including small RNAs) was extracted from the cells using the miRNeasy kit from Qiagen, according to the manufacturer's instructions, including DNAse treatment of the samples. cDNA was synthesized from total RNA using the Quantitect Reverse Transcription system from Qiagen. cDNA was added to mRhodopsin, hCHOP (*Ddit3*), hBiP (*Hspa5*) or hGAPDH TaqMan® gene expression assays (Life Technologies). Gene expression was normalized relative to hGAPDH using the $\Delta\Delta C_t$ method. miR-708 expression was quantified using the miR-708 TaqMan®expression assay (Life Technologies). miR-708 expression was displayed relative to endogenous miR-16 expression using the $\Delta\Delta C_t$ method.

Rhodopsin kinase promoter-driven expression of miR-708 in WERI Rb-1 cells

[0135] miR-708 sequence was subcloned downstream of the Rhodopsin Kinase (RK) promoter after excision from pcDNA 6.2 GW vector (Block-iT system, Invitrogen) into vector pRK-MVM, which contains the native hRK promoter and MVM intron sequences. WERI Rb-1 cells (ATCC) were transfected with 2 μg pRK-miR-708 or pRK-miR-Control vector using Fugene-HD (Promega), according to the manufacturer's instructions. At 48 hours post-transfection, the cells were collected, and total RNA (including small RNAs) was extracted using the miRNeasy kit protocol (Qiagen). miR-708 was quantified in each sample using the miR-708 TaqMan® gene expression assay as described earlier (Life Technologies). To quantify mRhodopsin knockdown in miR-708 expressing WERI Rb-1 cells, cells were co-transfected with 2 μg each of pRK-miR-708 (or control) and pSport6 mRhodopsin P23H using Fugene-HD according to the manufacturer's instructions

(Promega). RNA was extracted as described and mRhodopsin RNA levels were quantified as described above using the ΔΔCt method relative to hGAPDH RNA levels.

Extraction of RNA from mouse retinas injected with AAV vectors

[0136] RNA was extracted from mouse retinas using the miRNeasy kit according to the manufacturer's instructions (Qiagen). Individual mouse retinas were homogenized in Qiazol Lysis Buffer using 1 mm Zirconia/Silica beads (Biospec) for 10 min. After homogenization RNA was extracted according to the manufacturer's instructions. miR-708 levels in each retina were quantified using the qStar microRNA quantification system (Origene). cDNA was synthesized using the first strand cDNA synthesis kit (Origene), followed by miR-708 specific amplification and quantification using miR-708 specific primers and a miR-708 copy standard (Origene). For quantification of Rhodopsin levels in injected mouse eyes, mRhodopsin was amplified using specific primers (Life Technologies) and quantified against a Rhodopsin cDNA standard. RdCVF levels were qualitatively analyzed against GAPDH expression using the ΔΔCt method.

Rhodopsin suppression/replacement vector

[0137] hRhodopsin cDNA (with no flanking UTR sequences) was cloned into the pRK vector by excision from the pcDNA vector and performing a blunt ended ligation into pRK-MCS. cDNA was synthesized (Biobasic) containing the hRhodopsin Kinase promoter sequence and the hβ-globin Intron with a hmiR-708 sequence insertion (sequence taken from Genbank/NCBI) located between the intron's splice acceptor/donor sites. This sequence was subcloned from pUC57 vector, ligated into pcDNA hRhodopsin vector, and renamed pRK-miR-708 hRho/wt. miRNA-708 and hRhodopsin protein levels were assayed as described above in transfected WERI Rb-1 cells.

Quantification of XBP-1 splicing in P23H mRhodopsin-transfected WERI Rb-1 cells

[0138] hWERI Rb-1 cells were co-transfected with pcDNA vector encoding a non-glycosylated P23H mutated mRhodopsin and pRK-miR-708 vector. This P23H Rhodopsin cDNA was mutated using site-directed PCR mutagenesis (Agilent Technologies) to change two Asparagine codons (at positions 2 and 5) to Alanine. The cells were transfected as described with 2 μg of each vector and incubated for 72 hrs. Total RNA was collected from

the cells as described previously. cDNA was synthesized using the High Capacity cDNA synthesis kit (Invitrogen). XBP-1 spicing was assessed using primers specific for XBP-1 and High Fidelity PCR MasterMix (Roche). Amplified sequences were analyzed on a 2% agarose gel and the relative amounts of spliced (~280 nt) vs. unspliced (~300nt) XBP-1 transcript was quantified using Image-J software.

Additional methods

[0139] Methods for immunofluorescence, Western blotting with and without Endo-glycosidase H treatment, UPR marker expression, and TUNEL staining of cells expressing wild-type or P23H mutant rhodopsin were performed as described in Adamowicz, M., *et al.* (2012) *Adv. Exp. Med. Biol.* 723:573-9.

Results

[0140] Human retinal pigmented epithelial (RPE) cells were transiently transfected with a gene encoding either human wild-type (WT) or human P23H mutant rhodopsin (a mutation linked to RP). The localization of rhodopsin was investigated by confocal immunofluorescence microscopy using anti-rhodopsin antibody. In the case of the wild type protein, the majority of the protein was processed to the plasma membrane (**FIG. 1A**), indicating normal biogenesis. By contrast, the mutant P23H showed a perinuclear/reticular distribution characteristic of endoplasmic reticulum (ER) retention, with almost no expression at the cell surface (**FIG. 1B**). These results demonstrate that P23H mutant rhodopsin fails to be trafficked properly to the plasma membrane and is instead retained in the ER.

[0141] Aggregation of rhodopsin was assessed by SDS-PAGE immunoblot analysis of detergent soluble extracts from RPE cells transiently expressing wild type or P23H mutant protein (**FIG. 2A**). Wild-type rhodopsin migrated predominantly as a diffuse band at a molecular mass of ~ 40 kDa. This species corresponds to monomeric, mature rhodopsin containing N-linked glycans. The mobility of P23H mutant rhodopsin differed markedly from wild-type rhodopsin, with the majority of P23H migrating as higher-weight dimers and oligomers (**FIG. 2A**). P23H was also sensitive to Endoglycosidase H—note that treatment with Endoglycosidase H affects the migration of P23H rhodopsin, but not wild-type, as shown in **FIG. 2B**. Endoglycosidase H is specific for core glycosylated, high

mannose N-linked oligosaccharide structures typical of proteins that have not matured beyond the ER.

[0142] Together, these data suggest that in RPE cells wild type rhodopsin is able to fold and mature beyond the ER, whereas the P23H mutant is more prone to forming non-native oligomers and is retained within the ER, perhaps due to an inability to fold productively.

[0143] Next, P23H rhodopsin's ability to induce ER stress in transfected RPE cells was assessed by measuring the levels of two markers of the UPR, BiP and CHOP. Increased BiP mRNA levels were detected in cells transiently expressing both WT and P23H rhodopsin (**FIG. 3A**), suggesting that increasing the folding load of the ER *per se* induced the UPR. However, BiP mRNA expression was significantly higher in cells expressing P23H rhodopsin (43-fold over untransfected cells) as compared with cells expressing WT rhodopsin (14-fold over untransfected cells) (**FIG. 3A**). The rhodopsin mRNA levels were identical in cells expressing WT or mutant forms of the protein (**FIG. 3A**). Thus, P23H rhodopsin is a more potent inducer of BiP than WT rhodopsin. Without wishing to be bound to theory, this discrepancy may be due to the folding defect of the mutant protein.

[0144] CHOP expression was examined next. Cells expressing the WT rhodopsin protein showed a 15-fold induction of CHOP compared to untransfected cells, while cells expressing P23H mutant showed an even greater 23-fold induction (**FIG. 3A**). As CHOP is a UPR–induced transcription factor that mediates apoptosis (Lee, E.S., *et al.* (2007) *FEBS Lett.* 581(22):4325-32), the relative levels of apoptosis between WT and P23H mutant expressing cells was measured. In agreement with the mRNA levels of CHOP, TUNEL assay results further suggested that RPE cells transiently expressing the P23H mutant are more prone to apoptosis than those expressing the wild type rhodopsin (**FIG. 3B**).

Example 2: Modulation of miR-708 levels regulates rhodopsin expression and the UPR in HEK-293 cells

[0145] A consensus sequence corresponding to a putative miR-708 target site has been found in the 3' UTR of several mammalian rhodopsin genes (Behrman, S., *et al.* (2011) *J. Cell Biol.* 192(6):919-27). This Example demonstrates that miR-708 regulation of rhodopsin may be used as a tool to modulate rhodopsin expression in cultured cells.

[0146] HEK-293 cells expressing a P23H mutant mRhodopsin gene encoding a 3'UTR miR-708 target sequence were transfected with a plasmid expressing miR-708 or miR-Control as depicted in **FIG. 4**. After 72 hrs, the cells were collected, and mP23H Rhodopsin protein expression was analyzed using a Western blot (**FIG. 5**). P23H mRhodopsin protein expression was reduced to ~30% in cells transfected with CBA-miR-708, compared to cells transfected with a CBA-miR-Control vector.

[0147] Expression of UPR target genes (CHOP/BIP) was also analyzed by TaqMan® gene expression analysis. HEK-293 cells expressing miR-708 also showed reduced expression of CHOP and BiP RNA compared to control cells (**FIG. 6**). These results suggest that reducing the level of misfolded P23H mRhodopsin results in a concomitant reduction in expression of UPR genes BiP and CHOP.

[0148] In the converse experiment, HEK-293 cells expressing either mouse P23H Rhodopsin (including a 3' UTR miR-708 target sequence) or human P23H Rhodopsin (lacking the 3' UTR miR-708 target sequence) were transfected with anti-miR-708 pre-miRNA or negative control pre-miRNA (**FIG. 7**). In this experiment, exogenous anti-miR-708 was used to inhibit endogenous HEK293 miR-708. If endogenous miR-708 regulated rhodopsin expression through the putative miR-708 target sequence, then changes in levels of the P23H rhodopsin would be observed only if there was a miR-708 target sequence in the 3' UTR of the rhodopsin gene. Cells were transfected with 100 pmol of each RNA. Cell lysates were generated, and rhodopsin protein was quantified on a Western blot while mRNA levels were analyzed by TaqMan® analysis (**FIG. 7**). Inhibition of endogenous miR-708 resulted in an increase of both mouse Rhodopsin mRNA and protein (**FIG. 7A**), whereas the levels of both human rhodopsin mRNA and protein remained unaffected (**FIG. 7B**), despite lower levels of endogenous miR-708. These results demonstrate that the regulation of rhodopsin by miR-708 requires the miR-708 target sequence in the rhodopsin 3' UTR.

[0149] Together, these results show that rhodopsin is a functional target of miR-708, and that modulation of miR-708 activity may be used as a tool to affect rhodopsin expression.

Example 3: Design of an AAV ITR plasmid expressing miR-708 under the control of the photoreceptor-specific rhodopsin kinase promoter

[0150] It is thought that buildup of mutant rhodopsin protein in the ER contributes to the ER stress underlying photoreceptor cell death in RP. The previous Example demonstrates that miR-708 expression is able to regulate overall rhodopsin levels. An adeno-associated virus (AAV)-based vector was constructed for specific expression of miR-708 in the photoreceptor cells of the retina to determine if lowering total rhodopsin levels (including wild-type and mutant forms) may alleviate ER stress independent of the rhodopsin mutation.

[0151] **FIG. 8** depicts an AAV inverted terminal repeat (ITR) plasmid designed to express miR-708 specifically in retinal photoreceptor cells. miR-708 expression was driven by the rhodopsin kinase promoter (pRK), which is specifically expressed in rod photoreceptor cells. In this vector, miR-708 was expressed from the miR-155 scaffold shown in **FIG. 4**.

[0152] Next, this AAV ITR plasmid was validated in cultured cells. WERI or RPE cells were transfected with the pre-viral plasmid described in **FIG. 8**, and the levels of miR-708 were quantitated by TaqMan® analysis. **FIG. 9A** shows that WERI cells transfected with the pRK-driven miR-708 plasmid had over a 2000-fold increase in miR-708 levels compared to WERI cells transfected with a plasmid expressing miR-Scramble (control). In contrast, RPE cells, in which the RK promoter is not significantly expressed, did not show a significant increase in miR-708 levels (**FIG. 9A**).

[0153] The function of miR-708 in regulating rhodopsin expression was confirmed by co-transfecting the pRK-miR-708 plasmid (or a miR-Control plasmid) and a plasmid with the P23H mouse rhodopsin gene harboring a 3'miR708 target sequence into WERI cells. **FIG. 9B** shows that the P23H mRhodopsin mRNA was reduced in the presence of the miR-708, compared to a miR-Control. These results demonstrate that expression of miR-708 using an AAV ITR vector is effective in reducing the expression of rhodopsin in photoreceptor cells.

Example 4: Knockdown of rhodopsin in mouse retinas using a miR-708 AAV5 vector

[0154] To test whether an AAV vector could be used to reduce rhodopsin expression in the retina *in vivo*, the pRK-miR-708 plasmid described in **FIG. 8** was packaged into an AAV5 capsid to generate AAV5-RK miR-708. In addition, an AAV5 miR-Control vector was generated. Wild-type C57bl mice received a subretinal injection of $1x10^8$ vgs of AAV5-RK miR-708 or AAV5 miR-Control in the contralateral eye. At 1 month post-injection, the mice were euthanized, and the neuro retina was extracted and flash-frozen for qPCR analysis of gene expression.

[0155] **FIG. 10A** shows that mouse eyes that had been injected with an AAV5 vector expressing miR-708 had reduced rhodopsin expression, compared to mouse eyes injected with an AAV5 miR-Control vector. In contrast, the expression of another rod-specific gene, Rod Derived Cone Viability Factor (RdCVF), was not affected (**FIG. 10B**). **FIG. 10C** confirms that eyes injected with AAV5miR708 vector showed a significant increase in miR-708 copy number, compared to eyes that received AAV5miR control. These results suggest that AAV-based vectors expressing miR-708 in rod photoreceptors are effective in reducing endogenous rhodopsin expression *in vivo*.

[0156] To demonstrate the functional relevance of rhodopsin knockdown, mouse eyes treated with AAV5 miR-708 or AAV5 miR-Control were analyzed by electroretinogram (ERG) to assess retinal function. Eyes that received the AAV5 miR-708 vector showed a decreased scotopic response, as expected if levels of rhodopsin are reduced (**FIG. 11A**). Scotopic ERG responses are an assessment of rod function, and this measurement can be correlated to rhodopsin levels. However, cone function in the same animals, as assessed by photopic ERG, was unchanged following AAV5 miR-708 delivery (**FIG. 11B**), confirming that miR-708 had a biological effect on rod photoreceptor cells while sparing the cone cells. These data demonstrate that AAV5 miR-708 delivery results in a biological effect that is restricted to the rod target cell.

Example 5: Construction of a hRhodopsin suppression/replacement vector with an intron-embedded miR-708 expression cassette

[0157] miR-708 is normally expressed *in vivo* from the first intron in the *ODZ4* gene. Therefore, a novel construct was designed based on the sequence of miR-708 and its

endogenous scaffold/flanking sequence. The miR-708 sequence was embedded into a synthetic intron and cloned downstream of the photoreceptor specific promoter Rhodopsin Kinase (RK), but upstream of the hRhodopsin cDNA. The endogenous miR-708 sequence including its flanking regulatory and processing sequences were cloned into the β-globin intron sequence upstream of the hRhodopsin cDNA sequence but downstream of the RK promoter. As such, the miR-708 sequence is 5' relative to the rhodopsin coding sequence.

[0158] **FIG. 12** provides a diagram of this 5' suppression/replacement vector. hRhodopsin (lacking a 3' UTR mir708 target sequence) was controlled by the RK promoter. The endogenous miR-708 sequence including endogenous scaffold (*e.g.*, including any Drosha/Dicer recognition motifs) was embedded within the β-globin intron. hRhodopsin cDNA (with no 3' miR-708 UTR target sequence) was included downstream of the splice junction site. miR-708 was embedded within the β-globin, which is located downstream of the RK promoter, and therefore the miR-708 was processed after splicing of the β-globin intronic sequence. In addition vector with a similar structure harboring a control miR was generated.

[0159] The vector described in **FIG. 12**, or a vector with a control miRNA, was used to transfect WERI cells. WERI cells were used because they express little, if any, endogenous miR-708, and they are permissive to the RK promoter. WERI cells were co-transfected with a cDNA encoding P23H mRhodopsin (with a 3'UTR miR-708 sequence). Both rhodopsin knockdown (RNA levels) and levels of the UPR genes CHOP and BIP were examined in transfected cells.

[0160] **FIG. 13** shows that cells co-transfected with mRhodopsin (P23H) and the miR-708 vector had reduced mRhodopsin levels compared to cells co-transfected with mRhodopsin and control miRNA vector. Additionally, the UPR genes CHOP and BiP were also down regulated in the miR-708 transfected cells compared to control. This data suggests that using the endogenous miR708 scaffold with intronic expression of miR708 provides an alternative scaffold that supports miR708 processing and expression.

Example 6: Comparison of different miR-708 scaffolds

[0161] Lower levels of miR-708 expression may be beneficial in reducing any potential off-target effects of the miRNA in a clinical setting. Therefore, different miR scaffolds were tested for strength of expression in the WERI human retinoblastoma cell line.

[0162] **FIG. 14** depicts quantified miR-708 levels in WERI cells transfected with CBA-driven miR-708, RK-driven miR708 using the miR-155 scaffold shown in **FIG. 4**, or the RK intron-embedded miR-708 hRhodopsin vector shown in **FIG. 12**. miR-708 expression in the RK intronic system was not as robust as the CBA driven system. However, miR-708 expression was still well above background and about 5 fold lower than pRKmiR708 using the miR-155 scaffold. Note that hRhodopsin was co-expressed from the intron-embedded vectors, but not in the CBA or RK miR-155 scaffold vectors.

[0163] Next, the levels of hRhodopsin mRNA were compared in WERI cells expressing the miR-708 intron-embedded, suppression/replacement vector or a miR-Control vector. **FIG. 15** shows that WERI cells transfected with the miR-708 intron-embedded, suppression/replacement vector had a similar level of hRhodopsin compared to cells transfected with the control vector. These results indicate that hRhodopsin expression from the suppression/replacement vector, which lacks the 3' UTR miR-708 target sequence, is refractory to inhibition by miR-708 expression. Both cells showed higher hRhodopsin expression than untransfected WERI cells.

Example 7: Knockdown of mutant rhodopsin by the miR-708 suppression/replacement vector reduces a marker of ER stress

[0164] The ability of the miR-708 suppression/replacement vector to reduce ER stress in cells expressing mutant rhodopsin was examined. WERI cells expressing a non-glycosylated, P23H mutant rhodopsin (N2K/N15K/P23H), with or without a 3'UTR miR708 target sequence, were transfected with the suppression replacement vector described in **FIG. 12**. Cells were harvested and RNA extracted to measure X-box binding protein 1 (XBP-1) splicing. XBP-1 is a transcription factor important in regulating ER stress genes. Its splicing is a known marker of cellular ER stress/UPR; cells undergoing UPR show increased levels of spliced XBP-1.

[0165] As shown in **FIG. 16**, cells expressing mutant Rhodopsin with a 3' UTR target sequence had decreased XBP-1 splicing when transfected with the miR-708 suppression/replacement vector. In contrast, cells expressing the mutant P23H Rhodopsin lacking the 3'UTR miR-708 target sequence had equivalent levels of XBP-1 splicing compared to cells transfected with the miR-Control sequence. These results demonstrate that knockdown of mutant rhodopsin using the miR-708 suppression/replacement vector is effective in reducing ER stress.

Example 8: Expression of miR-708 in the β-globin intron scaffold placed in the rhodopsin 3' UTR increases the expression of rhodopsin and miR-708

[0166] In order to test whether the position of the miR-708 scaffold affects its expression, a vector was constructed where the miR-708 sequence (including its flanking regulatory/processing sequences) was cloned into the β-globin intron sequence downstream of the Rhodopsin cDNA, *i.e.,* within the 3' UTR. **FIG. 17** shows a diagram of this 3' suppression/replacement vector, which is similar to that shown in **FIG. 12**, except that the miR-708 human β-globin intron scaffold is in the 3' UTR of the rhodopsin cDNA, rather than the 5' UTR.

[0167] To determine if the position of the miR-708 human β-globin intron scaffold in the vector affected miR-708 or hRhodopsin expression from the vector, WERI cells were transfected with the 5' UTR vector of **FIG. 12** or the 3' UTR vector of **FIG. 17**. **FIG. 18** shows the expression of hRhodopsin and miR-708 in these cells. The vector with the miR-708 scaffold in the 3' UTR was found to produce higher levels of both hRhodopsin and miR-708 RNA than the vector using the 5' UTR configuration.

Example 9: Evaluation of the suppression/replacement vector in a P23H mouse model of retinal degeneration

[0168] Suppression/replacement constructs are evaluated in a P23H mouse model of retinal degeneration. In this model, the mutant P23H protein expressed in rod photoreceptor cells induces ER stress/UPR, causing apoptosis and ultimate rod cell death (Lee, E.S., *et al.* (2007) *FEBS Lett.* 581(22):4325-32). Following rod cell death there is a non-cell-autonomous death of cone cells.

[0169] The P23H mouse is treated with a suppression/replacement AAV vector expressing miR-708 and a human rhodopsin gene refractory to knockdown by miR708 (because it lacks a miR-708 target sequence). The suppression/replacement vector results in knockdown of both WT and P23H mouse rhodopsin, but the replacement rhodopsin gene compensates for the reduction in WT levels of rhodopsin. Therefore, the vector provides the necessary rod rhodopsin to maintain rod cell function and integrity.

[0170] An alternate suppression/replacement construct design is also tested. As shown in **FIG. 19**, this alternate vector drives expression of miR-708 from the RK promoter and co-express hRhodopsin (refractory to miR-708 knockdown) using the mouse opsin promoter.

[0171] These suppression/replacement vectors are also tested as described above in a P23H mouse model in which the endogenous mRhodopsin gene harbors a single copy loss-of-function allele (*e.g.*, the mouse is heterozygous with respect to a mRhodopsin knockout allele). This heterozygous mouse model may be constructed using standard mouse genetic techniques from a $mRho^{-/-}$ mouse and the P23H model described above. Without wishing to be bound to theory, it is thought that this $mRho^{+/-}$ P23H mouse model, which contains one copy of the mutant hRhodopsin P23H allele and one copy of the wild-type mouse gene, may resemble a human ADRP genotype in which patients have equal copies of the mutant and wild-type rhodopsin alleles.

Example 10: Evaluation of additional suppression/replacement vectors

[0172] Several vectors were cloned that express both miR-708 (or a control miRNA sequence) and hRhodopsin from a single vector. The vectors differ from each other in that the flanking sequences of the miRNA sequence are derived from either miR-155 (taken from Invitrogen "Block-It" system) or endogenous miR-708 5' and 3' flanking sequences. The miRNA sequences are embedded in the hβ-globin intron downstream of the Rhodopsin Kinase promoter and upstream of the hRhodopsin ORF. The goal was to test if expression and miRNA processing are similar from each construct. An additional pair of vectors contained the miRNA sequences (control or miR-708) downstream of the hRhodopsin ORF, also embedded in the β-globin intron. Only the vectors containing the miR-708 endogenous flanking 5' and 3' sequences located downstream of the hRhodopsin ORF were tested in this experiment, both endogenous miR-708 and miR-155 flanking sequences were tested in the vectors where the β-globin intron is located upstream of the hRhodopsin ORF.

WERI cells were transfected with each construct and both miR-708 expression and hRhodopsin expression were determined.

[0173] The results in **Fig. 20** indicate that the miR-155 flanking sequences generate better expression (or miRNA processing) of miR-708 compared to endogenous miR-708 flanking sequences. miR-708 expression was about 10 fold higher in those cells transfected with vectors containing the miR-155 flanking sequences compared to miR-708 flanking sequences. The vectors containing miR-708 flanking sequences had lower expression of miR-708 regardless of whether the sequences were upstream or downstream relative to the hRhodopsin ORF. hRhodopsin expression was unaffected by miR-708 overexpression, as its expression levels are approximately equal regardless of the miRNA sequence co-expressed in the vector. miR-708 expression was not detected in vectors containing control miRNA sequences, as expected.

Example 11: Evaluation of additional suppression/replacement vectors with a mutated miR-708 target sequence

[0174] As described above, a consensus sequence corresponding to a putative miR-708 target site has been found in the 3' UTR of several mammalian rhodopsin genes (Behrman, S., *et al.* (2011) *J. Cell Biol.* 192(6):919-27). This Example demonstrates that a rhodopsin with a mutated miR-708 target sequence can be used in a suppression/replacement vector.

[0175] An rAAV vector is constructed comprising nucleic acid encoding miR-708 and a human rhodopsin gene. The human rhodopsin gene is mutated in the miR-708 target sequence (SEQ ID NO:19) by nucleotide substitution, deletion or insertion to reduce or prevent recognition by miR-708. In some examples, the entire miR-708 target sequence is deleted. In some examples, reduction or prevention by miR-708 is measured in reference to miR-708 recognition of a wild-type rhodopsin 3'UTR comprising the miR-708 target sequence.

[0176] To test for suppression of autosomal dominant rhodopsin by miR-708 with concomitant expression of wild-type rhodopsin, HEK-293 cells expressing a P23H mutant mRhodopsin gene encoding a 3'UTR miR-708 target sequence are transfected with a plasmid expressing miR-708 and human rhodopsin with (CBA-miR-708-hRho-3'UTR$^-$) or without (CBA-miR-708-hRho-3'UTR$^+$) a mutated miR-708 target sequence. A miR-

Control as described in Example 2 is also used. After 72 hrs, the cells are collected, and mP23H Rhodopsin and human rhodopsin protein expression are analyzed using a Western blot. Reduction of P23H mRhodopsin protein expression in cells transfected with the CBA-miR-708-hRho-3'UTR$^-$ or CBA-miR-708-hRho-3'UTR$^+$ compared to cells transfected with a CBA-miR-Control vector indicates miR-708 activity. Expression of human rhodopsin in cells transfected with CBA-miR-708-hRho-3'UTR$^-$ but not CBA-miR-708-hRho-3'UTR$^+$ indicates that the rhodopsin encoded by CBA-miR-708-hRho-3'UTR$^-$ is refractory to suppression by miR-708.

Example 12: AAV-mediated suppression of endogenous rhodopsin and expression of human rhodopsin in the mouse retina

[0177] Based on the experiments described above, further experiments were performed to test the rhodopsin suppression/replacement strategy in an intact eye. This Example demonstrates the efficacy of a suppression/replacement AAV vector built using a miR-708 scaffold in the mouse retina.

[0178] An AAV5 capsid with a vector bearing the rod-specific opsin promoter, the miR-708 scaffold (*e.g.,* the miR-708 endogenous scaffold/flanking sequences), and a human rhodopsin replacement gene was constructed. In one version of this vector, the miR-708 sequence (*e.g.,* the miR-708 sequence that binds the miR-708 target sequence) was inserted to drive expression of miR-708 in the context of the miR708 scaffold and the human rhodopsin replacement gene (AAV5OPSmiR708$_{708}$hRHO). In another version of this vector, a control vector was generated that harbored a miR control sequence (AAV5OPSmiRcontrol$_{708}$hRHO). In both vectors, the replacement human rhodopsin gene was refractory to miR-708 knockdown because it lacks a miR-708 target sequence. Both vectors were injected subretinally into the retinas of wild type mice. For each mouse, the contralateral naïve eye was uninjected, and expression in each injected retina was normalized as fold expression compared to the contralateral uninjected retina. Three weeks post injection, the retinas were harvested and assayed for miR-708 levels (**FIG. 21A**), mouse rhodopsin mRNA levels (**FIG. 21B**), and human rhodopsin (**FIG. 21C**).

[0179] **FIG. 21A** shows an increase in miR-708 levels in the mouse retina following injection with the AAV5OPSmiR708$_{708}$hRHO vector, as compared to the contralateral naive eye. A significant reduction in mouse rhodopsin was measured in the eye that

received AAV5OPSmiR708$_{708}$hRHO, and no reduction in mouse rhodopsin was measured in eyes that received the control vector, AAV5OPSmiRcontrol$_{708}$hRHO (**FIG. 21B**). In addition, human rhodopsin levels were increased up to 100 fold by both vectors, compared to the contralateral uninjected naïve eye (**FIG. 21C**). These data demonstrate that the AAV5OPSmiR708$_{708}$hRHO vector was efficacious *in vivo*.

[0180] In summary, the optimized suppression/replacement vector AAV5OPSmiR708$_{708}$hRHO achieved knockdown of mouse rhodopsin by miR-708 (endogenous mouse rhodopsin has a 3'UTR target sequence) with concomitant expression of the replacement human rhodopsin, which was refractory to miR708 knockdown (the human rhodopsin replacement gene lacks a 3'UTR miR708 target sequence). These results show the efficacy of the suppression/replacement strategy in the intact mammalian eye.

Example 13: Validation of candidate vectors in human cells

[0181] Candidate AAV5-based vectors were next assayed for the ability to promote miR-708 and human rhodopsin expression in human cells (HeLa).

[0182] Two different promoters were tested: rhodopsin kinase (GRK1) and the opsin promoter. The rhodopsin kinase promoter is described above. The opsin promoter (shown in SEQ ID NO:22) contains a 676bp fragment encoding a 400bp CMV enhancer upstream of the opsin promoter sequence (-500bp - +15bp). In addition 65bp NRL sequence is included; this encodes a neural retinal basic zipper factor (a Rod photoreceptor specific transcription factor). Downstream of the promoter construct is a hybrid intron sequence from CBA exon1 and minute virus of mouse (MVM) – called MVM intron sequence (shown in SEQ ID NO:23). A diagram of this promoter construct is depicted in **FIG. 22**.

[0183] Two different scaffolds were used: the miR-155 scaffold or the miR-708 scaffold. Both were embedded in a beta globin intron. In total, 4 candidate vectors were tested: AAV5GRK1miR708_155hRho (AAV5 vector with rhodopsin kinase promoter driving expression of miR-708 in a miR-155 scaffold and human rhodopsin minus the miR-708 target sequence; SEQ ID NO:24), AAV5GRK1miR708_708hRho (AAV5 vector with rhodopsin kinase promoter driving expression of miR-708 in a miR-708 scaffold and human rhodopsin minus the miR-708 target sequence; SEQ ID NO:25), AAV5OPSmiR708_155hRho (AAV5 vector with opsin promoter driving expression of

miR-708 in a miR-155 scaffold and human rhodopsin minus the miR-708 target sequence; SEQ ID NO:26), and AAV5OPSmiR708_708hRho (AAV5 vector with opsin promoter driving expression of miR-708 in a miR-708 scaffold and human rhodopsin minus the miR-708 target sequence; SEQ ID NO:27). **FIG. 23A** shows the miR-708 sequence embedded in the beta globin intron. The miR-708 and miR-155 scaffolds are shown in **FIGS. 23B** and **23C**, respectively.

[0184] Each of the 4 candidate AAV5 vectors was used to infect HeLa cells (using the AdTs149 helper virus), and levels of miR-708 and hRhodopsin were measured. As shown in **FIG. 24**, all four vectors resulted in miR-708 and hRhodopsin expression in human cells *in vivo*, as compared to vectors driving expression of a control miR from either the opsin or the rhodopsin kinase promoter (Ops miR-Cont and RK miR-Cont, respectively). These results demonstrate the successful validation of several vectors that may be used for suppression/replacement strategies (such as those described above) in human cells.

SEQUENCES

miR-708 nucleotide sequence

AACTGCCCTCAAGGAGCTTACAATCTAGCTGGGGGTAAATGACTTGCACATGAACACAACTAGACTG
TGAGCTTCTAGAGGGCAGGGA (SEQ ID NO:1)

Human rhodopsin amino acid sequence

MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLYVTVQHKK
LRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLGGEIALWSLVVLAIE
RYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIPEGLQCSCGIDYYTLKPEVNNE
SFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQESATTQKAEKEVTRMVIIMVIAFLICWVPY
ASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAIYNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASA
TVSKTETSQVAPA (SEQ ID NO:2)

Human rhodopsin cDNA-UTR deleted

ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCC
CCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTGGCCGCCTACATGTT
TCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTACGTCACCGTCCAGCACAAGAAG
CTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTG
GCTTCACCAGCACCCTCTACACCTCTCTGCATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTT
GGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAG
CGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCG
TTGCCTTCACCTGGGTCATGGCGCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACAT
CCCCGAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAACAACGAG
TCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTTTTCTGCTATG
GGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCAGCCACCACACAGAAGGC
AGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTTCCTGATCTGCTGGGTGCCCTAC
GCCAGCGTGGCATTCTACATCTTCACCCACCAGGGCTCCAACTTCGGTCCCATCTTCATGACCATCC
CAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCTGTCATCTATATCATGATGAACAAGCAGTT
CCGGAACTGCATGCTCACCACCATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCT
ACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCC (SEQ ID NO:3)

Human rhodopsin cDNA-includes 3'UTR

AGAGTCATCCAGCTGGAGCCCTGAGTGGCTGAGCTCAGGCCTTCGCAGCATTCTTGGGTGGGAGCAG
CCACGGGTCAGCCACAAGGGCCACAGCCATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTC
TCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGC
AGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCAC
GCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCC
GTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCATGGATACT
TCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCCCT
GTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCGC
TTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGGCCTGCGCCGCAC
CCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTA
CACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCATC
CCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGC
AGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCAT
CGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGCTCC
AACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCTG
TCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACCATCTGCTGCGGCAAGAA
CCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCC
TAAGACCTGCCTAGGACTCTGTGGCCGACTATAGGCGTCTCCCATCCCCTACACCTTCCCCCAGCCA
CAGCCATCCCACCAGGAGCAGCGCCTGTGCAGAATGAACGAAGTCACATAGGCTCCTTAATTTTTTT
TTTTTTTTTAAGAAATAATTAATGAGGCTCCTCACTCACCTGGGACAGCCTGAGAAGGGACATCCAC

CAAGACCTACTGATCTGGAGTCCCACGTTCCCCAAGGCCAGCGGGATGTGTGCCCCTCCTCCTCCCA
ACTCATCTTTCAGGAACACGAGGATTCTTGCTTTCTGGAAAAGTGTCCCAGCTTAGGGATAAGTGTC
TAGCACAGAATGGGGCACACAGTAGGTGCTTAATAAATGCTGGATGGATGCAGGAAGGAATGGAGGA
ATGAATGGGAAGGGAGAACATATCTATCCTCTCAGACCCTCGCAGCAGCAGCAACTCATACTTGGCT
AATGATATGGAGCAGTTGTTTTTCCCTCCCTGGGCCTCACTTTCTTCTCCTATAAAATGGAAATCCC
AGATCCCTGGTCCTGCCGACACGCAGCTACTGAGAAGACCAAAAGAGGTGTGTGTGTGTCTATGTGT
GTGTTTCAGCACTTTGTAAATAGCAAGAAGCTGTACAGATTCTAGTTAATGTTGTGAATAACATCAA
TTAATGTAACTAGTTAATTACTATGATTATCACCTCCTGATAGTGAACATTTTGAGATTGGGCATTC
AGATGATGGGGTTTCACCCAACCTTGGGGCAGGTTTTTAAAAATTAGCTAGGCATCAAGGCCAGACC
AGGGCTGGGGGTTGGGCTGTAGGCAGGGACAGTCACAGGAATGCAGAATGCAGTCATCAGACCTGAA
AAAACAACACTGGGGGAGGGGGACGGTGAAGGCCAAGTTCCCAATGAGGGTGAGATTGGGCCTGGGG
TCTCACCCCTAGTGTGGGGCCCCAGGTCCCGTGCCTCCCCTTCCCAATGTGGCCTATGGAGAGACAG
GCCTTTCTCTCAGCCTCTGGAAGCCACCTGCTCTTTTGCTCTAGCACCTGGGTCCCAGCATCTAGAG
CATGGAGCCTCTAGAAGCCATGCTCACCCGCCCACATTTAATTAACAGCTGAGTCCCTGATGTCATC
CTTATCTCGAAGAGCTTAGAAACAAAGAGTGGGAAATTCCACTGGGCCTACCTTCCTTGGGGATGTT
CATGGGCCCCAGTTTCCAGTTTCCCTTGCCAGACAAGCCCATCTTCAGCAGTTGCTAGTCCATTCTC
CATTCTGGAGAATCTGCTCCAAAAAGCTGGCCACATCTCTGAGGTGTCAGAATTAAGCTGCCTCAGT
AACTGCTCCCCCTTCTCCATATAAGCAAAGCCAGAAGCTCTAGCTTTACCCAGCTCTGCCTGGAGAC
TAAGGCAAATTGGGCCATTAAAAGCTCAGCTCCTATGTTGGTATTAACGGTGGTGGGTTTTGTTGCT
TTCACACTCTATCCACAGGATAGATTGAAACTGCCAGCTTCCACCTGATCCCTGACCCTGGGATGGC
TGGATTGAGCAATGAGCAGAGCCAAGCAGCACAGAGTCCCCTGGGGCTAG
AGGTGGAGGAGGCAGTCCTGGGAATGGGAAAAACCCCA (SEQ ID NO:4)

RK-miR708 only

GGCCCCAGAAGCCTGGTGGTTGTTTGTCCTTCTCAGGGGAAAAGTGAGGCGGCCCCTTGGAGGAAGG
GGCCGGGCAGAATGATCTAATCGGATTCCAAGCAGCTCAGGGGATTGTCTTTTTCTAGCACCTTCTT
GCCACTCCTAAGCGTCCTCCGTGACCCCGGCTGGGATTTAGCCTGGTGCTGTGTCAGCCCCGGTCTC
CCAGGGGCTTCCCAGTGGTCCCCAGGAACCCTCGACAGGGCCCGGTCTCTCTCGTCCAGCAAGGGCA
GGGACGGGCCACAGGCCAAGGGCGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCG
CCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGG
CCCTTCTCCTCCGGGCTGTAATTAGCGCTTGGTTTAATGACGGCTTGTTTCTTTTCTGTGGCTGCGT
GAAAGCCTTGAGGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGT
GTGTGTGCGTGGGGAGCGCCGCGTGCGGCTCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGCGG
CGCGGGGCTTTGTGCGCTCCGCAGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCCGCGGTGC
GGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGTGAGCAGGGGGTG
TGGGCGCGTCGGTCGGGCTGCAACCCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGCACGGCCCGGC
TTCGGGTGCGGGGCTCCGTACGGGGCGTGGCGCGGGGCTCGCCGTGCCGGGCGGGGGGTGGCGGCAG
GTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCGGCGGCC
CCCGGAGCGCCGGCGGCTGTCGAGGCGCGGCGAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGA
GAGGGCGCAGGGACTTCCTTTGTCCCAAATCTGTGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACC
CCCTCTAGCGGGCGCGGGGCGAAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTC
GTGCGTCGCCGCGCCGCCGTCCCCTTCTCCCTCTCCAGCCTCGGGGCTGTCCGCGGGGGGACGGCTG
CCTTCGGGGGGGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCT
GCTAACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTATTGTGCTGT
CTCATCATTTTGGCAAAGAATTCTTCGAAAGATCCTGGAGGCTTGCTGAAGGCTGTATGCTGAAGGA
GCTTACAATCTAGCTGGGGTTTTGGCCACTGACTGACCCCAGCTAGTGTAAGCTCCTTCAGGACACA
AGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCA (SEQ ID NO:5)

RK-miR-708-op-rhodopsin

CAATCTCCCAGATGCTGATTCAGCCAGGAACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGT
TCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCC
AACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC
ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT
GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATG

ACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCACAAATAGTT
ATCGAGCCGCTGAGCCGGGGGGCGGGGGGTGTGAGACTGGAGGCGATGGACGGAGCTGACGGCACAC
ACAGCTCAGATCTGTCAAGTGAGCCATTGTCAGGGCTTGGGGACTGGATAAGTCAGGGGGTCTCCTG
GGAAGAGATGGGATAGGTGAGTTCAGGAGGAGACATTGTCAACTGGAGCCATGTGGAGAAGTGAATT
TAGGGCCCAAAGGTTCCAGTCGCAGCCTGAGGCCACCAGACTGACATGGGGAGGAATTCCCAGAGGA
CTCTGGGGCAGACAAGATGAGACACCCTTTCCTTTCTTTACCTAAGGGCCTCCACCCGATGTCACCT
TGGCCCCTCTGCAAGCCAATTAGGCCCCGGTGGCAGCAGTGGGATTAGCGTTAGTATGATATCTCGC
GGATGCTGAATCAGCCTCTGGCTTAGGGAGAGAAGGTCACTTTATAAGGGTCTGGGGGGGGTCAGTG
CCTGGAGTTGCGCTGTGGGAGCCGTCAGTGGCTGAGCTCAAGAGGTAAGGGTTTAAGGGATGGTTGG
TTGGTGGGGTATTAATGTTTAATTACCTGTTTTACAGGCCTGAAATCACTTGGTTTTAGGTTGGTAC
ATCTGCAGAATTCAGCCACCACCGGCACAATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTT
CTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGG
CAGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCA
CGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGC
CGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCATGGATAC
TTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCCC
TGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCG
CTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGGCCTGCGCCGCA
CCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAATCGACTACT
ACACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCAT
CCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAG
CAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCA
TCGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGCTC
CAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCT
GTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACCATCTGCTGCGGCAAGA
ACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGC
CTAACCAAGAAAGCTTAAGTTTGTGTCCCGGCTTAGGGCTAAATGTCTAGGACAGAATGGAACACAT
AGTAGCTGATTAATAAATGCTAGCTGGATGAAGGGAGGAATGAGTGACTGACTGAGTGGATATATGA
GTGAAGGGATTAATGGAAGGGAACATGGATGTCCTCAGGTGCCCAACCTGGCAGATCCAGTCATGTC
TGGCTGGAATCTATAAGCAGTTTTACATACCTGCCCTGAGCTTTATTGCGGTAGTTTATCACAGTTA
AATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAG
GTAGCCTTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAA
GGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAAAACCTAACCCCCATGGTTGGCGAGGGACT
GCTGTGTGTGAAATGGTAACTGCCCTCAAGGAGCTTACAATCTAGCTGGGGGTAAATGACTTGCACA
TGAACACAACTAGACTGTGAGCTTCTAGAGGGCAGGGACCTTACCCTAGTCATCTCTCTTCTCACCC
TGCACACCCTCCCTGAGGGATCTCATGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGAC
ATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCACACCGGCACAATGAATGGCACAGA
AGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCA
CAGTCAGAGATAAATGACAGTGACAGCAACGTGAGCTGCAGCCCTTAGGACTGAGAAAGCATCGAGA
CCAGGGGTCTCCGGCAAGGCCTAGGTCCTCCCTTCAGTATGGAAACCTTGCCTCATGTCTCTCAGCC
TCCTTGGCCTGTGGAGATCCAGCCCTTCCTCTTGGCTTCTGGATACATTTGCTCTTCTACACCAGCA
ACCAAGTGGCAACAGTTCCAGGCCAGTATGGAGTTTTAGAAGCCATGCCAATATGCCCACCTTCAGG
GAGCAGCTGAGTCCTTGATGCCACCCTTGTTCTGAAGAGTTCAGAAACACAGTGCAAGACATGACCA
GGCCTCATCCTTAGGATGCTCATGGATCCAGTTCTTAGCTCCCTTGTTGGATATGCTGTTTTCCTTG
GCCTTTGGTCTTTTCTTTATCCCAGAGGGTTTTGGCTTTAAGGCCAACAGGAACTATGGGGTACCAG
AATTGAGCAGCCTCAGTCTGCATCCCTCCTCTATAGAACCACAGCTGGGCCCTCAGCAGGCCCAACT
CTGCATGGGGACAGAGGCATTAAAAGC (SEQ ID NO:6)

RK-intron-rhodopsin-miR-708.

GGGCCCCAGAAGCCTGGTGGTTGTTTGTCCTTCTCAGGGGAAAAGTGAGGCGGCCCCTTGGAGGAAGGGGCCG
GGCAGAATGATCTAATCGGATTCCAAGCAGCTCAGGGGATTGTCTTTTTCTAGCACCTTCTTGCCACTCCTAA
GCGTCCTCCGTGACCCCGGCTGGGATTTAGCCTGGTGCTGTGTCAGCCCCGGTCTCCCAGGGGCTTCCCAGTG
GTCCCCAGGAACCCTCGACAGGGCCCGGTCTCTCTCGTCCAGCAAGGGCAGGGACGGGCCACAGGCCAAGGGC
GGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGA
CTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCAAGAGGTAA

GGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGTTTTACAGGCCTGAAATCACTTGGT
TTTAGGTTGGGGATCCGGTACCCAATTGCCATGGGCTAGCATGCATGAGCTCCCTGCAGGGTTTATCTGCAGA
ATTCAGCCACCACCGGCACAATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGG
TGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTGGCCGCC
TACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTACGTCACCGTCCAGCACAAGA
AGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTT
CACCAGCACCCTCTACACCTCTCTGCATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTC
TTTGCCACCCTGGGCGGTGAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGT
GTAAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGC
GCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGA
ATCGACTACTACACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCA
CCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCA
GCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTTC
CTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGCTCCAACTTCGGTCCCA
TCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCTGTCATCTATATCATGATGAA
CAAGCAGTTCCGGAACTGCATGCTCACCACCATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCT
GCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCCTAACCAAGAAAGCTTAAGTTTGTGTCCCGGC
TTAGGGCTAAATGTCTAGGACAGAATGGAACACATAGTAGCTGATTAATAAATGCTAGCTGGATGAAGGGAGG
AATGAGTGACTGACTGAGTGGATATATGAGTGAAGGGATTAATGGAAGGGAACATGGATGTCCTCAGGTGCCC
AACCTGGCAGATCCAGTCATGTCTGGCTGGAATCTATAAGCAGTTTTACATACCTGCCCTGAGCTTTATTGCG
GTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTG
ACTCTCTTAAGGTAGCCTTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGG
TTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAAAACCTAACCCCCATGGTTGGCGAGGGACTG
CTGTGTGTGAAATGGTAACTGCCCTCAAGGAGCTTACAATCTAGCTGGGGGTAAATGACTTGCACATGAACAC
AACTAGACTGTGAGCTTCTAGAGGGCAGGGACCTTACCCTAGTCATCTCTCTTCTCACCCTGCACACCCTCCC
TGAGGGATCTCATGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCT
CCACAGGTGTCCACTCCCAGTTCACACCGGCACAATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTC
TCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTCAGAGATAAATGACAGTGACAGCAACG
TGAGCTGCAGCCCTTAGGACTGAGAAAGCATCGAGACCAGGGGTCTCCGGCAAGGCCTAGGTCCTCCCTTCAG
TATGGAAACCTTGCCTCATGTCTCTCAGCCTCCTTGGCCTGTGGAGATCCAGCCCTTCCTCTTGGCTTCTGGA
TACATTTGCTCTTCTACACCAGCAACCAAGTGGCAACAGTTCCAGGCCAGTATGGAGTTTTAGAAGCCATGCC
AATATGCCCACCTTCAGGGAGCAGCTGAGTCCTTGATGCCACCCTTGTTCTGAAGAGTTCAGAAACACAGTGC
AAGACATGACCAGGCCTCATCCTTAGGATGCTCATGGATCCAGTTCTTAGCTCCCTTGTTGGATATGCTGTTT
TCCTTGGCCTTTGGTCTTTTCTTTATCCCAGAGGGTTTTGGCTTTAAGGCCAACAGGAACTATGGGGTACCAG
AATTGAGCAGCCTCAGTCTGCATCCCTCCTCTATAGAACCACAGCTGGGCCCTCAGCAGGCCCAACTCTGCAT
GGGGACAGAGGCATTAAAAGC (SEQ ID NO:7)

RK-miR-708-intron hRho wt

GGGCCCCAGAAGCCTGGTGGTTGTTTGTCCTTCTCAGGGGAAAAGTGAGGCGGCCCCTTGGAGGAAG
GGGCCGGGCAGAATGATCTAATCGGATTCCAAGCAGCTCAGGGGATTGTCTTTTTCTAGCACCTTCT
TGCCACTCCTAAGCGTCCTCCGTGACCCCGGCTGGGATTTAGCCTGGTGCTGTGTCAGCCCCGGTCT
CCCAGGGGCTTCCCAGTGGTCCCCAGGAACCCTCGACAGGGCCCGGTCTCTCTCGTCCAGCAAGGGC
AGGGACGGGCCACAGGCCAAGGGCACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTGCTA
ACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAGGTAGCCTT
GCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCA
ATAGAAACTGGGCTTGTCGAGACAGAGAAAAACCTAACCCCCATGGTTGGCGAGGGACTGCTGTGTG
TGAAATGGTAACTGCCCTCAAGGAGCTTACAATCTAGCTGGGGGTAAATGACTTGCACATGAACACA
ACTAGACTGTGAGCTTCTAGAGGGCAGGGACCTTACCCTAGTCATCTCTCTTCTCACCCTGCACACC
CTCCCTGAGGGATCTCATGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTT
TGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCACACCGGCACAATGAATGGCACAGAAGGCCCTA
ACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTA
CCTGGCTGAGCCATGGCAGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTC
CCCATCAACTTCCTCACGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACA
TCCTGCTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACAC
CTCTCTGCATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTG
GGCGGTGAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGC
CCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGC

GCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCG
TGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCG
TGGTCCACTTCACCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAA
GGAGGCCGCTGCCCAGCAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATG
GTCATCATCATGGTCATCGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCT
TCACCCACCAGGGCTCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGC
CGCCATCTACAACCCTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACC
ATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGA
GCCAGGTGGCCCCGGCC (SEQ ID NO:8)

RK-intron-miR-708-op-hRho wt

CAATCTCCCAGATGCTGATTCAGCCAGGAACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGT
TCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCC
AACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC
ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT
GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATG
ACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCACAAATAGTT
ATCGAGCCGCTGAGCCGGGGGGCGGGGGGTGTGAGACTGGAGGCGATGGACGGAGCTGACGGCACAC
ACAGCTCAGATCTGTCAAGTGAGCCATTGTCAGGGCTTGGGGACTGGATAAGTCAGGGGGTCTCCTG
GGAAGAGATGGGATAGGTGAGTTCAGGAGGAGACATTGTCAACTGGAGCCATGTGGAGAAGTGAATT
TAGGGCCCAAAGGTTCCAGTCGCAGCCTGAGGCCACCAGACTGACATGGGGAGGAATTCCCAGAGGA
CTCTGGGGCAGACAAGATGAGACACCCTTTCCTTTCTTTACCTAAGGGCCTCCACCCGATGTCACCT
TGGCCCCTCTGCAAGCCAATTAGGCCCCGGTGGCAGCAGTGGGATTAGCGTTAGTATGATATCTCGC
GGATGCTGAATCAGCCTCTGGCTTAGGGAGAGAAGGTCACTTTATAAGGGTCTGGGGGGGGGTCAGTG
CCTGGAGTTGCGCTGTGGGAGCCGTCAGTGGCTGAGCTCAAGAGGTAAGGGTTTAAGGGATGGTTGG
TTGGTGGGGTATTAATGTTTAATTACCTGTTTTACAGGCCTGAAATCACTTGGTTTTAGGTTGGTAC
ATCTGCAGAATTCAGCCACCACCGGCACAATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTT
CTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGG
CAGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCA
CGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGC
CGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCATGGATAC
TTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCCC
TGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCG
CTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGGCCTGCGCCGCA
CCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAATCGACTACT
ACACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCAT
CCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAG
CAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCA
TCGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGCTC
CAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCT
GTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACCATCTGCTGCGGCAAGA
ACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGC
CTAACCAAGAAAGCTTAAGTTTGTGTCCCGGCTTAGGGCTAAATGTCTAGGACAGAATGGAACACAT
AGTAGCTGATTAATAAATGCTAGCTGGATGAAGGGAGGAATGAGTGACTGACTGAGTGGATATATGA
GTGAAGGGATTAATGGAAGGGAACATGGATGTCCTCAGGTGCCCAACCTGGCAGATCCAGTCATGTC
TGGCTGGAATCTATAAGCAGTTTTACATACCTGCCCTGAGCTTTATTGCGGTAGTTTATCACAGTTA
AATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAG
GTAGCCTTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAA
GGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAAAACCTAACCCCCATGGTTGGCGAGGGACT
GCTGTGTGTGAAATGGTAACTGCCCTCAAGGAGCTTACAATCTAGCTGGGGGTAAATGACTTGCACA
TGAACACAACTAGACTGTGAGCTTCTAGAGGGCAGGGACCTTACCCTAGTCATCTCTCTTCTCACCC
TGCACACCCTCCCTGAGGGATCTCATGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGAC
ATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCACACCGGCACAATGAATGGCACAGA
AGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCA

CAGTCAGAGATAAATGACAGTGACAGCAACGTGAGCTGCAGCCCTTAGGACTGAGAAAGCATCGAGA
CCAGGGGTCTCCGGCAAGGCCTAGGTCCTCCCTTCAGTATGGAAACCTTGCCTCATGTCTCTCAGCC
TCCTTGGCCTGTGGAGATCCAGCCCTTCCTCTTGGCTTCTGGATACATTTGCTCTTCTACACCAGCA
ACCAAGTGGCAACAGTTCCAGGCCAGTATGGAGTTTTAGAAGCCATGCCAATATGCCCACCTTCAGG
GAGCAGCTGAGTCCTTGATGCCACCCTTGTTCTGAAGAGTTCAGAAACACAGTGCAAGACATGACCA
GGCCTCATCCTTAGGATGCTCATGGATCCAGTTCTTAGCTCCCTTGTTGGATATGCTGTTTTCCTTG
GCCTTTGGTCTTTTCTTTATCCCAGAGGGTTTTGGCTTTAAGGCCAACAGGAACTATGGGGTACCAG
AATTGAGCAGCCTCAGTCTGCATCCCTCCTCTATAGAACCACAGCTGGGCCCTCAGCAGGCCCAACT
CTGCATGGGGACAGAGGCATTAAAAGC (SEQ ID NO:9)

Chimeric Intron

GGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGG
CTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATT
AGCGCTTGGTTTAATGACGGCTTGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTGAGGGGCTCCGGGA
GGGCCCTTTGTGCGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTGTGTGCGTGGGGAGCGCCGCG
TGCGGCTCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTGTGCGCTCCGCA
GTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCCGCGGTGCGGGGGGGGCTGCGAGGGGAACAA
AGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGTGAGCAGGGGGTGTGGGCGCGTCGGTCGGGCTGCAA
CCCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTACGG
GGCGTGGCGCGGGGCTCGCCGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGG
GCCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCCGGAGCGCCGGCGGCTGTCGA
GGCGCGGCGAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGT
CCCAAATCTGTGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGGCGAA
GCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCCGCCGTCCC
CTTCTCCCTCTCCAGCCTCGGGGCTGTCCGCGGGGGGACGGCTGCCTTCGGGGGGGACGGGGCAGGG
CGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTAACCATGTTCATGCCTTCTT
CTTTTTCCTACA (SEQ ID NO:10)

Stuffer sequence

AAGCTTGAAATGCCACCTCCTCTGATATTCTAGGTGTCCTGGAAGCCTGTCTCATCTTGCCCTGTAG
TGTTGGGTCACCTGGCCCCCAGCCTGTAACATCCCCAGGGCCCTACACCCAGAGAAACACGGGGCTG
GTGGCAGTGCCCAGTGACAACCGTTTAGTGGATAAGAGAAGAGTGACCACACCAGGCTGAGTGCTCC
TCTCTGGTTTTCCATGGGGAGACAATGCCACCCTGAGCAGGGTCTGGTGTGAGCGGCAGCTGGCTCT
GGGCTCTCTGATCCGTTACCCTCTCAGCCTCTTTGTTCTTTCTCAACCCCTGGAGCAGAGACCTCAG
GAGGTGCTGGCATGGAACAGAGAAATTCCAGCCTCGATTCCTATTATGAACCCGACACCTTTTGTAT
TTTCATCTTGGTTTTACAGTGTACAAAACGAACTAGATCAGCAGGGCATGGGCATAATCACGAATGC
ACACACATACACTAATGTGTGGCTCATGTTTAAGTATCACTTACTACAGGACACCCAATCTAACAGC
ACCGATAAAGTGACAGAGAAACGCAAGCCTTCTGCGAACATGGCCTGGCTGTTCCAATTCCGAACCT
TGCTTTTCTGGGCCTTGCCACACAGGCTCTTCCCCCGTCCCCCCAGGGACATTCTACCCTTGAACTC
CACACTCCACTGCTGCCTTTGCCAGGAAGCCCATCTGTTCCTTTTTGGTTCTGCCAGAACGTGTGGT
GGTGCTGCTGTCCCTGCCTTGGGCACTGGATATTGGGAAGGGACAGTGTCCACACTGGAGTGGGAAG
TTCCCAGGGACGAGACCTTTACCTCCTCACCCTGGGTACTGTTCTCCTCATGGAGCATGGACGGCGC
TGCCTGAACTCAGTGGTGGCCTCATTCTGGAAGCCAAGTTTATACAGAGTAGCAGTGACCCAGGGAT
GTGGGGTTCACCCTCCTCAGCCCTCTGGCCAGTCCTGATGGGCCTCAGTCCCAACATGGCTAAGAGG
TGTGGGCAGCTTCTTGGTCACCCTCAGGTTGGGGAATCACCTTCTGTCTTCATTTTCCAGGAACTTG
GTGATGATATCGTGGGTGAGTTCATTTACCAGGTGCTGTAGTTTCCCCTCATCAGGCAGGAAGAAGA
TGGCGGTGGCATTGCCCAGGTATTTCATCAGCAGCACCCAGCTGGACAGCTTCTTACAGTGCTGGAT
GTTAAACATGCCTAAACGCTTCATCATAGGCACCTTCACGGTGGTCACCTGGTCCACGTGGAAGTCC
TCTTCCTCGGTGTCCTTGACTTCAAAGGGTCTCTCCCATTTGCCTGGAGAGAGGGGAAGGTGGGCAT
CACCAGGGGTGAGTGAAGGTTTGGAAGAGTGTAGCAGAATAAGAAACCATGAGTCCCCTCCCTGAGA
AGCCCTGAGCCCCCTTGACGACACACATCCCTCGAGGCTCAGCTTCATCATCTGTAAAAGGTGCTGA
AACTGACCATCCAAGCTGCCGAAAAAGATTGTGTGGGGATAATTCAAAACTAGAGGAAGATGCAGAA
TTTCTACATCGTGGCGATGTCAGGCTAAGAGATGCCATCGTGGCTGTGCATTTTTATTGGAATCATA
TGTTTATTTGAGGGTGTCTTGGATATTACAAATAAAATGTTGGAGCATCAGGCATATTTGGTACCTT

CTGTCTAAGGCTCCCTGCCCCTTGTTAATTGGCAGCTCAGTTATTCATCCAGGGCAAACATTCTGCT
TACTATTCCTGAGAGCTTTCCTCATCCTCTAGATTGGCAGGGGAAATGCAGATGCCTGAGCAGCCTC
CCCTCTGCCATACCAACAGAGCTTCACCATCGAGGCATGCAGAGTGGACAGGGGCCTCAGGGACCCC
TGATCCCAGCTTTCTCATTGGACAGAAGGAGGAGACTGGGGCTGGAGAGGGACCTGGGCCCCCACTA
AGGCCACAGCAGAGCCAGGACTTTAGCTGTGCTGACTGCAGCCTGGCTTGCCTCCACTGCCCTCCTT
TGCCTCAAGAGCAAGGGAGCCTCAGAGTGGAGGAAGCAGCCCCTGGCCTTGCCTCCCACCTCCCCTC
CCCTATGCTGTTTTCCTGGGACAGTGGGAGCTGGCTTAGAATGCCCTGGGGCCCCCAGGACCCTGGC
ATTTTAACCCCTCAGGGGCAGGAAGGCAGCCTGAGATACAGAAGAGTCCATCACCTGCTGTATGCCA
CACACCATCCCCACAGTTACGTACTAGT (SEQ ID NO:11)

pCBA-hRhodopsin-miR708 (miR-155 scaffold)

GAATTCGGACCGTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTT
CATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCA
ACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCA
TTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATG
CCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGA
CCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTCGAGGT
GAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTT
ATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGG
GGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCT
CCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGG
GCGGGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCC
CCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGT
AATTAGCGCTTGGTTTAATGACGGCTTGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTGAGGGGCTCC
GGGAGGGCCCTTTGTGCGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTGTGTGCGTGGGGAGCGC
CGCGTGCGGCTCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTGTGCGCTC
CGCAGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCCGCGGTGCGGGGGGGGCTGCGAGGGGA
ACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGTGAGCAGGGGGTGTGGGCGCGTCGGTCGGGCT
GCAACCCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGT
ACGGGGCGTGGCGCGGGGCTCGCCGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGG
CGGGGCCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCCGGAGCGCCGGCGGCTG
TCGAGGCGCGGCGAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCT
TTGTCCCAAATCTGTGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGG
CGAAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCCGCCG
TCCCCTTCTCCCTCTCCAGCCTCGGGGCTGTCCGCGGGGGGACGGCTGCCTTCGGGGGGGACGGGGC
AGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTAACCATGTTCATGCCT
TCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTATTGTGCTGTCTCATCATTTTGGCAAAGA
ATTCTTCGAAAGATCTGCTAGCTTAATTAACCCAAACGGGCCCTCTAGACTCGAGCGGCCGCCACTG
TGCTGGATATCTGCAGAATTCAGCCACCACCGGCACAATGAATGGCACAGAAGGCCCTAACTTCTAC
GTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTG
AGCCATGGCAGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAA
CTTCCTCACGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTC
AACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGC
ATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTGA
AATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAGC
AACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGGCCT
GCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAAT
CGACTACTACACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCAC
TTCACCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCG
CTGCCCAGCAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCAT
CATGGTCATCGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCAC
CAGGGCTCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCT
ACAACCCTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACCATCTGCTG
CGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTG

GCCCCGGCCTAACCAAGAAAGCTTAAGTTTGGGACTAGTGGCGGCCGCTCGAGCATGCATCTAGAGG
GCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTG
CCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTC
CTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTG
GGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGAGCTAGAGTC
GACCGGACCGCTGCAGGCATGCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTG
TTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAA
TGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGT
GCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGT
ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTT
GACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATC
AACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACG
GTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAA
ATTAATACGACTCACTATAGGGAGTCCCAAGCTGGCTAGTTAAGCTATCAACAAGTTTGTACAAAAA
AGCAGGCTTTAAAGGGAGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGCTGTATGCT
GAAGGAGCTTACAATCTAGCTGGGGTTTTGGCCACTGACTGACCCCAGCTAGTGTAAGCTCCTTCAG
GACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCAGATCTGGCCGCACTCGAGATGCT
TCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGG
CGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCA
AAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAG
CATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGT
TTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGC
CTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAG
GTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCG
GTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAA
CAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGC
TACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTG
GTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGAT
TACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG
AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTT
TAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCA
ATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTC
CCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGC
GAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAG
AAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGT
AGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGT
CGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTT
GTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTA
TCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTG
TGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCC
GGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGT
TCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTG
CACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCA
AAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAA
TATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAA
ATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTAT
TATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGAT
GACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCG
GGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGC
GGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGG
AGAAAATACCGCATCAGGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGC
GGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAAC
GCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGT (SEQ ID NO:12)

MIR155 scaffold

GATCCTGGAGGCTTGCTGAAGGCTGTATGCTGAAGGAGCTTACAATCTAGCTGGGGTTTTGGCCACT
GACTGACCCCAGCTAGTGTAAGCTCCTTCAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAA
ATGGCCCAGATCTGGCCGCAC(SEQ ID NO:13)

Endogenous MIR708 scaffold

AACCTAACCCCCATGGTTGGCGAGGGACTGCTGTGTGTGAAATGGTAACTGCCCTCAAGGAGCTTAC
AATCTAGCTGGGGGTAAATGACTTGCACATGAACACAACTAGACTGTGAGCTTCTAGAGGGCAGGGA
CCTTACCCTAGTCATCTCTCTTCTCACCCTGCACACCCTCCCTGAGGGATCTCAT (SEQ ID
NO:14)

pRK-hRhodopsin-miR-708 (mir708 in the miR708 endogenous scaffold, located in the 3' UTR of hRhodopsin)

TATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCATTC
AGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAG
GGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAAC
GACGGCCAGTGAATTCGGACCGTCGACATTGATTATTGGGCCCCAGAAGCCTGGTGGTTGTTTGTCC
TTCTCAGGGGAAAAGTGAGGCGGCCCCTTGGAGGAAGGGGCCGGGCAGAATGATCTAATCGGATTCC
AAGCAGCTCAGGGGATTGTCTTTTTCTAGCACCTTCTTGCCACTCCTAAGCGTCCTCCGTGACCCCG
GCTGGGATTTAGCCTGGTGCTGTGTCAGCCCCGGTCTCCCAGGGGCTTCCCAGTGGTCCCCAGGAAC
CCTCGACAGGGCCCGGTCTCTCTCGTCCAGCAAGGGCAGGGACGGGCCACAGGCCAAGGGCGGAGTC
GCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGA
CTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCAAG
AGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGTTTTACAGGCCTG
AAATCACTTGGTTTTAGGTTGGGGATCCGGTACCCAATTGCCATGGGCTAGCATGCATGAGCTCCCT
GCAGGGTTTATCTGCAGAATTCAGCCACCACCGGCACAATGAATGGCACAGAAGGCCCTAACTTCTA
CGTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCT
GAGCCATGGCAGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCA
ACTTCCTCACGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCT
CAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTG
CATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTG
AAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAG
CAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGGCC
TGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAA
TCGACTACTACACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCA
CTTCACCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCC
GCTGCCCAGCAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCA
TCATGGTCATCGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCA
CCAGGGCTCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATC
TACAACCCTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACCATCTGCT
GCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGT
GGCCCCGGCCTAACCAAGAAAGCTTAAGTTTGTGTCCCGGCTTAGGGCTAAATGTCTAGGACAGAAT
GGAACACATAGTAGCTGATTAATAAATGCTAGCTGGATGAAGGGAGGAATGAGTGACTGACTGAGTG
GATATATGAGTGAAGGGATTAATGGAAGGGAACATGGATGTCCTCAGGTGCCCAACCTGGCAGATCC
AGTCATGTCTGGCTGGAATCTATAAGCAGTTTTACATACCTGCCCTGAGCTTTATTGCGGTAGTTTA
TCACAGTTAAATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTGAC
TCTCTTAAGGTAGCCTTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGA
CAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAAAACCTAACCCCCATGGTTGG
CGAGGGACTGCTGTGTGTGAAATGGTAACTGCCCTCAAGGAGCTTACAATCTAGCTGGGGGTAAATG
ACTTGCACATGAACACAACTAGACTGTGAGCTTCTAGAGGGCAGGGACCTTACCCTAGTCATCTCTC
TTCTCACCCTGCACACCCTCCCTGAGGGATCTCATGACTCTTGCGTTTCTGATAGGCACCTATTGGT
CTTACTGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCACACCGGCACAATGAA
TGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTC
GAGTACCCACAGTCAGAGATAAATGACAGTGACAGCAACGTGAGCTGCAGCCCTTAGGACTGAGAAA

GCATCGAGACCAGGGGTCTCCGGCAAGGCCTAGGTCCTCCCTTCAGTATGGAAACCTTGCCTCATGT
CTCTCAGCCTCCTTGGCCTGTGGAGATCCAGCCCTTCCTCTTGGCTTCTGGATACATTTGCTCTTCT
ACACCAGCAACCAAGTGGCAACAGTTCCAGGCCAGTATGGAGTTTTAGAAGCCATGCCAATATGCCC
ACCTTCAGGGAGCAGCTGAGTCCTTGATGCCACCCTTGTTCTGAAGAGTTCAGAAACACAGTGCAAG
ACATGACCAGGCCTCATCCTTAGGATGCTCATGGATCCAGTTCTTAGCTCCCTTGTTGGATATGCTG
TTTTCCTTGGCCTTTGGTCTTTTCTTTATCCCAGAGGGTTTTGGCTTTAAGGCCAACAGGAACTATG
GGGTACCAGAATTGAGCAGCCTCAGTCTGCATCCCTCCTCTATAGAACCACAGCTGGGCCCTCAGCA
GGCCCAACTCTGCATGGGGACAGAGGCATTAAAAGCCTAGAGTATCCCTCGAGGGGCCCAAGCTTAC
GCGTACCCAGCTTTCTTGTACAAAGTGGTCCCTATAGTGAGTCGTATTATAAGCTAGGCACTGGCCG
TCGTTTTACAACGTCGTGACTGGGAAAACTGCTAGCTTGGGATCTTTGTGAAGGAACCTTACTTCTG
TGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTA
AGTGTATAATGTGTTAAACTAGCTGCAAAACCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCC
CCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGA
AATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAG
GGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGAACTAGTCGGACCGCTGCAGGCATGCAAGC
TTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACA
TACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGC
GTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAA
CGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCT
CGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATC
AGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCC
GCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC
AGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCG
CTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCG
CTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTG
TGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCC
GGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTA
GGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTA
TCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAAC
CACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAA
GAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTT
TGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATC
AATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATC
TCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATAC
GGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGA
TTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCC
TCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCA
ACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTC
CGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTC
GGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGC
ATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC
ATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCG
CCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGA
TCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTT
TACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGG
GCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTT
ATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCAC
ATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAAT
AGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGC
AGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGC
GTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGA
GTGCACCA (SEQ ID NO:15)

β-globin intron sequence

ACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGTGCTTCTGACACAA
CAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAGGTAGCCTTGCAGAAGTTGGTCGTGAGGCACTG
GGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACA
GAGAATGGATCCTGGAGGCTTGCTGAAGGCTGTATGCTGAAGGAGCTTACAATCTAGCTGGGGTTTT
GGCCACTGACTGACCCCAGCTAGTGTAAGCTCCTTCAGGACACAAGGCCTGTTACTAGCACTCACAT
GGAACAAATGGCCCAGATCTGAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCC
ACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCA (SEQ ID NO:16)

MIR708 sequence in a MIR155 scaffold

TGGATCCTGGAGGCTTGCTGAAGGCTGTATGCTGAAGGAGCTTACAATCTAGCTGGGGTTTTGGCCA
CTGACTGACCCCAGCTAGTGTAAGCTCCTTCAGGACACAAGGCCTGTTACTAGCACTCACATGGAAC
AAATGGCCCAGATCTG (SEQ ID NO:17)

MIR708 sequence in a native scaffold

AAACCTAACCCCCATGGTTGGCGAGGGACTGCTGTGTGTGAAATGGTAACTGCCCTCAAGGAGCTTA
CAATCTAGCTGGGGGTAAATGACTTGCACATGAACACAACTAGACTGTGAGCTTCTAGAGGGCAGGG
ACCTTACCCTAGTCATCTCTCTTCTCACCCTGCACACCCTCCCTGAGGGATCTCAT (SEQ ID
NO:18)

Human rhodopsin miR-708 target from 3'UTR

CUCUGCCUGGAGACUAAGGCAAAUUGGGCCAUUAAAAGCUCAGCUCCUAUGUUGGUAUUAACGGUGGU
GGGUUUUGUUG (SEQ ID NO:19)

Mutated AAV ITR

CCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGC
TTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGA (SEQ ID NO:20)

Wild Type ITR sequence

GGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGG
GCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGG
GGTTCCT (SEQ ID NO:21)

Opsin promoter

TGCTGATTCAGCCAGGAACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATAT
ATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCC
ATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGG
TGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCT
ATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCC
TACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCACAAATAGTTATCGAGCCGCTGAGCCGG
GGGGCGGGGGGTGTGAGACTGGAGGCGATGGACGGAGCTGACGGCACACACAGCTCAGATCTGTCAAG
TGAGCCATTGTCAGGGCTTGGGGACTGGATAAGTCAGGGGGTCTCCTGGGAAGAGATGGGATAGGTGA
GTTCAGGAGGAGACATTGTCAACTGGAGCCATGTGGAGAAGTGAATTTAGGGCCCAAAGGTTCCAGTC
GCAGCCTGAGGCCACCAGACTGACATGGGGAGGAATTCCCAGAGGACTCTGGGGCAGACAAGATGAGA
CACCCTTTCCTTTCTTTACCTAAGGGCCTCCACCCGATGTCACCTTGGCCCCTCTGCAAGCCAATTAG
GCCCCGGTGGCAGCAGTGGGATTAGCGTTAGTATGATATCTCGCGGA (SEQ ID NO:22)

MVM intron

GGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGC
TCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAG
CAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGTTTTACAGGC

CTGAAATCACTTGGTTTTAGGTTGGGGATCCGGTACCCAATTGCCATGGGCTAGCATGCATGAGCTCC
CTGCAGGGTTTTAATGCCAACTTTGTACAAAAAAGCAGGCACC (SEQ ID NO:23)

AAV5GRK1miR708_155hRho (AAV5 vector with rhodopsin kinase promoter driving expression of miR-708 in a miR-155 scaffold and human rhodopsin minus the miR-708 target sequence)

TGACTAGTTAGGGCCCCAGAAGCCTGGTGGTTGTTTGTCCTTCTCAGGGGAAAAGTGAGGCGGCCCCT
TGGAGGAAGGGGCCGGGCAGAATGATCTAATCGGATTCCAAGCAGCTCAGGGGATTGTCTTTTTCTAG
CACCTTCTTGCCACTCCTAAGCGTCCTCCGTGACCCCGGCTGGGATTTAGCCTGGTGCTGTGTCAGCC
CCGGTCTCCCAGGGGCTTCCCAGTGGTCCCCAGGAACCCTCGACAGGGCCCGGTCTCTCTCGTCCAGC
AAGGGCAGGGACGGGCCACAGGCCAAGGGCACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAAT
TGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAGGTAG
CCTTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGA
CCAATAGAAACTGGGCTTGTCGAGACAGAGAATGGATCCTGGAGGCTTGCTGAAGGCTGTATGCTGAA
GGAGCTTACAATCTAGCTGGGGTTTTGGCCACTGACTGACCCCAGCTAGTGTAAGCTCCTTCAGGACA
CAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCAGATCTGAGACTCTTGCGTTTCTGATAGG
CACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCACACCG
GCACAATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACGC
AGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTGGCCGCCTACAT
GTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTACGTCACCGTCCAGCACAAGA
AGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGT
GGCTTCACCAGCACCCTCTACACCTCTCTGCATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTT
GGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGC
GGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTT
GCCTTCACCTGGGTCATGGCGCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCC
CGAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAACAACGAGTCTT
TTGTCATCTACATGTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAG
CTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAA
GGAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCG
TGGCATTCTACATCTTCACCCACCAGGGCTCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTC
TTTGCCAAGAGCGCCGCCATCTACAACCCTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTG
CATGCTCACCACCATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCA
AGACGGAGACGAGCCAGGTGGCCCCGGCCTAACCAAGAAAGCTTAAGTTTAAACCGCTGATCAGCCTC
GACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAG
GTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCAT
TCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGC
TGGGGATGCGGTGGGCTCTATGGC (SEQ ID NO:24)

AAV5GRK1miR708_708hRho (AAV5 vector with rhodopsin kinase promoter driving expression of miR-708 in a miR-708 scaffold and human rhodopsin minus the miR-708 target sequence)

GGGCCCCAGAAGCCTGGTGGTTGTTTGTCCTTCTCAGGGGAAAAGTGAGGCGGCCCCTTGGAGGAAGG
GGCCGGGCAGAATGATCTAATCGGATTCCAAGCAGCTCAGGGGATTGTCTTTTTCTAGCACCTTCTTG
CCACTCCTAAGCGTCCTCCGTGACCCCGGCTGGGATTTAGCCTGGTGCTGTGTCAGCCCCGGTCTCCC
AGGGGCTTCCCAGTGGTCCCCAGGAACCCTCGACAGGGCCCGGTCTCTCTCGTCCAGCAAGGGCAGGG
ACGGGCCACAGGCCAAGGGCACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTGCTAACGCA
GTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAGGTAGCCTTGCAGAA
GTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAA
CTGGGCTTGTCGAGACAGAGAAAAACCTAACCCCCATGGTTGGCGAGGGACTGCTGTGTGTGAAATGG
TAACTGCCCTCAAGGAGCTTACAATCTAGCTGGGGGTAAATGACTTGCACATGAACACAACTAGACTG
TGAGCTTCTAGAGGGCAGGGACCTTACCCTAGTCATCTCTCTTCTCACCCTGCACACCCTCCCTGAGG
GATCTCATGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCT
CCACAGGTGTCCACTCCCAGTTCACACCGGCACAATGAATGGCACAGAAGGCCCTAACTTCTACGTGC
CCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCA

TGGCAGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCT
CACGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAG
CCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCATGGATAC
TTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCCCT
GTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCGCT
TCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGGCCTGCGCCGCACCC
CCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTACAC
GCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCATCCCCA
TGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCAGCAG
GAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTT
CCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGCTCCAACTTCG
GTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCTGTCATCTAT
ATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACCATCTGCTGCGGCAAGAACCCACTGGG
TGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCCTAACCAAGAA
AGCTTAAGTTTAAACCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCC
CTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAA
TTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGG
GAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGC (SEQ ID NO:25)

AAV5OPSmiR708_155hRho (AAV5 vector with opsin promoter driving expression of miR-708 in a miR-155 scaffold and human rhodopsin minus the miR-708 target sequence)

ACGCGTTTTCTGCAGCGGGGATTAATATGATTATGAACACCCCCAATCTCCCAGATGCTGATTCAGCC
AGGAACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCG
TTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATA
ATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACG
GTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG
ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAC
ATCTACGTATTAGTCATCGCTATTACCACAAATAGTTATCGAGCCGCTGAGCCGGGGGGCGGGGGGTG
TGAGACTGGAGGCGATGGACGGAGCTGACGGCACACACAGCTCAGATCTGTCAAGTGAGCCATTGTCA
GGGCTTGGGGACTGGATAAGTCAGGGGGTCTCCTGGGAAGAGATGGGATAGGTGAGTTCAGGAGGAGA
CATTGTCAACTGGAGCCATGTGGAGAAGTGAATTTAGGGCCCAAAGGTTCCAGTCGCAGCCTGAGGCC
ACCAGACTGACATGGGGAGGAATTCCCAGAGGACTCTGGGGCAGACAAGATGAGACACCCTTTCCTTT
CTTTACCTAAGGGCCTCCACCCGATGTCACCTTGGCCCCTCTGCAAGCCAATTAGGCCCCGGTGGCAG
CAGTGGGATTAGCGTTAGTATGATATCTCGCGGATGCTGAATCAGCCTCTGGCTTAGGGAGAGAAGGT
CACTTTATAAGGGTCTGGGGGGGGTCAGTGCCTGGAGTTGCGCTGTGGGAGCCGTCAGTGGCTGAGCT
CAACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGTGCTTCTGACACA
ACAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAGGTAGCCTTGCAGAAGTTGGTCGTGAGGCACTG
GGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAG
AGAATGGATCCTGGAGGCTTGCTGAAGGCTGTATGCTGAAGGAGCTTACAATCTAGCTGGGGTTTTGG
CCACTGACTGACCCCAGCTAGTGTAAGCTCCTTCAGGACACAAGGCCTGTTACTAGCACTCACATGGA
ACAAATGGCCCAGATCTGAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTT
TGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCACACCGGCACAATGAATGGCACAGAAGGCCCTAA
CTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACC
TGGCTGAGCCATGGCAGTTCTCCATGCTGGCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCC
ATCAACTTCCTCACGCTCTACGTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCT
GCTCAACCTAGCCGTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTC
TGCATGGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGT
GAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAG
CAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGGCCT
GCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAATC
GACTACTACACGCTCAAGCCGGAGGTCAACAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCACTT
CACCATCCCCATGATTATCATCTTTTTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTG
CCCAGCAGCAGGAGTCAGCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATG
GTCATCGCTTTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGG

CTCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACC
CTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACCATCTGCTGCGGCAAG
AACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGC
CTAACCAAGAAAGCTTAAGTTTAAACCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCT
GTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATA
AAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGG
ACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGC
(SEQ ID NO:26)

AAV5OPSmiR708_708hRho (AAV5 vector with opsin promoter driving expression of miR-708 in a miR-708 scaffold and human rhodopsin minus the miR-708 target sequence)

ACGCGTTTTCTGCAGCGGGGATTAATATGATTATGAACACCCCCAATCTCCCAGATGCTGATTCAGCC
AGGAACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCG
TTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATA
ATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACG
GTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG
ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAC
ATCTACGTATTAGTCATCGCTATTACCACAAATAGTTATCGAGCCGCTGAGCCGGGGGGCGGGGGGTG
TGAGACTGGAGGCGATGGACGGAGCTGACGGCACACACAGCTCAGATCTGTCAAGTGAGCCATTGTCA
GGGCTTGGGGACTGGATAAGTCAGGGGGTCTCCTGGGAAGAGATGGGATAGGTGAGTTCAGGAGGAGA
CATTGTCAACTGGAGCCATGTGGAGAAGTGAATTTAGGGCCCAAAGGTTCCAGTCGCAGCCTGAGGCC
ACCAGACTGACATGGGGAGGAATTCCCAGAGGACTCTGGGGCAGACAAGATGAGACACCCTTTCCTTT
CTTTACCTAAGGGCCTCCACCCGATGTCACCTTGGCCCCTCTGCAAGCCAATTAGGCCCCGGTGGCAG
CAGTGGGATTAGCGTTAGTATGATATCTCGCGGATGCTGAATCAGCCTCTGGCTTAGGGAGAGAAGGT
CACTTTATAAGGGTCTGGGGGGGGTCAGTGCCTGGAGTTGCGCTGTGGGAGCCGTCAGTGGCTGAGCT
CAACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGTGCTTCTGACACA
ACAGTCTCGAACTTAAGCTGCAGTGACTCTCTTAAGGTAGCCTTGCAGAAGTTGGTCGTGAGGCACTG
GGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAG
AGAAAAACCTAACCCCCATGGTTGGCGAGGGACTGCTGTGTGTGAAATGGTAACTGCCCTCAAGGAGC
TTACAATCTAGCTGGGGGTAAATGACTTGCACATGAACACAACTAGACTGTGAGCTTCTAGAGGGCAG
GGACCTTACCCTAGTCATCTCTCTTCTCACCCTGCACACCCTCCCTGAGGGATCTCATGACTCTTGCG
TTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCC
AGTTCACACCGGCACAATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGG
GTGTGGTACGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTG
GCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTACGTCACCGT
CCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCCGTGGCTGACCTCTTCA
TGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCATGGATACTTCGTCTTCGGGCCCACA
GGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGCGGTGAAATTGCCCTGTGGTCCTTGGTGGTCCT
GGCCATCGAGCGGTACGTGGTGGTGTGTAAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCA
TCATGGGCGTTGCCTTCACCTGGGTCATGGCGCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCC
AGGTACATCCCCGAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAA
CAACGAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTTTTCT
GCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCAGCCACCACACAG
AAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCTTTCCTGATCTGCTGGGTGCC
CTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGCTCCAACTTCGGTCCCATCTTCATGACCA
TCCCAGCGTTCTTTGCCAAGAGCGCCGCCATCTACAACCCTGTCATCTATATCATGATGAACAAGCAG
TTCCGGAACTGCATGCTCACCACCATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGC
TACCGTGTCCAAGACGGAGACGAGCCAGGTGGCCCCGGCCTAACCAAGAAAGCTTAAGTTTAAACCGC
TGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTT
GACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGA
GTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAAT
AGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGC (SEQ ID NO:27)

Cone Rod Homeobox Containing Transcription Factor

AGAGGACTAAGCCACAGGTGAGGAGAAAGGGGGGGGGGGGTCTGCTGACCCAGCAACACTCTTTCCTT
CTGAGGCTTAAGAGCTATTAGCGTAGGTGACTCAGTCCCTAATCCTCCATTCAATGCCCTGTGACTGC
CCCTGCTTC (SEQ ID NO:28)

CMV Enhancer

ACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTAC
ATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGA
CGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAA
ACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGG
TAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTACCA (SEQ ID NO:29)

Neural retinal basic leucine zipper factor

TTTCTGCAGCGGGGATTAATATGATTATGAACACCCCCAATCTCCCAGATGCTGATTCAGCCAGGA
(SEQ ID NO:30)

CLAIMS

What is claimed is:

1. A rAAV particle comprising nucleic acid encoding a miR-708 and nucleic acid encoding rhodopsin.

2. The rAAV particle of claim 1, wherein the nucleic acid encoding miR-708 and/or the nucleic acid encoding rhodopsin is operably linked to a promoter.

3. The rAAV particle of claim 2, wherein the promoter expresses the miR-708 and/or rhodopsin in photoreceptor cells.

4. The rAAV particle of claim 2 or 3, wherein the promoter comprises a RK promoter, an opsin promoter, or a CBA promoter.

5. The rAAV particle of claim 4, wherein i) the nucleic acid encoding miR-708 and the nucleic acid encoding rhodopsin are operably linked to one RK promoter or opsin promoter; or ii) the nucleic acid encoding miR-708 is operably linked to a first RK promoter or a first opsin promoter and the nucleic acid encoding rhodopsin is operably linked to a second RK promoter or a second opsin promoter.

6. The rAAV particle of claim 5, wherein the nucleic acid encoding miR-708 is 5' to the nucleic acid encoding rhodopsin or wherein the nucleic acid encoding miR-708 is 3' to the nucleic acid encoding rhodopsin.

7. The rAAV particle of any one of claims 1-6, wherein the nucleic acid encoding miR-708 is embedded in an intron.

8. The rAAV particle of any one of claims 1-7, wherein the nucleic acid encoding miR-708 comprises an endogenous miR-708 scaffold or a miR-155 scaffold.

9. The rAAV particle of any one of claims 1-8, wherein the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid in the miR-708 target sequence or lacks the 3' UTR miR-708 target sequence, wherein the substitution, insertion or deletion reduces or prevents recognition by miR-708.

10. The rAAV particle of any one of the preceding claims, wherein the nucleic acid encoding miR-708 comprises the nucleic acid of SEQ ID NO: 1, or wherein the nucleic acid encoding miR-708 comprises a nucleic acid having at least 90% identity to SEQ ID NO: 1; and wherein the rhodopsin comprises the amino acid sequence of SEQ ID NO: 2, or wherein the rhodopsin comprises an amino acid sequence having about at least 90% identity to SEQ ID NO:2, or wherein the nucleic acid encoding the rhodopsin comprises nucleic acid of SEQ ID NO:3, or wherein the nucleic acid encoding the rhodopsin comprises a nucleic acid having 90% identity to SEQ ID NO: 3.

11. The rAAV particle of claim 1, wherein the rAAV particle comprises a recombinant viral genome comprising a polynucleotide of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27; or wherein the rAAV particle comprises a recombinant viral genome comprises a polynucleotide having at least 90% identity to SEQ ID NO:5, SEQ ID NO:6 SEQ ID NO:7, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:27.

12. The rAAV particle of any one of the preceding claims, wherein the rAAV particle comprises AAV1, AAV2, AAV3, AAV4, AAV5, AAV5 tyrosine mutant, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, or mouse AAV capsid rAAV2/HBoV1 serotype capsid; and wherein the rAAV vector comprises AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype inverted terminal repeats (ITRs).

13. The rAAV particle claim 11, wherein the rAAV particle comprises an AAV-5 capsid or an AAV-5 tyrosine mutant capsid, and wherein the vector comprises AAV2 ITRs.

14. A composition comprising the rAAV particle of any one of claims 1-13.

15. A composition comprising a first rAAV particle comprising a rAAV vector comprising nucleic acid encoding miR-708, and a second rAAV particle comprising a rAAV vector comprising nucleic acid encoding rhodopsin.

16. A method for treating retinitis pigmentosa in a mammal, comprising administering to the eye of the mammal the rAAV particle of any one of claims 1-13 or the composition of claim 14 or 15, wherein the retinitis pigmentosa is associated with a mutation in the endogenous rhodopsin gene in the mammal.

17. A method for treating endoplasmic reticulum (ER) stress in a cell of a mammal, comprising administering to the mammal the rAAV particle of any one of claims 1-13 or the composition of claim 14 or 15, wherein the ER stress is associated with a mutation in the endogenous rhodopsin gene in the mammal.

18. The method of claim 17, wherein the cell is an ocular cell or a photoreceptor cell, optionally a rod photoreceptor cell.

19. The method of any one of claims 16-18, wherein the rAAV particles are injected into the subretinal space of the retina of the mammal at one or more locations.

20. The method of any one of claims 16-18, wherein the rAAV particles are injected intravitreally to the mammal.

21. The method of any one of claims 16-20, wherein the retinitis pigmentosa is autosomal dominant retinitis pigmentosa or autosomal recessive retinitis pigmentosa.

22. The method of any one of claims 16-21, wherein a first rAAV particle encoding the miR-708 and a second rAAV particle encoding rhodopsin are administered to the mammal at the same time or the first rAAV particle encoding the miR-708 and the second rAAV particle encoding the rhodopsin are administered to the mammal sequentially.

23. The method of any one of claims 16-22, wherein the mammal is a human, and wherein the human has a P23H mutation in the endogenous rhodopsin gene.

24. Use of a rAAV particle of any one of claims 1-13 or a composition of claim 14 or 15 in the preparation of a medicament for treating retinitis pigmentosa in a mammal, wherein the retinitis pigmentosa is associated with a mutation in the endogenous rhodopsin gene in the mammal.

25. Use of a rAAV particle of any one of claims 1-13 or a composition of claim 14 or 15 in the preparation of a medicament for treating endoplasmic reticulum (ER) stress in a cell of a mammal, wherein the ER stress is associated with a mutation in the endogenous rhodopsin gene in the mammal.

FIG. 1A



FIG. 1B



FIGS. 1A & 1B

FIG. 2B



FIG. 2A



FIGS. 2A & 2B



FIG. 3A



FIG.3B

FIGS. 3A & 3B


Loop Sequence
miR-708'
miR-708
CBA or RK Promoter
5' miR-155 Flanking Sequence
3' miR-155 Flanking Sequence

FIG. 4


miR-708 Rhodopsin Knockdown in HEK-293 Cells
% Rhodopsin Protein
Fold Rhodopsin Expression
1.25
1.00
0.75
0.50
0.25
0.00
miR-708
Control miRNA
Untransfected

FIG. 5


miR-708 Reduction in UPR Gene Expression
Fold Gene Expression
1.00
0.75
0.50
0.25
0.00
Fold CHOP RNA
Fold BiP RNA
pCBA-miR-708
pCBA-miR-Scramble
pCBA-miR-708
pCBA-miR-Scramble

FIG. 6

FIG. 7B



FIG. 7A



FIGS. 7A & 7B


Left ITR
Stuffer
RK promoter
Chimeric intron
miR-708
BGH polyA
Stuffer
Right ITR
4.5 kb

FIG. 8

FIG. 9A



FIG. 9B



FIGS. 9A & 9B


FIG.10A
P value = 0.06
Copies mRho/µg
100000
75000
50000
25000
0
AAV5 miR-708
AAV5 miR-Control

FIG. 10B
P value = 0.533
Fold RdCVF Expression (Relative GAPDH)
2.0
1.5
1.0
0.5
0.0
AAV5 miR-708
AAV5 miR-Control

FIG. 10C
P value = 0.01
Fold miR-708 Expression
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
AAV5 miR-708
AAV5 miR-Control

FIGS. 10A-10C

FIG. 11A

Animal # 45595



Animal # 45596



Animal # 45599



FIG. 11B

Animal # 45595



Animal # 45596



Animal # 45599




pRK-miR-708-Intron hRho wt
6524 bp
Rhodopsin Kinase Promoter
Beta-Globin Intron
miR-708
hRho wt
BGH polyA

FIG. 12


Gene Expression WERI Cells
pRK-hRho-Intron miR-708
pRK-hRho-Intron miR-Control
Fold Expression (RNA)
1.5
1.0
0.5
0.0
rhodopsin
hCHOP
hBiP

FIG. 13


miR-708 Expression (WERI Cells)
Copies miR-708 (5 µL Input)
1000000
100000
10000
1000
100
10
1
PCDA-miR-708
PRK-miR-708
PRK-hRho-Intron miR-708
PRK-hRho-Intron miR-Control
Untransfected

FIG. 14


hRhodopsin Expression (WERI Cells)
Copies hRhodopsin RNA (5 µL Input)
pRK-hRho-Intron miR-708
pRK-hRho-Intron-Control miR
WERI Untransfected

FIG. 15


N2K/N15K/P23H mRho + 3' UTR
N2K/N15K/P23H mRho - 3' UTR
XBP-1 splicing
(% of Unspliced)
0
5
10
15
20
PRK-intron miR-708 hRho
PRK-intron miR-Control hRho
Control Transfections

FIG. 16


Left ITR
Stuffer
RK promoter -112/+180
Chimeric intron
Human rhodopsin
miR-708
BGH polyA
Stuffer
Right ITR
4.6 kb

FIG. 17


WERI Cell Transfections
Copies hRhodopsin
Copies miR-708
Copies miR-708
8000
6000
4000
2000
0
3' hRpsn mIR-708 hRho
5' hRpsn mIR-708 hRho
Copies hRho mRNA
10^8
10^7
10^6

FIG. 18


Right ITR
BGH polyA
Human rhodopsin
Mouse Opsin Promoter
SV40 intron
miR-708
Chimeric intron
RK promoter
Stuffer
Left ITR
4.6 kb

FIG. 19


WERI Cell Transfections
Copies hRhodopsin
Copies miR-708
Copies miR-708
15000
10000
5000
0
Copies hRho mRNA
10^{10}
10^{9}
10^{8}
10^{7}
10^{6}
10^{5}
5' Intron miR-708 hRho
5' Intron miR-Cont hRho
5' Intron miR-708-155 hRho
5' Intron miR-Cont-155 hRho
3' Intron miR-708 hRho
3' Intron miR-Cont hRho

FIG. 20


SR Injection 1e9 drp AAV 5
Fold miR-708 Expression
(Compared to CL Naive Eye)
1000
100
10
1
OPS miR 708/708 hRho

FIG. 21A


SR Injection 1e9 drp AAV 5
P value = 0.0005
Fold mRhodopsin
(Compared to
CL Naive Eye)
2.0
1.5
1.0
0.5
0.0
OPS mut TdTOS hRho
OPS mut-Comi hRho

FIG. 21B


SR Injection 1e9 drp AAV 5
Fold hRhodopsin
(Compared to
CL Naive Eye)
10000
1000
100
10
1
OPS mIR 708/708 hRho
OPS mIR-Cont hRho

FIG. 21C


Neural Retinal basic Leucine zipper factor (Rod specific)
NRL
65 bp
CMV Enhancer
400 bp
-500 bp
Opsin Promoter
+17 bp
MVM intron

FIG. 22


Loop Sequence
miR-708'
miR-708
β-globin Intron
3' miR Flanking Sequence
5' miR flanking Sequence

FIG. 23A

FIG. 23C



FIG. 23B



FIGS. 23B & 23C


AAV 5 Infections
(HeLa Cells +5 IU AdTs149)
miR-708
hRhodopsin
Fold hRhodopsin
1200
1000
800
600
400
200
0
Copies miR-708
10^8
10^7
10^6
10^5
Ops miR-708/155
Ops miR-708/708
Ops miR-Cont
RK miR-708/155
RK miR-708/708
RK miR-Cont

FIG. 24

SEQUENCE LISTING

<110> Catherine O'Riordan
Matthew Adamowicz

<120> GENE THERAPY FOR RETINITIS PIGMENTOSA

<130> 159792010040

<140> Not Yet Assigned
<141> Concurrently Herewith

<150> US 61/969,027
<151> 2014-03-21

<160> 30

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 88
<212> DNA
<213> Homo sapiens

<400> 1
aactgccctc aaggagctta caatctagct gggggtaaat gacttgcaca tgaacacaac 60
tagactgtga gcttctagag ggcaggga 88

<210> 2
<211> 348
<212> PRT
<213> Homo sapiens

<400> 2
Met Asn Gly Thr Glu Gly Pro Asn Phe Tyr Val Pro Phe Ser Asn Ala
 1   5   10   15
Thr Gly Val Val Arg Ser Pro Phe Glu Tyr Pro Gln Tyr Tyr Leu Ala
            20   25   30
Glu Pro Trp Gln Phe Ser Met Leu Ala Ala Tyr Met Phe Leu Leu Ile
        35   40   45
Val Leu Gly Phe Pro Ile Asn Phe Leu Thr Leu Tyr Val Thr Val Gln
    50   55   60
His Lys Lys Leu Arg Thr Pro Leu Asn Tyr Ile Leu Leu Asn Leu Ala
65   70   75   80
Val Ala Asp Leu Phe Met Val Leu Gly Gly Phe Thr Ser Thr Leu Tyr
                85   90   95
Thr Ser Leu His Gly Tyr Phe Val Phe Gly Pro Thr Gly Cys Asn Leu
            100   105   110
Glu Gly Phe Phe Ala Thr Leu Gly Gly Glu Ile Ala Leu Trp Ser Leu
        115   120   125
Val Val Leu Ala Ile Glu Arg Tyr Val Val Val Cys Lys Pro Met Ser
    130   135   140
Asn Phe Arg Phe Gly Glu Asn His Ala Ile Met Gly Val Ala Phe Thr
145   150   155   160
Trp Val Met Ala Leu Ala Cys Ala Ala Pro Pro Leu Ala Gly Trp Ser
                165   170   175
Arg Tyr Ile Pro Glu Gly Leu Gln Cys Ser Cys Gly Ile Asp Tyr Tyr
            180   185   190
Thr Leu Lys Pro Glu Val Asn Asn Glu Ser Phe Val Ile Tyr Met Phe
        195   200   205
Val Val His Phe Thr Ile Pro Met Ile Ile Ile Phe Phe Cys Tyr Gly
    210   215   220
Gln Leu Val Phe Thr Val Lys Glu Ala Ala Ala Gln Gln Gln Glu Ser
225   230   235   240
Ala Thr Thr Gln Lys Ala Glu Lys Glu Val Thr Arg Met Val Ile Ile
                245   250   255

```
Met Val Ile Ala Phe Leu Ile Cys Trp Val Pro Tyr Ala Ser Val Ala
            260                 265                 270
Phe Tyr Ile Phe Thr His Gln Gly Ser Asn Phe Gly Pro Ile Phe Met
        275                 280                 285
Thr Ile Pro Ala Phe Phe Ala Lys Ser Ala Ala Ile Tyr Asn Pro Val
    290                 295                 300
Ile Tyr Ile Met Met Asn Lys Gln Phe Arg Asn Cys Met Leu Thr Thr
305                 310                 315                 320
Ile Cys Cys Gly Lys Asn Pro Leu Gly Asp Asp Glu Ala Ser Ala Thr
                325                 330                 335
Val Ser Lys Thr Glu Thr Ser Gln Val Ala Pro Ala
            340                 345
```

<210> 3
<211> 1044
<212> DNA
<213> Homo sapiens

<400> 3
atgaatggca cagaaggccc taacttctac gtgcccttct ccaatgcgac gggtgtggta 60
cgcagcccct tcgagtaccc acagtactac ctggctgagc catggcagtt ctccatgctg 120
gccgcctaca tgtttctgct gatcgtgctg ggcttcccca tcaacttcct cacgctctac 180
gtcaccgtcc agcacaagaa gctgcgcacg cctctcaact acatcctgct caacctagcc 240
gtggctgacc tcttcatggt cctaggtggc ttcaccagca ccctctacac ctctctgcat 300
ggatacttcg tcttcgggcc cacaggatgc aatttggagg gcttctttgc caccctgggc 360
ggtgaaattg ccctgtggtc cttggtggtc ctggccatcg agcggtacgt ggtggtgtgt 420
aagcccatga gcaacttccg cttcggggag aaccatgcca tcatgggcgt tgccttcacc 480
tgggtcatgg cgctggcctg cgccgcaccc ccactcgccg gctggtccag gtacatcccc 540
gagggcctgc agtgctcgtg tggaatcgac tactacacgc tcaagccgga ggtcaacaac 600
gagtcttttg tcatctacat gttcgtggtc cacttcacca tccccatgat tatcatcttt 660
ttctgctatg ggcagctcgt cttcaccgtc aaggaggccg ctgcccagca gcaggagtca 720
gccaccacac agaaggcaga gaaggaggtc acccgcatgg tcatcatcat ggtcatcgct 780
ttcctgatct gctgggtgcc ctacgccagc gtggcattct acatcttcac ccaccagggc 840
tccaacttcg gtcccatctt catgaccatc ccagcgttct ttgccaagag cgccgccatc 900
tacaaccctg tcatctatat catgatgaac aagcagttcc ggaactgcat gctcaccacc 960
atctgctgcg gcaagaaccc actgggtgac gatgaggcct ctgctaccgt gtccaagacg 1020
gagacgagcc aggtggcccc ggcc   1044

<210> 4
<211> 2768
<212> DNA
<213> Homo sapiens

<400> 4
agagtcatcc agctggagcc ctgagtggct gagctcaggc cttcgcagca ttcttgggtg 60
ggagcagcca cgggtcagcc acaagggcca cagccatgaa tggcacagaa ggccctaact 120
tctacgtgcc cttctccaat gcgacgggtg tggtacgcag ccccttcgag tacccacagt 180
actacctggc tgagccatgg cagttctcca tgctggccgc ctacatgttt ctgctgatcg 240
tgctgggctt ccccatcaac ttcctcacgc tctacgtcac cgtccagcac aagaagctgc 300
gcacgcctct caactacatc ctgctcaacc tagccgtggc tgacctcttc atggtcctag 360
gtggcttcac cagcaccctc tacacctctc tgcatggata cttcgtcttc gggcccacag 420
gatgcaattt ggagggcttc tttgccaccc tgggcggtga aattgccctg tggtccttgg 480
tggtcctggc catcgagcgg tacgtggtgg tgtgtaagcc catgagcaac ttccgcttcg 540
gggagaacca tgccatcatg ggcgttgcct tcacctgggt catggcgctg gcctgcgccg 600
caccccact cgccggctgg tccaggtaca tccccgaggg cctgcagtgc tcgtgtggaa 660
tcgactacta cacgctcaag ccggaggtca acaacgagtc ttttgtcatc tacatgttcg 720
tggtccactt caccatcccc atgattatca tcttttctg ctatgggcag ctcgtcttca 780
ccgtcaagga ggccgctgcc cagcagcagg agtcagccac cacacagaag gcagagaagg 840
aggtcacccg catggtcatc atcatggtca tcgctttcct gatctgctgg gtgccctacg 900
ccagcgtggc attctacatc ttcacccacc agggctccaa cttcggtccc atcttcatga 960
ccatcccagc gttctttgcc aagagcgccg ccatctacaa ccctgtcatc tatatcatga 1020
tgaacaagca gttccggaac tgcatgctca ccaccatctg ctgcggcaag aacccactgg 1080
gtgacgatga ggcctctgct accgtgtcca agacggagac gagccaggtg gccccggcct 1140
aagacctgcc taggactctg tggccgacta taggcgtctc ccatccccta caccttcccc 1200
cagccacagc catcccacca ggagcagcgc ctgtgcagaa tgaacgaagt cacataggct 1260
ccttaatttt ttttttttt ttaagaaata attaatgagg ctcctcactc acctgggaca 1320
gcctgagaag ggacatccac caagacctac tgatctggag tcccacgttc cccaaggcca 1380

gcgggatgtg tgcccctcct cctcccaact catctttcag gaacacgagg attcttgctt 1440
tctggaaaag tgtcccagct tagggataag tgtctagcac agaatggggc acacagtagg 1500
tgcttaataa atgctggatg gatgcaggaa ggaatggagg aatgaatggg aagggagaac 1560
atatctatcc tctcagaccc tcgcagcagc agcaactcat acttggctaa tgatatggag 1620
cagttgtttt tccctccctg ggcctcactt tcttctccta taaaatggaa atcccagatc 1680
cctggtcctg ccgacacgca gctactgaga agaccaaaag aggtgtgtgt gtgtctatgt 1740
gtgtgtttca gcactttgta aatagcaaga agctgtacag attctagtta atgttgtgaa 1800
taacatcaat taatgtaact agttaattac tatgattatc acctcctgat agtgaacatt 1860
ttgagattgg gcattcagat gatggggttt cacccaacct tggggcaggt ttttaaaaat 1920
tagctaggca tcaaggccag accagggctg ggggttgggc tgtaggcagg gacagtcaca 1980
ggaatgcaga atgcagtcat cagacctgaa aaaacaacac tgggggaggg ggacggtgaa 2040
ggccaagttc ccaatgaggg tgagattggg cctggggtct cacccctagt gtggggcccc 2100
aggtcccgtg cctcccccttc ccaatgtggc ctatggagag acaggccttt ctctcagcct 2160
ctggaagcca cctgctcttt tgctctagca cctgggtccc agcatctaga gcatggagcc 2220
tctagaagcc atgctcaccc gcccacattt aattaacagc tgagtccctg atgtcatcct 2280
tatctcgaag agcttagaaa caaagagtgg gaaattccac tgggcctacc ttccttgggg 2340
atgttcatgg gccccagttt ccagtttccc ttgccagaca agcccatctt cagcagttgc 2400
tagtccattc tccattctgg agaatctgct ccaaaaagct ggccacatct ctgaggtgtc 2460
agaattaagc tgcctcagta actgctcccc cttctccata taagcaaagc cagaagctct 2520
agctttaccc agctctgcct ggagactaag gcaaattggg ccattaaaag ctcagctcct 2580
atgttggtat taacggtggt gggttttgtt gctttcacac tctatccaca ggatagattg 2640
aaactgccag cttccacctg atccctgacc ctgggatggc tggattgagc aatgagcaga 2700
gccaagcagc acagagtccc ctggggctag aggtggagga ggcagtcctg ggaatgggaa 2760
aaacccca 2768

<210> 5
<211> 1512
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 5
ggccccagaa gcctggtggt tgtttgtcct tctcagggga aaagtgaggc ggccccttgg 60
aggaaggggc cgggcagaat gatctaatcg gattccaagc agctcagggg attgtctttt 120
tctagcacct tcttgccact cctaagcgtc ctccgtgacc ccggctggga tttagcctgg 180
tgctgtgtca gccccggtct cccaggggct tcccagtggt ccccaggaac cctcgacagg 240
gcccggtctc tctcgtccag caagggcagg gacgggccac aggccaaggg cggagtcgct 300
gcgacgctgc cttcgccccg tgccccgctc cgccgccgcc tcgcgccgcc cgccccggct 360
ctgactgacc gcgttactcc cacaggtgag cgggcgggac ggcccttctc ctccgggctg 420
taattagcgc ttggtttaat gacggcttgt ttcttttctg tggctgcgtg aaagccttga 480
ggggctccgg gagggccctt tgtgcggggg gagcggctcg gggggtgcgt gcgtgtgtgt 540
gtgcgtgggg agcgccgcgt gcggctccgc gctgcccggc ggctgtgagc gctgcgggcg 600
cggcgcgggg ctttgtgcgc tccgcagtgt gcgcgagggg agcgcggccg ggggcggtgc 660
cccgcggtgc gggggggct gcgaggggaa caaaggctgc gtgcggggtg tgtgcgtggg 720
ggggtgagca gggggtgtgg gcgcgtcggt cgggctgcaa ccccccctgc acccccctcc 780
ccgagttgct gagcacggcc cggcttcggg tgcggggctc cgtacggggc gtggcgcggg 840
gctcgccgtg ccgggcgggg ggtggcggca ggtgggggtg ccgggcgggg cggggccgcc 900
tcgggccggg gagggctcgg gggaggggcg cggcggcccc cggagcgccg gcggctgtcg 960
aggcgcggcg agccgcagcc attgcctttt atggtaatcg tgcgagaggg cgcagggact 1020
tcctttgtcc caaatctgtg cggagccgaa atctgggagg cgccgccgca ccccctctag 1080
cgggcgcggg gcgaagcggt gcggcgccgg caggaaggaa atgggcgggg agggccttcg 1140
tgcgtcgccg cgccgccgtc cccttctccc tctccagcct cggggctgtc cgcgggggga 1200
cggctgcctt cgggggggac ggggcagggc ggggttcggc ttctggcgtg tgaccggcgg 1260
ctctagagcc tctgctaacc atgttcatgc cttcttcttt ttcctacagc tcctgggcaa 1320
cgtgctggtt attgtgctgt ctcatcattt tggcaaagaa ttcttcgaaa gatcctggag 1380
gcttgctgaa ggctgtatgc tgaaggagct tacaatctag ctggggtttt ggccactgac 1440
tgaccccagc tagtgtaagc tccttcagga cacaaggcct gttactagca ctcacatgga 1500
acaaatggcc ca 1512

<210> 6
<211> 3444
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 6
caatctccca gatgctgatt cagccaggaa ctagttatta atagtaatca attacggggt 60
cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc 120
ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag 180
taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc 240
acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg 300
gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc 360
agtacatcta cgtattagtc atcgctatta ccacaaatag ttatcgagcc gctgagccgg 420
ggggcggggg gtgtgagact ggaggcgatg gacggagctg acggcacaca cagctcagat 480
ctgtcaagtg agccattgtc agggcttggg gactggataa gtcagggggt ctcctgggaa 540
gagatgggat aggtgagttc aggaggagac attgtcaact ggagccatgt ggagaagtga 600
atttagggcc caaaggttcc agtcgcagcc tgaggccacc agactgacat ggggaggaat 660
tcccagagga ctctggggca gacaagatga gacacccttt cctttcttta cctaagggcc 720
tccacccgat gtcaccttgg cccctctgca agccaattag gccccggtgg cagcagtggg 780
attagcgtta gtatgatatc tcgcggatgc tgaatcagcc tctggcttag ggagagaagg 840
tcactttata agggtctggg gggggtcagt gcctggagtt gcgctgtggg agccgtcagt 900
ggctgagctc aagaggtaag ggtttaaggg atggttggtt ggtggggtat taatgtttaa 960
ttacctgttt tacaggcctg aaatcacttg gttttaggtt ggtacatctg cagaattcag 1020
ccaccaccgg cacaatgaat ggcacagaag gccctaactt ctacgtgccc ttctccaatg 1080
cgacgggtgt ggtacgcagc cccttcgagt acccacagta ctacctggct gagccatggc 1140
agttctccat gctggccgcc tacatgtttc tgctgatcgt gctgggcttc cccatcaact 1200
tcctcacgct ctacgtcacc gtccagcaca agaagctgcg cacgcctctc aactacatcc 1260
tgctcaacct agccgtggct gacctcttca tggtcctagg tggcttcacc agcaccctct 1320
acacctctct gcatggatac ttcgtcttcg ggcccacagg atgcaatttg gagggcttct 1380
ttgccaccct gggcggtgaa attgccctgt ggtccttggt ggtcctggcc atcgagcggt 1440
acgtggtggt gtgtaagccc atgagcaact tccgcttcgg ggagaaccat gccatcatgg 1500
gcgttgcctt cacctgggtc atggcgctgg cctgcgccgc acccccactc gccggctggt 1560
ccaggtacat ccccgagggc ctgcagtgct cgtgtggaat cgactactac acgctcaagc 1620
cggaggtcaa caacgagtct tttgtcatct acatgttcgt ggtccacttc accatcccca 1680
tgattatcat ctttttctgc tatgggcagc tcgtcttcac cgtcaaggag gccgctgccc 1740
agcagcagga gtcagccacc acacagaagg cagagaagga ggtcacccgc atggtcatca 1800
tcatggtcat cgctttcctg atctgctggg tgccctacgc cagcgtggca ttctacatct 1860
tcacccacca gggctccaac ttcggtccca tcttcatgac catcccagcg ttctttgcca 1920
agagcgccgc catctacaac cctgtcatct atatcatgat gaacaagcag ttccggaact 1980
gcatgctcac caccatctgc tgcggcaaga acccactggg tgacgatgag gcctctgcta 2040
ccgtgtccaa gacggagacg agccaggtgg ccccggccta accaagaaag cttaagtttg 2100
tgtcccggct tagggctaaa tgtctaggac agaatggaac acatagtagc tgattaataa 2160
atgctagctg gatgaaggga ggaatgagtg actgactgag tggatatatg agtgaaggga 2220
ttaatggaag ggaacatgga tgtcctcagg tgcccaacct ggcagatcca gtcatgtctg 2280
gctggaatct ataagcagtt ttacatacct gccctgagct ttattgcggt agtttatcac 2340
agttaaattg ctaacgcagt cagtgcttct gacacaacag tctcgaactt aagctgcagt 2400
gactctctta aggtagcctt gcagaagttg gtcgtgaggc actgggcagg taagtatcaa 2460
ggttacaaga caggtttaag gagaccaata gaaactgggc ttgtcgagac agagaaaaac 2520
ctaaccccca tggttggcga gggactgctg tgtgtgaaat ggtaactgcc ctcaaggagc 2580
ttacaatcta gctgggggta aatgacttgc acatgaacac aactagactg tgagcttcta 2640
gagggcaggg accttaccct agtcatctct cttctcaccc tgcacaccct ccctgaggga 2700
tctcatgact cttgcgtttc tgataggcac ctattggtct tactgacatc cactttgcct 2760
ttctctccac aggtgtccac tcccagttca caccggcaca atgaatggca cagaaggccc 2820
taacttctac gtgcccttct ccaatgcgac gggtgtggta cgcagcccct tcgagtaccc 2880
acagtcagag ataaatgaca gtgacagcaa cgtgagctgc agcccttagg actgagaaag 2940
catcgagacc aggggtctcc ggcaaggcct aggtcctccc ttcagtatgg aaaccttgcc 3000
tcatgtctct cagcctcctt ggcctgtgga gatccagccc ttcctcttgg cttctggata 3060
catttgctct tctacaccag caaccaagtg gcaacagttc caggccagta tggagtttta 3120
gaagccatgc caatatgccc accttcaggg agcagctgag tccttgatgc caccttgtt 3180
ctgaagagtt cagaaacaca gtgcaagaca tgaccaggcc tcatccttag gatgctcatg 3240
gatccagttc ttagctccct tgttggatat gctgttttcc ttggcctttg gtcttttctt 3300
tatcccagag ggttttggct ttaaggccaa caggaactat ggggtaccag aattgagcag 3360
cctcagtctg catccctcct ctatagaacc acagctgggc cctcagcagg cccaactctg 3420
catggggaca gaggcattaa aagc 3444

<210> 7
<211> 3014
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 7
gggccccaga agcctggtgg ttgtttgtcc ttctcagggg aaaagtgagg cggccccttg 60
gaggaagggg ccgggcagaa tgatctaatc ggattccaag cagctcaggg gattgtcttt 120
ttctagcacc ttcttgccac tcctaagcgt cctccgtgac cccggctggg atttagcctg 180
gtgctgtgtc agccccggtc tcccaggggc ttcccagtgg tccccaggaa ccctcgacag 240
ggcccggtct ctctcgtcca gcaagggcag ggacgggcca caggccaagg gcggagtcgc 300
tgcgacgctg ccttcgcccc gtgccccgct ccgccgccgc ctcgcgccgc ccgccccggc 360
tctgactgac cgcgttactc ccacaggtga gcgggcggga cggcccttct cctccgggct 420
gtaattagca agaggtaagg gtttaaggga tggttggttg gtggggtatt aatgtttaat 480
tacctgtttt acaggcctga aatcacttgg ttttaggttg gggatccggt acccaattgc 540
catgggctag catgcatgag ctccctgcag ggtttatctg cagaattcag ccaccaccgg 600
cacaatgaat ggcacagaag gccctaactt ctacgtgccc ttctccaatg cgacgggtgt 660
ggtacgcagc cccttcgagt acccacagta ctacctggct gagccatggc agttctccat 720
gctggccgcc tacatgtttc tgctgatcgt gctgggcttc cccatcaact tcctcacgct 780
ctacgtcacc gtccagcaca agaagctgcg cacgcctctc aactacatcc tgctcaacct 840
agccgtggct gacctcttca tggtcctagg tggcttcacc agcaccctct acacctctct 900
gcatggatac ttcgtcttcg ggcccacagg atgcaatttg gagggcttct ttgccaccct 960
gggcggtgaa attgccctgt ggtccttggt ggtcctggcc atcgagcggt acgtggtggt 1020
gtgtaagccc atgagcaact tccgcttcgg ggagaaccat gccatcatgg gcgttgcctt 1080
cacctgggtc atggcgctgg cctgcgccgc acccccactc gccggctggt ccaggtacat 1140
ccccgagggc ctgcagtgct cgtgtggaat cgactactac acgctcaagc cggaggtcaa 1200
caacgagtct tttgtcatct acatgttcgt ggtccacttc accatcccca tgattatcat 1260
ctttttctgc tatgggcagc tcgtcttcac cgtcaaggag gccgctgccc agcagcagga 1320
gtcagccacc acacagaagg cagagaagga ggtcacccgc atggtcatca tcatggtcat 1380
cgctttcctg atctgctggg tgccctacgc cagcgtggca ttctacatct tcacccacca 1440
gggctccaac ttcggtccca tcttcatgac catcccagcg ttctttgcca agagcgccgc 1500
catctacaac cctgtcatct atatcatgat gaacaagcag ttccggaact gcatgctcac 1560
caccatctgc tgcggcaaga acccactggg tgacgatgag gcctctgcta ccgtgtccaa 1620
gacggagacg agccaggtgg ccccggccta accaagaaag cttaagtttg tgtcccggct 1680
tagggctaaa tgtctaggac agaatggaac acatagtagc tgattaataa atgctagctg 1740
gatgaaggga ggaatgagtg actgactgag tggatatatg agtgaaggga ttaatggaag 1800
ggaacatgga tgtcctcagg tgcccaacct ggcagatcca gtcatgtctg gctggaatct 1860
ataagcagtt ttacatacct gccctgagct ttattgcggt agtttatcac agttaaattg 1920
ctaacgcagt cagtgcttct gacacaacag tctcgaactt aagctgcagt gactctctta 1980
aggtagcctt gcagaagttg gtcgtgaggc actgggcagg taagtatcaa ggttacaaga 2040
caggtttaag gagaccaata gaaactgggc ttgtcgagac agagaaaaac ctaaccccca 2100
tggttggcga gggactgctg tgtgtgaaat ggtaactgcc ctcaaggagc ttacaatcta 2160
gctgggggta aatgacttgc acatgaacac aactagactg tgagcttcta gagggcaggg 2220
accttaccct agtcatctct cttctcaccc tgcacaccct ccctgaggga tctcatgact 2280
cttgcgtttc tgataggcac ctattggtct tactgacatc cactttgcct ttctctccac 2340
aggtgtccac tcccagttca caccggcaca atgaatggca cagaaggccc taacttctac 2400
gtgcccttct ccaatgcgac gggtgtggta cgcagcccct tcgagtaccc acagtcagag 2460
ataaatgaca gtgacagcaa cgtgagctgc agcccttagg actgagaaag catcgagacc 2520
aggggtctcc ggcaaggcct aggtcctccc ttcagtatgg aaaccttgcc tcatgtctct 2580
cagcctcctt ggcctgtgga gatccagccc ttcctcttgg cttctggata catttgctct 2640
tctacaccag caaccaagtg gcaacagttc caggccagta tggagtttta gaagccatgc 2700
caatatgccc accttcaggg agcagctgag tccttgatgc caccttgtt ctgaagagtt 2760
cagaaacaca gtgcaagaca tgaccaggcc tcatccttag gatgctcatg gatccagttc 2820
ttagctccct tgttggatat gctgttttcc ttggcctttg gtcttttctt tatcccagag 2880
ggttttggct ttaaggccaa caggaactat ggggtaccag aattgagcag cctcagtctg 2940
catccctcct ctatagaacc acagctgggc cctcagcagg cccaactctg catggggaca 3000
gaggcattaa aagc 3014

<210> 8
<211> 1826
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 8
gggccccaga agcctggtgg ttgtttgtcc ttctcagggg aaaagtgagg cggccccttg 60
gaggaagggg ccgggcagaa tgatctaatc ggattccaag cagctcaggg gattgtcttt 120
ttctagcacc ttcttgccac tcctaagcgt cctccgtgac cccggctggg atttagcctg 180
gtgctgtgtc agccccggtc tcccaggggc ttcccagtgg tccccaggaa ccctcgacag 240
ggcccggtct ctctcgtcca gcaagggcag ggacgggcca caggccaagg gcactagaag 300

ctttattgcg gtagtttatc acagttaaat tgctaacgca gtcagtgctt ctgacacaac 360
agtctcgaac ttaagctgca gtgactctct taaggtagcc ttgcagaagt tggtcgtgag 420
gcactgggca ggtaagtatc aaggttacaa gacaggttta aggagaccaa tagaaactgg 480
gcttgtcgag acagagaaaa acctaacccc catggttggc gagggactgc tgtgtgtgaa 540
atggtaactg ccctcaagga gcttacaatc tagctggggg taaatgactt gcacatgaac 600
acaactagac tgtgagcttc tagagggcag ggaccttacc ctagtcatct ctcttctcac 660
cctgcacacc ctccctgagg gatctcatga ctcttgcgtt tctgataggc acctattggt 720
cttactgaca tccactttgc ctttctctcc acaggtgtcc actcccagtt cacaccggca 780
caatgaatgg cacagaaggc cctaacttct acgtgccctt ctccaatgcg acgggtgtgg 840
tacgcagccc cttcgagtac ccacagtact acctggctga gccatggcag ttctccatgc 900
tggccgccta catgtttctg ctgatcgtgc tgggcttccc catcaacttc ctcacgctct 960
acgtcaccgt ccagcacaag aagctgcgca cgcctctcaa ctacatcctg ctcaacctag 1020
ccgtggctga cctcttcatg gtcctaggtg gcttcaccag caccctctac acctctctgc 1080
atggatactt cgtcttcggg cccacaggat gcaatttgga gggcttcttt gccaccctgg 1140
gcggtgaaat tgccctgtgg tccttggtgg tcctggccat cgagcggtac gtggtggtgt 1200
gtaagcccat gagcaacttc cgcttcgggg agaaccatgc catcatgggc gttgccttca 1260
cctgggtcat ggcgctggcc tgcgccgcac ccccactcgc cggctggtcc aggtacatcc 1320
ccgagggcct gcagtgctcg tgtggaatcg actactacac gctcaagccg gaggtcaaca 1380
acgagtcttt tgtcatctac atgttcgtgg tccacttcac catccccatg attatcatct 1440
ttttctgcta tgggcagctc gtcttcaccg tcaaggaggc cgctgcccag cagcaggagt 1500
cagccaccac acagaaggca gagaaggagg tcacccgcat ggtcatcatc atggtcatcg 1560
ctttcctgat ctgctgggtg ccctacgcca gcgtggcatt ctacatcttc acccaccagg 1620
gctccaactt cggtcccatc ttcatgacca tcccagcgtt ctttgccaag agcgccgcca 1680
tctacaaccc tgtcatctat atcatgatga acaagcagtt ccggaactgc atgctcacca 1740
ccatctgctg cggcaagaac ccactgggtg acgatgaggc ctctgctacc gtgtccaaga 1800
cggagacgag ccaggtggcc ccggcc 1826

<210> 9
<211> 3444
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 9
caatctccca gatgctgatt cagccaggaa ctagttatta atagtaatca attacggggt 60
cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc 120
ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag 180
taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc 240
acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg 300
gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc 360
agtacatcta cgtattagtc atcgctatta ccacaaatag ttatcgagcc gctgagccgg 420
ggggcggggg gtgtgagact ggaggcgatg gacggagctg acggcacaca cagctcagat 480
ctgtcaagtg agccattgtc agggcttggg gactggataa gtcaggggt ctcctgggaa 540
gagatgggat aggtgagttc aggaggagac attgtcaact ggagccatgt ggagaagtga 600
atttagggcc caaaggttcc agtcgcagcc tgaggccacc agactgacat ggggaggaat 660
tcccagagga ctctggggca gacaagatga gacacccttt cctttcttta cctaagggcc 720
tccacccgat gtcaccttgg cccctctgca agccaattag gccccggtgg cagcagtggg 780
attagcgtta gtatgatatc tcgcggatgc tgaatcagcc tctggcttag ggagagaagg 840
tcactttata agggtctggg gggggtcagt gcctggagtt gcgctgtggg agccgtcagt 900
ggctgagctc aagaggtaag ggtttaaggg atggttggtt ggtggggtat taatgtttaa 960
ttacctgttt tacaggcctg aaatcacttg gttttaggtt ggtacatctg cagaattcag 1020
ccaccaccgg cacaatgaat ggcacagaag gccctaactt ctacgtgccc ttctccaatg 1080
cgacgggtgt ggtacgcagc cccttcgagt acccacagta ctacctggct gagccatggc 1140
agttctccat gctggccgcc tacatgtttc tgctgatcgt gctgggcttc cccatcaact 1200
tcctcacgct ctacgtcacc gtccagcaca agaagctgcg cacgcctctc aactacatcc 1260
tgctcaacct agccgtggct gacctcttca tggtcctagg tggcttcacc agcaccctct 1320
acacctctct gcatggatac ttcgtcttcg ggcccacagg atgcaatttg gagggcttct 1380
ttgccaccct gggcggtgaa attgccctgt ggtccttggt ggtcctggcc atcgagcggt 1440
acgtggtggt gtgtaagccc atgagcaact tccgcttcgg ggagaaccat gccatcatgg 1500
gcgttgcctt cacctgggtc atggcgctgg cctgcgccgc acccccactc gccggctggt 1560
ccaggtacat ccccgagggc ctgcagtgct cgtgtggaat cgactactac acgctcaagc 1620
cggaggtcaa caacgagtct tttgtcatct acatgttcgt ggtccacttc accatcccca 1680
tgattatcat ctttttctgc tatgggcagc tcgtcttcac cgtcaaggag gccgctgccc 1740
agcagcagga gtcagccacc acacagaagg cagagaagga ggtcacccgc atggtcatca 1800
tcatggtcat cgctttcctg atctgctggg tgccctacgc cagcgtggca ttctacatct 1860
tcacccacca gggctccaac ttcggtccca tcttcatgac catcccagcg ttctttgcca 1920

agagcgccgc catctacaac cctgtcatct atatcatgat gaacaagcag ttccggaact 1980
gcatgctcac caccatctgc tgcggcaaga acccactggg tgacgatgag gcctctgcta 2040
ccgtgtccaa gacggagacg agccaggtgg ccccggccta accaagaaag cttaagtttg 2100
tgtcccggct tagggctaaa tgtctaggac agaatggaac acatagtagc tgattaataa 2160
atgctagctg gatgaaggga ggaatgagtg actgactgag tggatatatg agtgaaggga 2220
ttaatggaag ggaacatgga tgtcctcagg tgcccaacct ggcagatcca gtcatgtctg 2280
gctggaatct ataagcagtt ttacatacct gccctgagct ttattgcggt agtttatcac 2340
agttaaattg ctaacgcagt cagtgcttct gacacaacag tctcgaactt aagctgcagt 2400
gactctctta aggtagcctt gcagaagttg gtcgtgaggc actgggcagg taagtatcaa 2460
ggttacaaga caggtttaag gagaccaata gaaactgggc ttgtcgagac agagaaaaac 2520
ctaaccccca tggttggcga gggactgctg tgtgtgaaat ggtaactgcc ctcaaggagc 2580
ttacaatcta gctgggggta aatgacttgc acatgaacac aactagactg tgagcttcta 2640
gagggcaggg accttaccct agtcatctct cttctcaccc tgcacaccct ccctgaggga 2700
tctcatgact cttgcgtttc tgataggcac ctattggtct tactgacatc cactttgcct 2760
ttctctccac aggtgtccac tcccagttca caccggcaca atgaatggca cagaaggccc 2820
taacttctac gtgcccttct ccaatgcgac gggtgtggta cgcagcccct tcgagtaccc 2880
acagtcagag ataaatgaca gtgacagcaa cgtgagctgc agcccttagg actgagaaag 2940
catcgagacc aggggtctcc ggcaaggcct aggtcctccc ttcagtatgg aaaccttgcc 3000
tcatgtctct cagcctcctt ggcctgtgga gatccagccc ttcctcttgg cttctggata 3060
catttgctct tctacaccag caaccaagtg gcaacagttc caggccagta tggagtttta 3120
gaagccatgc caatatgccc accttcaggg agcagctgag tccttgatgc caccttgtt 3180
ctgaagagtt cagaaacaca gtgcaagaca tgaccaggcc tcatccttag gatgctcatg 3240
gatccagttc ttagctccct tgttggatat gctgttttcc ttggcctttg gtcttttctt 3300
tatcccagag ggttttggct ttaaggccaa caggaactat ggggtaccag aattgagcag 3360
cctcagtctg catccctcct ctatagaacc acagctgggc cctcagcagg cccaactctg 3420
catggggaca gaggcattaa aagc 3444

<210> 10
<211> 1017
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 10
ggagtcgctg cgacgctgcc ttcgccccgt gccccgctcc gccgccgcct cgcgccgccc 60
gccccggctc tgactgaccg cgttactccc acaggtgagc gggcgggacg gcccttctcc 120
tccgggctgt aattagcgct tggtttaatg acggcttgtt tcttttctgt ggctgcgtga 180
aagccttgag gggctccggg agggcccttt gtgcgggggg agcggctcgg ggggtgcgtg 240
cgtgtgtgtg tgcgtgggga gcgccgcgtg cggctccgcg ctgcccggcg gctgtgagcg 300
ctgcgggcgc ggcgcggggc tttgtgcgct ccgcagtgtg cgcgagggga gcgcggccgg 360
gggcggtgcc ccgcggtgcg gggggggctg cgaggggaac aaaggctgcg tgcggggtgt 420
gtgcgtgggg gggtgagcag ggggtgtggg cgcgtcggtc gggctgcaac ccccccctgca 480
ccccccctccc cgagttgctg agcacggccc ggcttcgggt gcggggctcc gtacggggcg 540
tggcgcgggg ctcgccgtgc cgggcggggg gtggcggcag gtgggggtgc cgggcggggc 600
ggggccgcct cgggccgggg agggctcggg ggaggggcgc ggcggccccc ggagcgccgg 660
cggctgtcga ggcgcggcga gccgcagcca ttgcctttta tggtaatcgt gcgagagggc 720
gcagggactt cctttgtccc aaatctgtgc ggagccgaaa tctgggaggc gccgccgcac 780
cccctctagc gggcgcgggg cgaagcggtg cggcgccggc aggaaggaaa tgggcgggga 840
gggccttcgt gcgtcgccgc gccgccgtcc ccttctccct ctccagcctc ggggctgtcc 900
gcgggggac ggctgccttc gggggggacg gggcagggcg gggttcggct tctggcgtgt 960
gaccggcggc tctagagcct ctgctaacca tgttcatgcc ttcttctttt tcctaca 1017

<210> 11
<211> 2239
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 11
aagcttgaaa tgccacctcc tctgatattc taggtgtcct ggaagcctgt ctcatcttgc 60
cctgtagtgt tgggtcacct ggcccccagc ctgtaacatc cccagggccc tacacccaga 120
gaaacacggg gctggtggca gtgcccagtg acaaccgttt agtggataag agaagagtga 180
ccacaccagg ctgagtgctc ctctctggtt ttccatgggg agacaatgcc accctgagca 240
gggtctggtg tgagcggcag ctggctctgg gctctctgat ccgttaccct ctcagcctct 300

ttgttctttc tcaacccctg gagcagagac ctcaggaggt gctggcatgg aacagagaaa 360
ttccagcctc gattcctatt atgaacccga caccttttgt attttcatct tggttttaca 420
gtgtacaaaa cgaactagat cagcagggca tgggcataat cacgaatgca cacacataca 480
ctaatgtgtg gctcatgttt aagtatcact tactacagga cacccaatct aacagcaccg 540
ataaagtgac agagaaacgc aagccttctg cgaacatggc ctggctgttc caattccgaa 600
ccttgctttt ctgggccttg ccacacaggc tcttcccccg tccccccagg gacattctac 660
ccttgaactc cacactccac tgctgccttt gccaggaagc ccatctgttc cttttggtt 720
ctgccagaac gtgtggtggt gctgctgtcc ctgccttggg cactggatat tgggaaggga 780
cagtgtccac actggagtgg gaagttccca gggacgagac ctttacctcc tcaccctggg 840
tactgttctc ctcatggagc atggacggcg ctgcctgaac tcagtggtgg cctcattctg 900
gaagccaagt ttatacagag tagcagtgac ccagggatgt ggggttcacc ctcctcagcc 960
ctctggccag tcctgatggg cctcagtccc aacatggcta agaggtgtgg gcagcttctt 1020
ggtcaccctc aggttgggga atcaccttct gtcttcattt tccaggaact tggtgatgat 1080
atcgtgggtg agttcattta ccaggtgctg tagtttcccc tcatcaggca ggaagaagat 1140
ggcggtggca ttgcccaggt atttcatcag cagcacccag ctggacagct tcttacagtg 1200
ctggatgtta aacatgccta aacgcttcat cataggcacc ttcacggtgg tcacctggtc 1260
cacgtggaag tcctcttcct cggtgtcctt gacttcaaag ggtctctccc atttgcctgg 1320
agagagggga aggtgggcat caccaggggt gagtgaaggt ttggaagagt gtagcagaat 1380
aagaaaccat gagtcccctc cctgagaagc cctgagcccc cttgacgaca cacatccctc 1440
gaggctcagc ttcatcatct gtaaaaggtg ctgaaactga ccatccaagc tgccgaaaaa 1500
gattgtgtgg ggataattca aaactagagg aagatgcaga atttctacat cgtggcgatg 1560
tcaggctaag agatgccatc gtggctgtgc atttttattg gaatcatatg tttatttgag 1620
ggtgtcttgg atattacaaa taaaatgttg gagcatcagg catatttggt accttctgtc 1680
taaggctccc tgcccccttgt taattggcag ctcagttatt catccagggc aaacattctg 1740
cttactattc ctgagagctt tcctcatcct ctagattggc aggggaaatg cagatgcctg 1800
agcagcctcc cctctgccat accaacagag cttcaccatc gaggcatgca gagtggacag 1860
gggcctcagg gacccctgat cccagctttc tcattggaca gaaggaggag actggggctg 1920
gagagggacc tgggccccca ctaaggccac agcagagcca ggactttagc tgtgctgact 1980
gcagcctggc ttgcctccac tgccctcctt tgcctcaaga gcaagggagc ctcagagtgg 2040
aggaagcagc ccctggcctt gcctcccacc tcccctcccc tatgctgttt tcctgggaca 2100
gtgggagctg gcttagaatg ccctggggcc cccaggaccc tggcatttta acccctcagg 2160
ggcaggaagg cagcctgaga tacagaagag tccatcacct gctgtatgcc acacaccatc 2220
cccacagtta cgtactagt 2239

<210> 12
<211> 6408
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 12
gaattcggac cgtcgacatt gattattgac tagttattaa tagtaatcaa ttacggggtc 60
attagttcat agcccatata tggagttccg cgttacataa cttacggtaa atggcccgcc 120
tggctgaccg cccaacgacc cccgcccatt gacgtcaata atgacgtatg ttcccatagt 180
aacgccaata gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca 240
cttggcagta catcaagtgt atcatatgcc aagtacgccc cctattgacg tcaatgacgg 300
taaatggccc gcctggcatt atgcccagta catgacctta tgggactttc ctacttggca 360
gtacatctac gtattagtca tcgctattac catggtcgag gtgagcccca cgttctgctt 420
cactctcccc atctcccccc cctccccacc cccaattttg tatttattta ttttttaatt 480
attttgtgca gcgatggggg cgggggggg gggggggcgc gcgccaggcg gggcggggcg 540
gggcgagggg cggggcgggg cgaggcggag aggtgcggcg gcagccaatc agagcggcgc 600
gctccgaaag tttccttta tggcgaggcg gcggcggcgg cggccctata aaaagcgaag 660
cgcgcggcgg gcggggagtc gctgcgacgc tgccttcgcc ccgtgccccg ctccgccgcc 720
gcctcgcgcc gcccgccccg gctctgactg accgcgttac tcccacaggt gagcgggcgg 780
gacggccctt ctcctccggg ctgtaattag cgcttggttt aatgacggct tgtttctttt 840
ctgtggctgc gtgaaagcct tgaggggctc cgggagggcc ctttgtgcgg ggggagcggc 900
tcgggggggtg cgtgcgtgtg tgtgtgcgtg gggagcgccg cgtgcggctc cgcgctgccc 960
ggcggctgtg agcgctgcgg gcgcggcgcg gggctttgtg cgctccgcag tgtgcgcgag 1020
gggagcgcgg ccgggggcgg tgccccgcgg tgcgggggggg gctgcgaggg gaacaaaggc 1080
tgcgtgcggg gtgtgtgcgt gggggggtga gcaggggtg tgggcgcgtc ggtcgggctg 1140
caaccccccc tgcacccccc tccccgagtt gctgagcacg gcccggcttc gggtgcgggg 1200
ctccgtacgg ggcgtggcgc ggggctcgcc gtgccgggcg gggggtggcg gcaggtgggg 1260
gtgccgggcg gggcggggcc gcctcgggcc ggggagggct cgggggaggg gcgcggcggc 1320
ccccggagcg ccggcggctg tcgaggcgcg gcgagccgca gccattgcct tttatggtaa 1380
tcgtgcgaga gggcgcaggg acttcctttg tcccaaatct gtgcggagcc gaaatctggg 1440
aggcgccgcc gcacccccctc tagcgggcgc ggggcgaagc ggtgcggcgc cggcaggaag 1500

gaaatgggcg gggagggcct tcgtgcgtcg ccgcgccgcc gtccccttct ccctctccag 1560
cctcggggct gtccgcgggg ggacggctgc cttcgggggg gacggggcag ggcggggttc 1620
ggcttctggc gtgtgaccgg cggctctaga gcctctgcta accatgttca tgccttcttc 1680
tttttcctac agctcctggg caacgtgctg gttattgtgc tgtctcatca ttttggcaaa 1740
gaattcttcg aaagatctgc tagcttaatt aacccaaacg ggccctctag actcgagcgg 1800
ccgccactgt gctggatatc tgcagaattc agccaccacc ggcacaatga atggcacaga 1860
aggccctaac ttctacgtgc ccttctccaa tgcgacgggt gtggtacgca gccccttcga 1920
gtacccacag tactacctgg ctgagccatg gcagttctcc atgctggccg cctacatgtt 1980
tctgctgatc gtgctgggct tccccatcaa cttcctcacg ctctacgtca ccgtccagca 2040
caagaagctg cgcacgcctc tcaactacat cctgctcaac ctagccgtgg ctgacctctt 2100
catggtccta ggtggcttca ccagcaccct ctacacctct ctgcatggat acttcgtctt 2160
cgggcccaca ggatgcaatt tggagggctt ctttgccacc ctgggcggtg aaattgccct 2220
gtggtccttg gtggtcctgg ccatcgagcg gtacgtggtg gtgtgtaagc ccatgagcaa 2280
cttccgcttc ggggagaacc atgccatcat gggcgttgcc ttcacctggg tcatggcgct 2340
ggcctgcgcc gcacccccac tcgccggctg gtccaggtac atccccgagg gcctgcagtg 2400
ctcgtgtgga atcgactact acacgctcaa gccggaggtc aacaacgagt cttttgtcat 2460
ctacatgttc gtggtccact tcaccatccc catgattatc atctttttct gctatgggca 2520
gctcgtcttc accgtcaagg aggccgctgc ccagcagcag gagtcagcca ccacacagaa 2580
ggcagagaag gaggtcaccc gcatggtcat catcatggtc atcgctttcc tgatctgctg 2640
ggtgccctac gccagcgtgg cattctacat cttcacccac cagggctcca acttcggtcc 2700
catcttcatg accatcccag cgttctttgc caagagcgcc gccatctaca accctgtcat 2760
ctatatcatg atgaacaagc agttccggaa ctgcatgctc accaccatct gctgcggcaa 2820
gaacccactg ggtgacgatg aggcctctgc taccgtgtcc aagacggaga cgagccaggt 2880
ggccccggcc taaccaagaa agcttaagtt tgggactagt ggcggccgct cgagcatgca 2940
tctagagggc cctattctat agtgtcacct aaatgctaga gctcgctgat cagcctcgac 3000
tgtgccttct agttgccagc catctgttgt ttgcccctcc cccgtgcctt ccttgaccct 3060
ggaaggtgcc actcccactg tcctttccta ataaaatgag gaaattgcat cgcattgtct 3120
gagtaggtgt cattctattc tgggggggtgg ggtggggcag gacagcaagg gggaggattg 3180
ggaagacaat agcaggcatg ctggggagct agagtcgacc ggaccgctgc aggcatgcaa 3240
gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa ttgttatccg ctcacaattc 3300
cacacaacat acgagccgga agcataaagt gtaaagcctg gggtgcctaa tgagtgagct 3360
aactcacatt aattgcgttg cgctcactgc ccgctttcca gtcgggaaac ctgtcgtgcc 3420
agctgcatta atgaatcggc caacgcgcgg ggagaggcgg tttgcgtatt gggcgctctt 3480
ccgtattagt catcgctatt accatggtga tgcggttttg gcagtacatc aatgggcgtg 3540
gatagcggtt tgactcacgg ggatttccaa gtctccaccc cattgacgtc aatgggagtt 3600
tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc gccccattga 3660
cgcaaatggg cggtaggcgt gtacggtggg aggtctatat aagcagagct ctctggctaa 3720
ctagagaacc cactgcttac tggcttatcg aaattaatac gactcactat agggagtccc 3780
aagctggcta gttaagctat caacaagttt gtacaaaaaa gcaggcttta aagggaggta 3840
gtgagtcgac cagtggatcc tggaggcttg ctgaaggctg tatgctgaag gagcttacaa 3900
tctagctggg gttttggcca ctgactgacc ccagctagtg taagctcctt caggacacaa 3960
ggcctgttac tagcactcac atggaacaaa tggcccagat ctggccgcac tcgagatgct 4020
tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac 4080
tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga 4140
gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat 4200
aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac 4260
ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct 4320
gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg 4380
ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg 4440
ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt 4500
cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg 4560
attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac 4620
ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga 4680
aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt 4740
gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt 4800
tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga 4860
ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc 4920
taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct 4980
atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt cgtgtagata 5040
actacgatac gggagggctt accatctggc cccagtgctg caatgatacc gcgagaccca 5100
cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga 5160
agtggtcctg caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga 5220
gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg ccattgctac aggcatcgtg 5280
gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga 5340
gttacatgat cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt 5400
gtcagaagta agttggccgc agtgttatca ctcatggtta tggcagcact gcataattct 5460
cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca 5520
ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat acgggataat 5580

accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga 5640
aaactctcaa ggatcttacc gctgttgaga tccagttcga tgtaacccac tcgtgcaccc 5700
aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg 5760
caaaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc 5820
ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt 5880
gaatgtattt agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcca 5940
cctgacgtct aagaaaccat tattatcatg acattaacct ataaaaatag gcgtatcacg 6000
aggccctttc gtctcgcgcg tttcggtgat gacggtgaaa acctctgaca catgcagctc 6060
ccggagacgg tcacagcttg tctgtaagcg gatgccggga gcagacaagc ccgtcagggc 6120
gcgtcagcgg gtgttggcgg gtgtcggggc tggcttaact atgcggcatc agagcagatt 6180
gtactgagag tgcaccatat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac 6240
cgcatcaggc gccattcgcc attcaggctg cgcaactgtt gggaagggcg atcggtgcgg 6300
gcctcttcgc tattacgcca gctggcgaaa gggggatgtg ctgcaaggcg attaagttgg 6360
gtaacgccag ggttttccca gtcacgacgt tgtaaaacga cggccagt 6408

<210> 13
<211> 155
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 13
gatcctggag gcttgctgaa ggctgtatgc tgaaggagct tacaatctag ctggggtttt 60
ggccactgac tgaccccagc tagtgtaagc tccttcagga cacaaggcct gttactagca 120
ctcacatgga acaaatggcc cagatctggc cgcac 155

<210> 14
<211> 189
<212> DNA
<213> Homo sapiens

<400> 14
aacctaaccc ccatggttgg cgagggactg ctgtgtgtga aatggtaact gccctcaagg 60
agcttacaat ctagctgggg gtaaatgact tgcacatgaa cacaactaga ctgtgagctt 120
ctagagggca gggaccttac cctagtcatc tctcttctca ccctgcacac cctccctgag 180
ggatctcat 189

<210> 15
<211> 6172
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 15
tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggcgccattc 60
gccattcagg ctgcgcaact gttgggaagg gcgatcggtg cgggcctctt cgctattacg 120
ccagctggcg aaaggggat gtgctgcaag gcgattaagt tgggtaacgc cagggttttc 180
ccagtcacga cgttgtaaaa cgacggccag tgaattcgga ccgtcgacat tgattattgg 240
gccccagaag cctggtggtt gtttgtcctt ctcaggggaa aagtgaggcg gcccccttgga 300
ggaaggggcc gggcagaatg atctaatcgg attccaagca gctcagggga ttgtcttttt 360
ctagcacctt cttgccactc ctaagcgtcc tccgtgaccc cggctgggat ttagcctggt 420
gctgtgtcag ccccggtctc ccaggggctt cccagtggtc cccaggaacc ctcgacaggg 480
cccggtctct ctcgtccagc aagggcaggg acgggccaca ggccaagggc ggagtcgctg 540
cgacgctgcc ttcgccccgt gccccgctcc gccgccgcct cgcgccgccc gccccggctc 600
tgactgaccg cgttactccc acaggtgagc gggcgggacg gcccttctcc tccgggctgt 660
aattagcaag aggtaagggt ttaagggatg gttggttggt ggggtattaa tgtttaatta 720
cctgttttac aggcctgaaa tcacttggtt ttaggttggg gatccggtac ccaattgcca 780
tgggctagca tgcatgagct ccctgcaggg tttatctgca gaattcagcc accaccggca 840
caatgaatgg cacagaaggc cctaacttct acgtgccctt ctccaatgcg acgggtgtgg 900
tacgcagccc cttcgagtac ccacagtact acctggctga gccatggcag ttctccatgc 960
tggccgccta catgtttctg ctgatcgtgc tgggcttccc catcaacttc ctcacgctct 1020
acgtcaccgt ccagcacaag aagctgcgca cgcctctcaa ctacatcctg ctcaacctag 1080
ccgtggctga cctcttcatg gtcctaggtg gcttcaccag caccctctac acctctctgc 1140

atggatactt cgtcttcggg cccacaggat gcaatttgga gggcttcttt gccaccctgg 1200
gcggtgaaat tgccctgtgg tccttggtgg tcctggccat cgagcggtac gtggtggtgt 1260
gtaagcccat gagcaacttc cgcttcgggg agaaccatgc catcatgggc gttgccttca 1320
cctgggtcat ggcgctggcc tgcgccgcac ccccactcgc cggctggtcc aggtacatcc 1380
ccgagggcct gcagtgctcg tgtggaatcg actactacac gctcaagccg gaggtcaaca 1440
acgagtcttt tgtcatctac atgttcgtgg tccacttcac catccccatg attatcatct 1500
ttttctgcta tgggcagctc gtcttcaccg tcaaggaggc cgctgcccag cagcaggagt 1560
cagccaccac acagaaggca gagaaggagg tcacccgcat ggtcatcatc atggtcatcg 1620
ctttcctgat ctgctgggtg ccctacgcca gcgtggcatt ctacatcttc acccaccagg 1680
gctccaactt cggtcccatc ttcatgacca tcccagcgtt ctttgccaag agcgccgcca 1740
tctacaaccc tgtcatctat atcatgatga acaagcagtt ccggaactgc atgctcacca 1800
ccatctgctg cggcaagaac ccactgggtg acgatgaggc ctctgctacc gtgtccaaga 1860
cggagacgag ccaggtggcc ccggcctaac caagaaagct taagtttgtg tcccggctta 1920
gggctaaatg tctaggacag aatggaacac atagtagctg attaataaat gctagctgga 1980
tgaagggagg aatgagtgac tgactgagtg gatatatgag tgaagggatt aatggaaggg 2040
aacatggatg tcctcaggtg cccaacctgg cagatccagt catgtctggc tggaatctat 2100
aagcagtttt acatacctgc cctgagcttt attgcggtag tttatcacag ttaaattgct 2160
aacgcagtca gtgcttctga cacaacagtc tcgaacttaa gctgcagtga ctctcttaag 2220
gtagccttgc agaagttggt cgtgaggcac tgggcaggta agtatcaagg ttacaagaca 2280
ggtttaagga gaccaataga aactgggctt gtcgagacag agaaaaacct aacccccatg 2340
gttggcgagg gactgctgtg tgtgaaatgg taactgccct caaggagctt acaatctagc 2400
tgggggtaaa tgacttgcac atgaacacaa ctagactgtg agcttctaga gggcagggac 2460
cttaccctag tcatctctct tctcaccctg cacaccctcc ctgagggatc tcatgactct 2520
tgcgtttctg ataggcacct attggtctta ctgacatcca ctttgccttt ctctccacag 2580
gtgtccactc ccagttcaca ccggcacaat gaatggcaca gaaggcccta acttctacgt 2640
gcccttctcc aatgcgacgg gtgtggtacg cagccccttc gagtacccac agtcagagat 2700
aaatgacagt gacagcaacg tgagctgcag cccttaggac tgagaaagca tcgagaccag 2760
gggtctccgg caaggcctag gtcctccctt cagtatggaa accttgcctc atgtctctca 2820
gcctccttgg cctgtggaga tccagccctt cctcttggct tctggataca tttgctcttc 2880
tacaccagca accaagtggc aacagttcca ggccagtatg gagttttaga agccatgcca 2940
atatgcccac cttcagggag cagctgagtc cttgatgcca cccttgttct gaagagttca 3000
gaaacacagt gcaagacatg accaggcctc atccttagga tgctcatgga tccagttctt 3060
agctcccttg ttggatatgc tgttttcctt ggcctttggt cttttcttta tcccagaggg 3120
ttttggcttt aaggccaaca ggaactatgg ggtaccagaa ttgagcagcc tcagtctgca 3180
tccctcctct atagaaccac agctgggccc tcagcaggcc caactctgca tggggacaga 3240
ggcattaaaa gcctagagta tccctcgagg ggcccaagct tacgcgtacc cagctttctt 3300
gtacaaagtg gtccctatag tgagtcgtat tataagctag gcactggccg tcgttttaca 3360
acgtcgtgac tgggaaaact gctagcttgg gatctttgtg aaggaacctt acttctgtgg 3420
tgtgacataa ttggacaaac tacctacaga gatttaaagc tctaaggtaa atataaaatt 3480
tttaagtgta taatgtgtta aactagctgc aaaacctgtg ccttctagtt gccagccatc 3540
tgttgtttgc ccctcccccg tgccttcctt gaccctggaa ggtgccactc ccactgtcct 3600
ttcctaataa aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg 3660
gggtggggtg gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcatgctgg 3720
ggaactagtc ggaccgctgc aggcatgcaa gcttggcgta atcatggtca tagctgtttc 3780
ctgtgtgaaa ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt 3840
gtaaagcctg gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc 3900
ccgctttcca gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg 3960
ggagaggcgg tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct 4020
cggtcgttcg gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca 4080
cagaatcagg ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga 4140
accgtaaaaa ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc 4200
acaaaaatcg acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg 4260
cgtttccccc tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat 4320
acctgtccgc ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt 4380
atctcagttc ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc 4440
agcccgaccg ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg 4500
acttatcgcc actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg 4560
gtgctacaga gttcttgaag tggtggccta actacggcta cactagaagg acagtatttg 4620
gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg 4680
gcaaacaaac caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca 4740
gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga 4800
acgaaaactc acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga 4860
tccttttaaa ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt 4920
ctgacagtta ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt 4980
catccatagt tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat 5040
ctggccccag tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag 5100
caataaacca gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct 5160
ccatccagtc tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt 5220

tgcgcaacgt tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg 5280
cttcattcag ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca 5340
aaaaagcggt tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt 5400
tatcactcat ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat 5460
gcttttctgt gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac 5520
cgagttgctc ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa 5580
aagtgctcat cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt 5640
tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt 5700
tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa 5760
gggcgacacg gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt 5820
atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa 5880
taggggttcc gcgcacattt ccccgaaaag tgccacctga cgtctaagaa accattatta 5940
tcatgacatt aacctataaa aataggcgta tcacgaggcc ctttcgtctc gcgcgtttcg 6000
gtgatgacgg tgaaaacctc tgacacatgc agctcccgga gacggtcaca gcttgtctgt 6060
aagcggatgc cgggagcaga caagcccgtc agggcgcgtc agcgggtgtt ggcgggtgtc 6120
ggggctggct taactatgcg gcatcagagc agattgtact gagagtgcac ca 6172

<210> 16
<211> 441
<212> DNA
<213> Homo sapiens

<400> 16
actagaagct ttattgcggt agtttatcac agttaaattg ctaacgcagt cagtgcttct 60
gacacaacag tctcgaactt aagctgcagt gactctctta aggtagcctt gcagaagttg 120
gtcgtgaggc actgggcagg taagtatcaa ggttacaaga caggtttaag gagaccaata 180
gaaactgggc ttgtcgagac agagaatgga tcctggaggc ttgctgaagg ctgtatgctg 240
aaggagctta caatctagct ggggttttgg ccactgactg accccagcta gtgtaagctc 300
cttcaggaca caaggcctgt tactagcact cacatggaac aaatggccca gatctgagac 360
tcttgcgttt ctgataggca cctattggtc ttactgacat ccactttgcc tttctctcca 420
caggtgtcca ctcccagttc a 441

<210> 17
<211> 150
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 17
tggatcctgg aggcttgctg aaggctgtat gctgaaggag cttacaatct agctggggtt 60
ttggccactg actgacccca gctagtgtaa gctccttcag gacacaaggc ctgttactag 120
cactcacatg gaacaaatgg cccagatctg 150

<210> 18
<211> 190
<212> DNA
<213> Homo sapiens

<400> 18
aaacctaacc cccatggttg gcgagggact gctgtgtgtg aaatggtaac tgccctcaag 60
gagcttacaa tctagctggg ggtaaatgac ttgcacatga acacaactag actgtgagct 120
tctagagggc agggacctta ccctagtcat ctctcttctc accctgcaca ccctccctga 180
gggatctcat 190

<210> 19
<211> 79
<212> RNA
<213> Homo sapiens

<400> 19
cucugccugg agacuaaggc aaauugggcc auuaaaagcu cagcuccuau guugguauua 60
acgguggugg guuuuguug 79

<210> 20
<211> 113

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 20
ccactccctc tctgcgcgct cgctcgctca ctgaggccgg gcgaccaaag gtcgcccgac 60
gcccgggctt tgcccgggcg gcctcagtga gcgagcgagc gcgcagagag gga 113

<210> 21
<211> 143
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 21
ggccactccc tctctgcgcg ctcgctcgct cactgaggcc gggcgaccaa aggtcgcccg 60
acgcccgggc tttgcccggg cggcctcagt gagcgagcga gcgcgcagag agggagtggc 120
caactccatc actaggggtt cct 143

<210> 22
<211> 795
<212> DNA
<213> Mus musculus

<400> 22
tgctgattca gccaggaact agttattaat agtaatcaat tacggggtca ttagttcata 60
gcccatatat ggagttccgc gttacataac ttacggtaaa tggcccgcct ggctgaccgc 120
ccaacgaccc ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag 180
ggactttcca ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac 240
atcaagtgta tcatatgcca agtacgcccc ctattgacgt caatgacggt aaatggcccg 300
cctggcatta tgcccagtac atgaccttat gggactttcc tacttggcag tacatctacg 360
tattagtcat cgctattacc acaaatagtt atcgagccgc tgagccgggg ggcgggggt 420
gtgagactgg aggcgatgga cggagctgac ggcacacaca gctcagatct gtcaagtgag 480
ccattgtcag ggcttgggga ctggataagt caggggtct cctgggaaga gatgggatag 540
gtgagttcag gaggagacat tgtcaactgg agccatgtgg agaagtgaat ttagggccca 600
aaggttccag tcgcagcctg aggccaccag actgacatgg ggaggaattc ccagaggact 660
ctggggcaga caagatgaga caccctttcc tttctttacc taagggcctc cacccgatgt 720
caccttggcc cctctgcaag ccaattaggc cccggtggca gcagtgggat tagcgttagt 780
atgatatctc gcgga 795

<210> 23
<211> 315
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 23
ggagtcgctg cgacgctgcc ttcgccccgt gccccgctcc gccgccgcct cgcgccgccc 60
gccccggctc tgactgaccg cgttactccc acaggtgagc gggcgggacg gcccttctcc 120
tccgggctgt aattagcaag aggtaagggt ttaagggatg gttggttggt ggggtattaa 180
tgtttaatta cctgttttac aggcctgaaa tcacttggtt ttaggttggg gatccggtac 240
ccaattgcca tgggctagca tgcatgagct ccctgcaggg ttttaatgcc aactttgtac 300
aaaaaagcag gcacc 315

<210> 24
<211> 2064
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 24
tgactagtta gggccccaga agcctggtgg ttgtttgtcc ttctcagggg aaaagtgagg 60
cggccccttg gaggaagggg ccgggcagaa tgatctaatc ggattccaag cagctcaggg 120
gattgtcttt ttctagcacc ttcttgccac tcctaagcgt cctccgtgac cccggctggg 180
atttagcctg gtgctgtgtc agccccggtc tcccaggggc ttcccagtgg tccccaggaa 240
ccctcgacag ggcccggtct ctctcgtcca gcaagggcag ggacgggcca caggccaagg 300
gcactagaag ctttattgcg gtagtttatc acagttaaat tgctaacgca gtcagtgctt 360
ctgacacaac agtctcgaac ttaagctgca gtgactctct taaggtagcc ttgcagaagt 420
tggtcgtgag gcactgggca ggtaagtatc aaggttacaa gacaggttta aggagaccaa 480
tagaaactgg gcttgtcgag acagagaatg gatcctggag gcttgctgaa ggctgtatgc 540
tgaaggagct tacaatctag ctggggtttt ggccactgac tgaccccagc tagtgtaagc 600
tccttcagga cacaaggcct gttactagca ctcacatgga acaaatggcc cagatctgag 660
actcttgcgt ttctgatagg cacctattgg tcttactgac atccactttg cctttctctc 720
cacaggtgtc cactcccagt tcacaccggc acaatgaatg gcacagaagg ccctaacttc 780
tacgtgccct tctccaatgc gacgggtgtg gtacgcagcc ccttcgagta cccacagtac 840
tacctggctg agccatggca gttctccatg ctggccgcct acatgtttct gctgatcgtg 900
ctgggcttcc ccatcaactt cctcacgctc tacgtcaccg tccagcacaa gaagctgcgc 960
acgcctctca actacatcct gctcaaccta gccgtggctg acctcttcat ggtcctaggt 1020
ggcttcacca gcaccctcta cacctctctg catggatact tcgtcttcgg gcccacagga 1080
tgcaatttgg agggcttctt tgccaccctg ggcggtgaaa ttgccctgtg gtccttggtg 1140
gtcctggcca tcgagcggta cgtggtggtg tgtaagccca tgagcaactt ccgcttcggg 1200
gagaaccatg ccatcatggg cgttgccttc acctgggtca tggcgctggc ctgcgccgca 1260
cccccactcg ccggctggtc caggtacatc cccgagggcc tgcagtgctc gtgtggaatc 1320
gactactaca cgctcaagcc ggaggtcaac aacgagtctt ttgtcatcta catgttcgtg 1380
gtccacttca ccatccccat gattatcatc tttttctgct atgggcagct cgtcttcacc 1440
gtcaaggagg ccgctgccca gcagcaggag tcagccacca cacagaaggc agagaaggag 1500
gtcacccgca tggtcatcat catggtcatc gctttcctga tctgctgggt gccctacgcc 1560
agcgtggcat tctacatctt cacccaccag ggctccaact tcggtcccat cttcatgacc 1620
atcccagcgt tctttgccaa gagcgccgcc atctacaacc ctgtcatcta tatcatgatg 1680
aacaagcagt tccggaactg catgctcacc accatctgct gcggcaagaa cccactgggt 1740
gacgatgagg cctctgctac cgtgtccaag acggagacga gccaggtggc cccggcctaa 1800
ccaagaaagc ttaagtttaa accgctgatc agcctcgact gtgccttcta gttgccagcc 1860
atctgttgtt tgcccctccc ccgtgccttc cttgaccctg gaaggtgcca ctcccactgt 1920
cctttcctaa taaaatgagg aaattgcatc gcattgtctg agtaggtgtc attctattct 1980
ggggggtggg gtggggcagg acagcaaggg ggaggattgg gaagacaata gcaggcatgc 2040
tggggatgcg gtgggctcta tggc 2064

<210> 25
<211> 2093
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 25
gggccccaga agcctggtgg ttgtttgtcc ttctcagggg aaaagtgagg cggccccttg 60
gaggaagggg ccgggcagaa tgatctaatc ggattccaag cagctcaggg gattgtcttt 120
ttctagcacc ttcttgccac tcctaagcgt cctccgtgac cccggctggg atttagcctg 180
gtgctgtgtc agccccggtc tcccaggggc ttcccagtgg tccccaggaa ccctcgacag 240
ggcccggtct ctctcgtcca gcaagggcag ggacgggcca caggccaagg gcactagaag 300
ctttattgcg gtagtttatc acagttaaat tgctaacgca gtcagtgctt ctgacacaac 360
agtctcgaac ttaagctgca gtgactctct taaggtagcc ttgcagaagt tggtcgtgag 420
gcactgggca ggtaagtatc aaggttacaa gacaggttta aggagaccaa tagaaactgg 480
gcttgtcgag acagagaaaa acctaacccc catggttggc gagggactgc tgtgtgtgaa 540
atggtaactg ccctcaagga gcttacaatc tagctggggg taaatgactt gcacatgaac 600
acaactagac tgtgagcttc tagagggcag ggaccttacc ctagtcatct ctcttctcac 660
cctgcacacc ctccctgagg gatctcatga ctcttgcgtt tctgataggc acctattggt 720
cttactgaca tccactttgc ctttctctcc acaggtgtcc actcccagtt cacaccggca 780
caatgaatgg cacagaaggc cctaacttct acgtgccctt ctccaatgcg acgggtgtgg 840
tacgcagccc cttcgagtac ccacagtact acctggctga gccatggcag ttctccatgc 900
tggccgccta catgtttctg ctgatcgtgc tgggcttccc catcaacttc ctcacgctct 960
acgtcaccgt ccagcacaag aagctgcgca cgcctctcaa ctacatcctg ctcaacctag 1020
ccgtggctga cctcttcatg gtcctaggtg gcttcaccag caccctctac acctctctgc 1080
atggatactt cgtcttcggg cccacaggat gcaatttgga gggcttcttt gccaccctgg 1140
gcggtgaaat tgccctgtgg tccttggtgg tcctggccat cgagcggtac gtggtggtgt 1200
gtaagcccat gagcaacttc cgcttcgggg agaaccatgc catcatgggc gttgccttca 1260
cctgggtcat ggcgctggcc tgcgccgcac ccccactcgc cggctggtcc aggtacatcc 1320

ccgagggcct gcagtgctcg tgtggaatcg actactacac gctcaagccg gaggtcaaca 1380
acgagtcttt tgtcatctac atgttcgtgg tccacttcac catccccatg attatcatct 1440
ttttctgcta tgggcagctc gtcttcaccg tcaaggaggc cgctgcccag cagcaggagt 1500
cagccaccac acagaaggca gagaaggagg tcacccgcat ggtcatcatc atggtcatcg 1560
ctttcctgat ctgctgggtg ccctacgcca gcgtggcatt ctacatcttc acccaccagg 1620
gctccaactt cggtcccatc ttcatgacca tcccagcgtt ctttgccaag agcgccgcca 1680
tctacaaccc tgtcatctat atcatgatga acaagcagtt ccggaactgc atgctcacca 1740
ccatctgctg cggcaagaac ccactgggtg acgatgaggc ctctgctacc gtgtccaaga 1800
cggagacgag ccaggtggcc ccggcctaac caagaaagct taagtttaaa ccgctgatca 1860
gcctcgactg tgccttctag ttgccagcca tctgttgttt gcccctcccc cgtgccttcc 1920
ttgaccctgg aaggtgccac tcccactgtc ctttcctaat aaaatgagga aattgcatcg 1980
cattgtctga gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg 2040
gaggattggg aagacaatag caggcatgct ggggatgcgg tgggctctat ggc 2093

<210> 26
<211> 2716
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 26
acgcgttttc tgcagcgggg attaatatga ttatgaacac ccccaatctc ccagatgctg 60
attcagccag gaactagtta ttaatagtaa tcaattacgg ggtcattagt tcatagccca 120
tatatggagt tccgcgttac ataacttacg gtaaatggcc cgcctggctg accgcccaac 180
gacccccgcc cattgacgtc aataatgacg tatgttccca tagtaacgcc aatagggact 240
ttccattgac gtcaatgggt ggagtattta cggtaaactg cccacttggc agtacatcaa 300
gtgtatcata tgccaagtac gccccctatt gacgtcaatg acggtaaatg gcccgcctgg 360
cattatgccc agtacatgac cttatgggac tttcctactt ggcagtacat ctacgtatta 420
gtcatcgcta ttaccacaaa tagttatcga gccgctgagc cgggggggcgg ggggtgtgag 480
actggaggcg atggacggag ctgacggcac acacagctca gatctgtcaa gtgagccatt 540
gtcagggctt ggggactgga taagtcaggg ggtctcctgg gaagagatgg gataggtgag 600
ttcaggagga gacattgtca actggagcca tgtggagaag tgaatttagg gcccaaaggt 660
tccagtcgca gcctgaggcc accagactga catggggagg aattcccaga ggactctggg 720
gcagacaaga tgagacaccc tttccttttct ttacctaagg gcctccaccc gatgtcacct 780
tggcccctct gcaagccaat taggccccgg tggcagcagt gggattagcg ttagtatgat 840
atctcgcgga tgctgaatca gcctctggct tagggagaga aggtcacttt ataagggtct 900
gggggggggtc agtgcctgga gttgcgctgt gggagccgtc agtggctgag ctcaactaga 960
agctttattg cggtagttta tcacagttaa attgctaacg cagtcagtgc ttctgacaca 1020
acagtctcga acttaagctg cagtgactct cttaaggtag ccttgcagaa gttggtcgtg 1080
aggcactggg caggtaagta tcaaggttac aagacaggtt taaggagacc aatagaaact 1140
gggcttgtcg agacagagaa tggatcctgg aggcttgctg aaggctgtat gctgaaggag 1200
cttacaatct agctggggtt ttggccactg actgacccca gctagtgtaa gctccttcag 1260
gacacaaggc ctgttactag cactcacatg gaacaaatgg cccagatctg agactcttgc 1320
gtttctgata ggcacctatt ggtcttactg acatccactt tgcctttctc tccacaggtg 1380
tccactccca gttcacaccg gcacaatgaa tggcacagaa ggccctaact tctacgtgcc 1440
cttctccaat gcgacgggtg tggtacgcag ccccttcgag tacccacagt actacctggc 1500
tgagccatgg cagttctcca tgctggccgc ctacatgttt ctgctgatcg tgctgggctt 1560
ccccatcaac ttcctcacgc tctacgtcac cgtccagcac aagaagctgc gcacgcctct 1620
caactacatc ctgctcaacc tagccgtggc tgacctcttc atggtcctag gtggcttcac 1680
cagcaccctc tacacctctc tgcatggata cttcgtcttc gggcccacag gatgcaattt 1740
ggagggcttc tttgccaccc tgggcggtga aattgccctg tggtccttgg tggtcctggc 1800
catcgagcgg tacgtggtgg tgtgtaagcc catgagcaac ttccgcttcg gggagaacca 1860
tgccatcatg ggcgttgcct tcacctgggt catggcgctg gcctgcgccg cacccccact 1920
cgccggctgg tccaggtaca tccccgaggg cctgcagtgc tcgtgtggaa tcgactacta 1980
cacgctcaag ccggaggtca acaacgagtc ttttgtcatc tacatgttcg tggtccactt 2040
caccatcccc atgattatca tctttttctg ctatgggcag ctcgtcttca ccgtcaagga 2100
ggccgctgcc cagcagcagg agtcagccac cacacagaag gcagagaagg aggtcacccg 2160
catggtcatc atcatggtca tcgctttcct gatctgctgg gtgccctacg ccagcgtggc 2220
attctacatc ttcacccacc agggctccaa cttcggtccc atcttcatga ccatcccagc 2280
gttctttgcc aagagcgccg ccatctacaa ccctgtcatc tatatcatga tgaacaagca 2340
gttccggaac tgcatgctca ccaccatctg ctgcggcaag aacccactgg gtgacgatga 2400
ggcctctgct accgtgtcca agacggagac gagccaggtg gccccggcct aaccaagaaa 2460
gcttaagttt aaaccgctga tcagcctcga ctgtgccttc tagttgccag ccatctgttg 2520
tttgcccctc ccccgtgcct tccttgaccc tggaaggtgc cactcccact gtcctttcct 2580
aataaaatga ggaaattgca tcgcattgtc tgagtaggtg tcattctatt ctgggggggtg 2640
gggtggggca ggacagcaag ggggaggatt gggaagacaa tagcaggcat gctggggatg 2700

cggtgggctc tatggc 2716

<210> 27
<211> 2755
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 27
acgcgttttc tgcagcgggg attaatatga ttatgaacac ccccaatctc ccagatgctg 60
attcagccag gaactagtta ttaatagtaa tcaattacgg ggtcattagt tcatagccca 120
tatatggagt tccgcgttac ataacttacg gtaaatggcc cgcctggctg accgcccaac 180
gacccccgcc cattgacgtc aataatgacg tatgttccca tagtaacgcc aatagggact 240
ttccattgac gtcaatgggt ggagtattta cggtaaactg cccacttggc agtacatcaa 300
gtgtatcata tgccaagtac gccccctatt gacgtcaatg acggtaaatg gcccgcctgg 360
cattatgccc agtacatgac cttatgggac tttcctactt ggcagtacat ctacgtatta 420
gtcatcgcta ttaccacaaa tagttatcga gccgctgagc cgggggggcgg ggggtgtgag 480
actggaggcg atggacggag ctgacggcac acacagctca gatctgtcaa gtgagccatt 540
gtcagggctt ggggactgga taagtcaggg ggtctcctgg gaagagatgg gataggtgag 600
ttcaggagga gacattgtca actggagcca tgtggagaag tgaatttagg gcccaaaggt 660
tccagtcgca gcctgaggcc accagactga catggggagg aattcccaga ggactctggg 720
gcagacaaga tgagacaccc tttccttttct ttacctaagg gcctccaccc gatgtcacct 780
tggcccctct gcaagccaat taggccccgg tggcagcagt gggattagcg ttagtatgat 840
atctcgcgga tgctgaatca gcctctggct tagggagaga aggtcacttt ataagggtct 900
ggggggggtc agtgcctgga gttgcgctgt gggagccgtc agtggctgag ctcaactaga 960
agctttattg cggtagttta tcacagttaa attgctaacg cagtcagtgc ttctgacaca 1020
acagtctcga acttaagctg cagtgactct cttaaggtag ccttgcagaa gttggtcgtg 1080
aggcactggg caggtaagta tcaaggttac aagacaggtt taaggagacc aatagaaact 1140
gggcttgtcg agacagagaa aaacctaacc cccatggttg gcgagggact gctgtgtgtg 1200
aaatggtaac tgccctcaag gagcttacaa tctagctggg ggtaaatgac ttgcacatga 1260
acacaactag actgtgagct tctagagggc agggacctta ccctagtcat ctctcttctc 1320
accctgcaca ccctccctga gggatctcat gactcttgcg tttctgatag gcacctattg 1380
gtcttactga catccacttt gcctttctct ccacaggtgt ccactcccag ttcacaccgg 1440
cacaatgaat ggcacagaag gccctaactt ctacgtgccc ttctccaatg cgacgggtgt 1500
ggtacgcagc cccttcgagt acccacagta ctacctggct gagccatggc agttctccat 1560
gctggccgcc tacatgtttc tgctgatcgt gctgggcttc cccatcaact tcctcacgct 1620
ctacgtcacc gtccagcaca agaagctgcg cacgcctctc aactacatcc tgctcaacct 1680
agccgtggct gacctcttca tggtcctagg tggcttcacc agcaccctct acacctctct 1740
gcatggatac ttcgtcttcg ggcccacagg atgcaatttg gagggcttct ttgccaccct 1800
gggcggtgaa attgccctgt ggtccttggt ggtcctggcc atcgagcggt acgtggtggt 1860
gtgtaagccc atgagcaact tccgcttcgg ggagaaccat gccatcatgg gcgttgcctt 1920
cacctgggtc atggcgctgg cctgcgccgc acccccactc gccggctggt ccaggtacat 1980
ccccgagggc ctgcagtgct cgtgtggaat cgactactac acgctcaagc cggaggtcaa 2040
caacgagtct tttgtcatct acatgttcgt ggtccacttc accatcccca tgattatcat 2100
ctttttctgc tatgggcagc tcgtcttcac cgtcaaggag gccgctgccc agcagcagga 2160
gtcagccacc acacagaagg cagagaagga ggtcacccgc atggtcatca tcatggtcat 2220
cgctttcctg atctgctggg tgccctacgc cagcgtggca ttctacatct tcacccacca 2280
gggctccaac ttcggtccca tcttcatgac catcccagcg ttctttgcca agagcgccgc 2340
catctacaac cctgtcatct atatcatgat gaacaagcag ttccggaact gcatgctcac 2400
caccatctgc tgcggcaaga acccactggg tgacgatgag gcctctgcta ccgtgtccaa 2460
gacggagacg agccaggtgg ccccggccta accaagaaag cttaagttta aaccgctgat 2520
cagcctcgac tgtgccttct agttgccagc catctgttgt ttgcccctcc cccgtgcctt 2580
ccttgaccct ggaaggtgcc actcccactg tcctttccta ataaaatgag gaaattgcat 2640
cgcattgtct gagtaggtgt cattctattc tgggggggtgg ggtggggcag gacagcaagg 2700
gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct atggc 2755

<210> 28
<211> 145
<212> DNA
<213> Mus musculus

<400> 28
agaggactaa gccacaggtg aggagaaagg ggggggggggg tctgctgacc cagcaacact 60
ctttccttct gaggcttaag agctattagc gtaggtgact cagtccctaa tcctccattc 120
aatgccctgt gactgcccct gcttc 145

<210> 29
<211> 364
<212> DNA
<213> Cytomegalovirus

<400> 29
actagttatt aatagtaatc aattacgggg tcattagttc atagcccata tatggagttc 60
cgcgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga cccccgccca 120
ttgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggacttt ccattgacgt 180
caatgggtgg agtatttacg gtaaactgcc cacttggcag tacatcaagt gtatcatatg 240
ccaagtacgc cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag 300
tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt catcgctatt 360
acca 364

<210> 30
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 30
tttctgcagc ggggattaat atgattatga acacccccaa tctcccagat gctgattcag 60
ccagga 66